

## CURRICULUM VITAE

**DATE PREPARED:** July 7, 2023

**NAME:** LISA GEORGIANNE RIDER, M.D.

**Office Address:** Environmental Autoimmunity Group  
National Institute of Environmental Health Sciences,  
National Institutes of Health  
CRC, Room 6-5700, MSC-1301  
10 Center Drive  
Bethesda, MD 20892-1301

**Work Phone:** (301) 451-6272  
**Work FAX:** (301) 480-2813  
**Email:** riderl@mail.nih.gov  
**Web address:** <https://www.niehs.nih.gov/research/atniehs/labs/crb/pi/ea/index.cfm>

### EDUCATION

1979 High School Diploma, Ridge High School, Basking Ridge, NJ

1979 – 1983 A.B., Duke University, Durham, N.C.  
Chemistry with Biochemical Specialization

1983 – 1987 M.D., Duke University School of Medicine, Durham, N.C.

### POSTDOCTORAL TRAINING

1987 – 1990 Internship/Residency in Pediatrics, University of Washington,  
Children's Hospital and Medical Center, Seattle, WA

1990 – 1991 Pediatric Rheumatology Fellow, University of Washington, Children's  
Hospital and Medical Center, Seattle, WA

1991 – 1993 Clinical Associate, Laboratory of Chemical Immunology (Dr. Henry  
Metzger, PI), Arthritis and Rheumatism Branch, National Institute  
of Arthritis and Musculoskeletal and Skin Diseases, National  
Institutes of Health, Bethesda, Maryland

1991 – 1993 Pediatric Rheumatology Fellow, Children's Hospital National Medical  
Center, Washington, DC

### PROFESSIONAL POSITIONS

09/20/1993 – 09/01/1996 Medical Officer, Division of Cellular and Gene Therapies,  
Center for Biologics Evaluation and Research, Food and  
Drug Administration, Bethesda, MD

09/1996 – 12/31/2000 Medical Officer and Staff Scientist, Division of Monoclonal  
Antibodies, Center for Biologics Evaluation and Research  
(CBER), Food and Drug Administration, Bethesda, MD

01/01/2001 – 01/26/2004 Senior Clinical Investigator and Medical Officer, Environmental  
Autoimmunity Group, Office of Clinical Research, National  
Institute of Environmental Health Sciences, National  
Institutes of Health, Bethesda, MD

01/27/2004 – 10/10/2020	Deputy Unit Chief, Environmental Autoimmunity Group (EAG), Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD (note: Senior Research Physician from 5/2018)
10/11/2020 – 5/31/2021	Acting Head, Environmental Autoimmunity Group (EAG), Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD
06/01/2021 – present	Head, Environmental Autoimmunity Group (EAG) and Senior Clinician, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD

**FACULTY ACADEMIC APPOINTMENTS**

07/1993 – 08/1993	Acting Instructor, Div. of Immunology/Rheumatology, Department of Pediatrics, University of Washington, Children's Hospital and Medical Center, Seattle, WA
03/1994 – 11/2002	Assistant Professor, Department of Pediatrics, Uniformed Services University of Health Sciences, Bethesda, MD
11/2002 – 10/2010	Adjunct Associate Professor, Department of Pediatrics, Uniformed Services University of Health Sciences (USUHS) Bethesda, MD
09/2008 – present	Clinical Professor, Department of Medicine, George Washington University School of Medicine & Health Sciences, Washington, DC
11/2010 – present	Adjunct Professor, Department of Pediatrics, Uniformed Services University of Health Sciences (USUHS) Bethesda, MD

**APPOINTMENTS AT HOSPITALS/AFFILIATED INSTITUTIONS**

10/1993 – 2001	Junior Medical Staff, NIAMS, National Institutes of Health Clinical Center, Bethesda, MD
03/1994 – 08/2005	Attending Physician, Pediatric Rheumatology, Walter Reed Army Medical Center, Washington, DC (2 days/month)
2001 – present	Senior Medical Staff, NIEHS, National Institutes of Health Clinical Center, Bethesda, MD
02/2005 – 06/2007	Attending Physician, Rheumatology, Children's National Medical Center (1 day/month)
04/2008 – present	Attending Physician, Myositis Clinic, Division of Rheumatology, George Washington University (2 days/month)

**U.S. PUBLIC HEALTH SERVICE APPOINTMENTS**

02/1991 – 10/1991	Commissioned as a Medical Corps Officer: Senior Assistant Surgeon
10/1991 – 07/1998	Lieutenant Commander
07/1998 – 04/2002	Permanent Lieutenant Commander
04/2002 – 07/2005	Commander
09/2003 – 07/2005	Permanent Commander
07/2005 – 07/2007	Captain
07 2007 – 06/2021	Permanent Captain

## **LICENSURE AND CERTIFICATION:**

Maryland Medical License #D0046950, 12/30/94 – present (expires 9/30/2023)  
District of Columbia Medical License #MD035811, 10/27/2005 – 12/31/2020  
American Board of Pediatrics, Certification in Pediatric Rheumatology (1994 – 2001, recertified 2002 – 2008, Certificate No 000113; recertified 2009 – 1016; recertified 2016 – 2025, certificate No. 00113)  
American Board of Pediatrics (1990, re-certified for 1998 – 2004, Certificate No. 045457)  
(ABP ID # 216495)  
Federal DEA Registration Number, #BR5314543  
State Controlled Substance Numbers: MD M40025, DC CS06-10806  
National Provider Identifier 1669566691  
Basic Life Support, American Heart Association (2003 – present)  
Pediatric Advanced Life Support, American Heart Association (Nov 2019)  
CITI training: Biomedical investigators (refresher), Good Clinical Practice (US FDA focus),  
Biomedical 101, Vulnerable Subjects - Children

## **MAJOR ADMINISTRATIVE LEADERSHIP POSITIONS**

### **Local**

Chair, Licensure Committee for Etanercept for Polyarticular Juvenile Rheumatoid Arthritis, CBER, FDA  
(1998 – May 1999)  
Co-organizer, NIEHS Clinical Research Branch Seminar Series (2017 – 6/2021)  
Co-organizer, Frederick Miller Retirement Symposium, virtual event (3/5/2021),  
Terrance O'Hanlon Retirement Symposium, virtual event (8/26/2020)  
NIEHS representative, NIH Clinical Center Medical Executive Committee, as backup to NIEHS Clinical  
Director Janet Hall (December 2020 – present)  
Acting Deputy Clinical Director- Bethesda, NIEHS (June 2021 – present)  
Co-Host, NIEHS Distinguished Lecture, Michael V Holers, Professor of Rheumatology, University of  
Colorado School of Medicine (December 13, 2022)

### **National**

Founding Chair, Juvenile Dermatomyositis Working Group, American College Rheumatology  
(1993 – 1999)  
Co-Chair/Co-Organizer, Workshop on Juvenile Rheumatoid Arthritis, Rheumatology Working Group,  
Food and Drug Administration (1996)  
FDA Representative, Advisory Council, Pediatric Rheumatology Collaborative Study Group  
(1998 – 2000)  
NIH Representative, Advisory Council, Pediatric Rheumatology Collaborative Study Group  
(2001 – present)  
The Myositis Association: Chair, Nominating Committee (2001 – 2006), Vice Chair of Medical Advisory  
Board (2005 – 2007), Chair, Research Committee (2008 – 2009)  
Vice Chair, Executive Council, Pediatric Subsection, American College of Rheumatology  
(2006 – 2008)  
Chair, Pediatric Rheumatology Study Section, American College of Rheumatology (2006 – 2009)  
Chair, James T. Cassidy Award Selection Committee, American Academy of Pediatrics (2010 – 2012)  
Chair, Cure JM Foundation Medical Advisory Committee (April 2016 – present)  
Co-organizer, Cure JM Annual Medical Conference, George Washington University, Washington DC,  
June 30, 2018  
Co-Chair, American College of Rheumatology Abstract Review Committee for Pediatric Rheumatology-  
Clinical Research (2018 – 2020)  
Chair, U.S. Public Health Service Appointment Board (date of service confidential)

## **International**

Co-Chair and Co-Founder, International Myositis Assessment and Clinical Studies Group (IMACS) (2000 – present)  
Chair, IMACS Meeting Committee (2010 – 2016), Past Chair (2017 – 2018), Member (2019 – present)  
Chair, Steering Committee, Response Criteria Project for Adult and Juvenile Dermatomyositis and Polymyositis (2012 – 2022)  
Vice Chair, Scientific Committee, 2<sup>nd</sup> Global Conference on Myositis in Potomac, MD (2016 – 2017)  
Vice Chair, International Myositis Genetics Consortium (MYOGEN) (2021 – present)

## **COMMITTEE SERVICE**

### **Local**

Pediatric Use Working Group, Food and Drug Administration (1995 – 1998)  
Rheumatology Working Group, Food and Drug Administration (1995 – 2001)  
Rheumatology Focus Group, Center for Biologics Evaluation and Research, Food and Drug Administration (1996 – 2001)  
Pediatric Clinical Trial Guidance Document (1999)  
Consulting reviewer, NIDDK/NIAMS and NIEHS Institutional Review Boards (2001 – 2005)  
Member, Search Committees for NIEHS Staff Clinician (2001 – 2002; 2009 – 2010)  
NIEHS representative to NIH Pediatric Care Committee (2002 – present)  
Data Safety Monitoring Board, Ingested Interferon Alpha: Prolongation of Permanence of the “Honeymoon” Phase in Newly Diagnosed Diabetes Mellitus (01-DK-0249) (2002 – 2006)  
NIEHS representative, NIH Clinical Research Center Pediatric Partners Care Team (2003 – 2015)  
Consultant, NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease (2004 – 2007)  
Resource Committee, NIH Clinical Center Barriers to Clinical Research Working Group (2008)  
NIEHS alternate representative, NIH Clinical Center Medical Executive Committee (2008 – present)  
Member, National Institute of Environmental Health Sciences Institutional Review Board (2010 – 2019)  
NIEHS Committee on Promotions IV (2011 – 2014)  
Consultant to NIEHS Office of the Director on asbestos exposure and autoimmune/ autoinflammatory diseases (2011 – 2016)  
Consultant to NIEHS Office of Director on environmental exposures and autoimmune disease, including representing the institute at Briefing for the Assistant Secretary for Health (HHS) on *America’s Children and the Environment* (Dec 21, 2011), and made presentations at 2 Congressional briefings (2011, 2012)  
NIEHS Inflammation Cross-Divisional Implementation Working Group (2012 – present)  
NIEHS Clinical Advisory Committee (ad hoc 2009 – 2013; member 2014 – present)  
NIEHS Clinical/CRU IT Strategy Planning Committee (2018 – present)  
Trans-NIH Pediatric Research Consortium (NIEHS representative) (2018 – present)  
NIEHS Clinical Research Branch Clinical Nurse Scientist Search Committee (2018)  
NIEHS Division of Intramural Research Awards Committee (2018 – 2019)  
NIEHS Clinical Research Branch Staff Clinician and NIA-NIEHS Post-doctoral Research Fellow Search Committees (2020)  
Trans-NIH Pediatric Research Consortium COVID-19 Subcommittee (March 2020 – Sept. 2022)  
NIH Occupational Medical Service COVID-19 Screening Volunteer (April – July 2020)  
Trans-NIH Task Force on Multisystem Inflammatory Syndrome in Children (MIS-C), COVID-19 related (May 2020 – January 2021)

NIEHS Scientific Review Committee (June 2020 – present)  
Mentorship Committee, Dr. Hanna Kim, Assistant Clinical Investigator, NIAMS (Sept. 2020 – present)  
NIH Autoimmune Disease Coordinating Committee, Back-up NIEHS intramural representative (June 2021- April 2023)  
NIH IRP Clinical Research Informatics Strategic Plan Initiative (CRISPI)- advisor to NIEHS IT (April 2022)  
Search Committee, Branch Chief, Division Autoimmunity, Immunology, Transplantation (DAIT), AMIB, NIAID (2022)  
NIH IRP Strategic Plan Working Group for Trans-NIH Pediatric Research (June 2022 – present)  
NIEHS Data Management and Sharing Plan Working Group (November 2022 – present)  
NIEHS CIO Search Committee (December 2022 – present)  
NIH Pediatric Research Committee (N-PeRC) subcommittee: All of Us Pediatric Brain Trust (March 2023 – present)  
NIH Coordinating Committee for Autoimmune Disease Research (CCADR) – NIEHS representative (April 2023 – present)

### **National**

Juvenile Dermatomyositis Working Group, American College Rheumatology (1993 – present)  
Advisory Committee, NIH/Hospital for Joint Diseases Registry for Neonatal Lupus (1994 – 2005)  
Advisor, the National Dermatomyositis Support Group, 1994 –1996  
Co-organizer and co-chair, FDA Juvenile Rheumatoid Arthritis Workshop, Bethesda, MD, July 23, 1996  
The Myositis Association: Medical Advisory Board Member (1996 – 2010), Nominating Committee (2001– 2006), Research Committee (2006 – 2009), Registry Committee (2009 – 2010)  
American College of Rheumatology Annual Meeting Abstract Selection Committee: Pediatric Rheumatology (1998, 2018 – 2020), Myositis/Myopathies (2002, 2004, 2010, 2012, 2021, 2022)  
U.S. Public Health Service Medical Review Board member (June 2002, December 2003, February 2014, July 28, 2015)  
Childhood Arthritis and Rheumatology Research Alliance (CARRA), Member: Juvenile Dermatomyositis Scientific Group, Translational Research Working Group (2002 – present); Disease Registry Working Group (2008 – 2014); Chair, Juvenile Dermatomyositis Data Repository Working Group (2009 – 2014)  
Children's Longitudinal Environmental Health Study (National Children's Study), Immunity, Infections and Vaccines Working Group (2002 – 2005)  
Executive Council, Pediatric Subsection, American College of Rheumatology (2003 – 2008)  
U.S. Public Health Service Physician's Professional Advisory Committee Subcommittee on Mentoring (2004 – 2009)  
U.S. Public Health Service Promotion Board (date of service confidential)  
Communications Committee, Clinical Immunology Society (2006 – 2009)  
Editorial Board, Table of Biologic Therapies, Clinical Immunology Society (2008 – 2009)  
Vaccine and Related Biologic Products Advisory Committee, Safety and Efficacy of HPV Bivalent (Types 16 & 18) Vaccine for the Prevention of Cervical Cancer, Sept 9, 2009, Gaithersburg, MD  
James T. Cassidy Award Selection Committee, American Academy of Pediatrics (2009 – 2012)  
Cure JM Foundation Medical Advisory Committee (2011 – present)  
Invited participant, Libby Amphibole Research Symposium, Libby, MT (October 13-15, 2011)  
Medical Advisor to aTyr, MedImmune, and Idera Pharmaceuticals (2014 – 2018)  
Foundation of NIH Biomarkers Consortium Inflammation and Immunity Steering Committee (2015 – present)  
Medical Advisor to Bristol Myers Squibb (2016 – 2018) (unpaid)

Medical Advisor to Astra Zeneca and CSL Behring (2017 – 2018, 2022) (unpaid)  
Steering Committee, Trial of Vamorolone for Juvenile Dermatomyositis (2018 – 2019)  
Member, COVID-19 Global Rheumatology Alliance Vaccine Survey Group (2020 – 2022)  
Medical Advisor to Alexion (2021 – 2022). Boehringer Ingelheim (2021 – 2022) (unpaid)  
Back-up NIEHS Liaison, American Academy of Pediatrics Committee on Environmental Health  
(Sept 2021 – present)  
American College of Rheumatology Climate Change Task Force (2022 – present)  
Stanley Manne Children’s Research Institute/ Ann & Robert H. Lurie Children’s Hospital of Chicago  
Cure Juvenile Myositis Center of Excellence Biorepository and Registry Review Committee  
(2022 – present)

### **International**

Steering Committee, International Myositis Classification Criteria Project (2004 – 2018)  
Steering Committee, Trial of Rituximab in Adult and Juvenile Idiopathic Inflammatory Myopathies (2002  
– 2014); Publications Committee (2010 – 2014)  
Member and lead investigator of pediatric studies, International Myositis Genetics Consortium  
(MYOGEN) (2006 – present)  
Steering and Scientific Committees, First International Conferences on Myositis, Stockholm Sweden,  
May 2015 (2014 – 2015)  
Steering Committee and Scientific Committees, 2<sup>nd</sup> Global Conference on Myositis in Potomac, MD,  
May 2017 (2016 – 2017)  
Scientific Committee, 3<sup>rd</sup> Global Conference on Myositis in Berlin, Germany, March 2019  
(2018 – 2019)  
Temporary Steering Committee, International Myositis Society (2018 – 2021)  
Participant, Anti-Synthetase Syndrome Classification Criteria project (2019 – present)  
Steering Committee and Scientific Committees, Abstract review committee, 4th Global Conference on  
Myositis in Prague, Czech Republic, June 6-9, 2022 (2019 – 2022)  
Expert Panel, 255th ENMC International Workshop: Muscle Imaging in Idiopathic Inflammatory  
Myopathies  
Medical Advisor to Argenx (2021 – 2022) and Pfizer (2021 – present) (unpaid)  
Expert Panel, IMACS Myositis Cancer Screening Guidelines (2021-2022)  
IMACS representative to MYONET and iMyoS (2021 – present)  
Steering Committee, Whole Body MRI in Myositis, IMACS Group (2022)  
Medical Advisor to Horizon Therapeutics, CSL Behring (2022 – present), Cabaletta Bio (2023 – present)  
Steering Committee Meeting on the Revision of the EULAR/ACR Myositis Classification Criteria Project  
(2023 – present)  
Steering Committee, Treat2Target for Juvenile Dermatomyositis (2023 – present)  
Scientific Committee, 5th Global Conference on Myositis in Pittsburgh, PA, March 13-16, 2024 (2023 –  
present)

### **COMMUNITY SERVICE RELATED TO PROFESSIONAL WORK**

NIH Occupational Medical Service: COVID19 screening (spring - summer 2020)  
Temple Shalom COVID Taskforce, Committee on Continuing Operations (2021 – 2022)

### **PROFESSIONAL SOCIETIES**

Fellow, American College of Rheumatology (1990 – present)  
Fellow, American Academy of Pediatrics (1990 – present)  
Washington DC Rheumatism Society (1991 – 1994, 2003 – present)  
Pediatric Rheumatology Subsection, American College of Rheumatology (1994 – present)

Section on Pediatric Rheumatology, American Academy of Pediatrics (1994 – present)  
American Medical Association (1996 – present)  
Section on Uniformed Services, American Academy of Pediatrics (2000 – present)  
U.S. Public Health Service Commissioned Officers Association (2003 – present)  
Section on Environmental Health, American Academy of Pediatrics (2004 – present)  
Henry Kunkel Society, Elected Member (2006 – present)  
Clinical Immunology Society (2006 – 2018)  
Society for Clinical and Translational Science (2009 – 2017)  
American Association for the Advancement of Science (2017 – present)  
International Myositis Society (iMyoS) (2021 – present)

### **GRANT REVIEW ACTIVITIES**

Univ. Pittsburgh NIAMS Multipurpose Arthritis Center Development and Feasibility grants (2000)  
NIAMS PO1 Program Project Grant Applications (2002)  
The Myositis Association (2002 – 2008), Research Review Committee (2006 – 2008); Chair, Research Review Committee (2008 – 2009)  
Member, Study Section for NIAMS Clinical Trials Outcomes Instrument Development Grant Program, RO1 applications (2004)  
American College of Rheumatology Research and Education Fund (2008)  
Prinses Beatrix Fonds (2008)  
Member, Study Section for NIAMS Special Emphasis Panel - Clinical Trial Proposals (2011)  
Action Medical Research and Medical Research Council, UK (2012)  
Arthritis Research UK (2013)  
EU-Rare JTC 2013 - European Research Projects on Rare Diseases European Union (2013)  
Dutch Arthritis Foundation, Reumafonds (2016)  
Deutsche Forschungsgemeinschaft (German Research Foundation) (2017, 2018)  
Cure JM Foundation (2019)

### **EDITORIAL ACTIVITIES**

#### **Ad hoc journal reviewer:**

Last 5 years: *Annals of Rheumatic Diseases, Arthritis and Rheumatology, Journal of Clinical Investigation, Nature Reviews Rheumatology, Frontiers in Medicine, Arthritis Care and Research, PLoS One, Rheumatology, Seminars Arthritis and Rheumatism, Arthritis Research and Therapy, European Journal of Rheumatology, Clinical and Experimental Rheumatology, Journal of Rheumatology, Journal of Clinical Immunology, Inhalation Toxicology, International Journal of Hygiene and Environmental Health, BMC Rheumatology, Clinical and Experimental Immunology, ACR Open, Scandinavian Journal of Rheumatology, Frontiers in Pediatrics*

Previous: *Lancet, British Medical Journal, Rheumatology International, Nature Reviews Neurology, Pediatrics, Muscle and Nerve, Journal of Neuroimmunology, Pediatric Rheumatology, Scandinavian Journal of Rheumatology, Expert Reviews in Clinical Immunology, Journal of Pediatrics, Journal of Clinical Rheumatology, International Journal of Clinical Rheumatology, International Journal of Rheumatic Diseases, Archives of Dermatology, Pediatric Dermatology, British Journal of Dermatology, Expert Opinion on Drug Safety, Expert Reviews in Clinical Immunology, Neuromuscular Disorders, Lupus, Clinical and Developmental Immunology, Journal of Molecular Diagnostics, Biomarkers in Medicine, Disease Biomarkers, Autoimmunity, International Journal of Rheumatic Diseases, World Journal of Pediatrics, Seminars in Ophthalmology*

### **Other Editorial Roles:**

Co-Editor, *Myositis and You: A Complete Family Guide to Juvenile Dermatomyositis and Other Inflammatory Myopathies*, The Myositis Association, Washington, 2007  
Editorial Board, *The Open Arthritis Journal*, 2008 – 2012  
Editorial Board, *International Journal of Rheumatology*, 2010 – 2018  
Editorial Board, *World Journal of Rheumatology*, 2011 – 2015  
Associate Editor, *Annals of Pediatric Rheumatology*, 2011 – 2018  
Editorial Board, *Journal of Neuromuscular Diseases*, 2013 – present  
Associate Editor, *Frontiers in Immunology, Autoimmune and Autoinflammatory Disorders*, 2018 – 2022, *Autoimmune and Autoinflammatory Disorders: Autoimmune Disorders*, 2022 – present  
Editorial Board, Annual issue on Idiopathic Inflammatory Myopathies, *Clinical Experimental Rheumatology*, 2021 – present  
Associate Editor, *Arthritis & Rheumatology*, July 2022 – present

### **HONORS AND PRIZES**

1983	Phi Beta Kappa, Summa cum laude, Duke University
1985 – 1986	Eugene Stead Research Fellowship, Duke University School of Medicine
1985 – 1986	Pharmaceutical Manufacturer's Medical Student Research Fellowship in Pharmacology Clinical Pharmacology
1998	Achievement Medal, US Public Health Service (“For validating the usefulness of clinical tools to assess disease activity in juvenile myositis with implications for many other pediatric and orphan diseases”)
1999	Unit Commendation, US Public Health Service (“For significant and exceptional performance in the review and licensing of new anti-TNF therapies for autoimmune disease”)
1999	Outstanding Unit Citation, US Public Health Service (“For innovative collaboration with academia, industry and the public in the development of programs for the treatment of rheumatoid arthritis”)
2000	Commendation Medal, US Public Health Service (“For exemplary performance of duty” in clinical review and policy development)
2003	Schlager Family Visiting Professor Lectureship in Juvenile Dermatomyositis, Children’s Hospital, Boston, MA, April 30, 2003
2004	Commendation Medal, US Public Health Service (“For superior service in identifying the presence of microchimerism in juvenile-onset myositis”)
2006	Ann Hengel Lecturer in Pediatric Rheumatology. Medical College of Wisconsin, Milwaukee, Wisconsin. April 28, 2006
2006	Certificate of Appreciation, US Public Health Service (“For exceptional performance in response to the USPHS Transformation objectives and mission by developing resources to mentor the professional development of Commissioned Corps physicians”)
2006	Elected member of the Henry Kunkel Society



2007	Hero Certificate, Cure JM Foundation (“For dedication to finding a cure for juvenile myositis”)
2008, 2009, 2012	America’s Top Pediatricians
2009	Selected for listing in Women in Science at the National Institutes of Health, Office of Research on Women’s Health
2009 - 2020	Best Doctors
2011	Physician Researcher of the Year, US Public Health Service Physician’s Professional Advisory Committee
2016	Who’s Who Top Doctor’s Honors edition
2016	Pharmaceutical Research and Manufacturers of America (PhRMA) Research and Hope Award: Government Research in Autoimmune Disease
2017	Lifetime Achievement in Research Award, Cure JM Foundation
2017	Suzanne Bowyer Memorial Lectureship, Riley Hospital for Children at Indiana University Health, September 13, 2017
2018	10 Year Center of Excellence Award, Cure JM Foundation (to George Washington University Myositis Center)
2018	The Myositis Association’s 25th Anniversary Research Award: For Outstanding Contributions to Myositis Research over past 15 years
2019	NIEHS Group Merit Award: For excellence in research, design, and implementation of the International Myositis Assessment and Clinical Studies application and launching an online mentorship program
2019	The Mary Jane Keller Memorial Lecture, Yale University School of Medicine, New Haven, CT, May 22, 2019
2019	Global Genes Rare Champion of Hope Award for Research Collaboration to the International Myositis Assessment and Clinical Studies Group (co-chair IMACS)
2019	James and Nancy Cassidy Endowed Lectureship and Rheumatology Symposium, University of Missouri School of Medicine, Columbia, MO, September 27, 2019
2019	NICHD Directors’ Award to the NIH Trans Pediatric Research Committee (N-PERC); NIEHS representative
2020	James T. Cassidy Award, American Academy of Pediatrics Section on Rheumatology (“For outstanding achievement in pediatric rheumatology”)
2020	NICHD Partnership Award for Collaboration with NICHD on NIH Pediatric Research Committee (N-PERC) COVID-19 Subgroup (NICHD Director’s Award)
2021	NIEHS Group Merit Award to the STIC Team: For exemplary integrity, efficiency, and professionalism in conducting the Intravenous Sodium Thiosulfate in Dermatomyositis Clinical Trial (NIEHS Director’s Award)
2021	9th Annual Kennedy Lectureship, Children’s Hospital of Alabama, University of Alabama, Birmingham, AL (November 11, 2021, virtual)

- 2022 Excellence in Investigative Mentoring, American College of Rheumatology Award of Distinction
- 2022 NIAMS Director's Group Award, COVID-19 Systemic Autoimmunity Team: "In recognition of exceptional work studying the interaction between systemic autoimmunity and COVID-19"
- 2023 Cure JM Foundation Advocate Scholarship: Lisa G. Rider Scholarship (named scholarship in my honor for students)

## **REPORT OF FUNDED AND UNFUNDED PROJECTS**

### **PROTOCOL INVESTIGATIONS (FUNDED)**

#### NIHES Protocols at National Institutes of Health Clinical Center, Bethesda, MD

- Principal Investigator, "Studies in the Natural History and Pathogenesis of the Idiopathic Inflammatory Myopathies of Childhood" (NIAMS 94-AR-0165, after 2001: NIEHS 94-E-0165) (1994 – present)
- Principal Investigator, "Studies in the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases" (FDA RIHSC CBER #121; NIEHS 05-E-N200) (1994 – present)
- Principal Investigator, "Pathogenic Studies in Families with Twins or Siblings Discordant for Systemic Rheumatic Disorders" (NIEHS 03-E-0099) (2003 – present)
- Principal Investigator, "Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis" (NIEHS 07-E-0012) (2006 – present)
- Lead Associate Investigator, "Environmental Risk Factors for the Anti-Synthetase Syndrome (MYORISK)" (NIEHS 11-E-0072) (2010 – present)
- Lead Associate Investigator, "Environmental Risk Factors for the Development of Myositis in Military Personnel" (NIEHS 13-E-0015) (2013 – present)
- Lead Associate Investigator, "An Open-label Study of Sodium Thiosulfate for Treatment of Calcinosis Associated with Juvenile and Adult Dermatomyositis" (NIEHS 17-E-0012) (2017 – present)

#### Protocols from Other Institutes, NIH Clinical Center, Bethesda, MD

- Associate Investigator, "A Randomized, Double-Blind, Placebo-Controlled Trial of Infliximab in Patients with Dermatomyositis and Polymyositis" (NIAMS 02-AR-0156) (2002 – 2008)
- Associate Investigator, "Studies on Tissues from Patients with Fibrous Dysplasia of Bone/McCune Albright Syndrome and Other Disorders of Calcified Tissues" (NIDR 97-D-0055) (2002 – 2008)
- Associate Investigator, "Studies in the Natural History and Pathogenesis of Adult Myositis" (NIAMS 91-AR-0196) (2005 – 2023)
- Associate Investigator, "Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID / CAPS, DIRA, CRMO, Still's Disease, Behçet's Disease, Juvenile Dermatomyositis, and other Undifferentiated Autoinflammatory Diseases)" (NIAMS 03-AR-0173) (2011 – present)
- Associate Investigator, "Compassionate Use Treatment Protocol I4V-MC-JAGA; Treatment of Autoinflammatory Syndromes Expected to Benefit from JAK Inhibition" (NIAMS 12-AR-8001) (2015 – 2021)
- Associate Investigator, "Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still's-like Diseases, and other Undifferentiated Autoinflammatory Diseases)" (NIAID 17-I-0016) (2016 – present)
- Associate Investigator, "Studies on the Natural History and Pathogenesis of Spondylarthritis" (11-AR-0223) (2019 – present)
- Associate Investigator, "Studies of the Pathogenesis and Natural History of Systemic Lupus Erythematosus (SLE)" (94-AR-0066) (2019 – present)

Associate Investigator, “The Natural History of Coronavirus Disease (COVID-19) in Systemic Autoimmune Diseases; An Observational Prospective Study” (20-AR-0227) (2020 – present)  
 Associate Investigator, “Natural History of Inflammatory Muscle Disease” (000894) (2023- present)  
 Associate Investigator, “A Phase II Placebo-Controlled Double-Blind Study of Baricitinib in REfrAcTory Juvenile Dermatomyositis (BEAT JDM)” (IRB pending) (2023 – present)

Extramural Protocols

Associate Investigator, “Health Care Transitioning for Pediatric Myositis Patients,” George Washington University (IRB #060829) (2009 - 2013)  
 Associate Investigator, “Environmental Exposures and Disease Flare in Adult and Juvenile Dermatomyositis and Polymyositis,” George Washington University (IRB #011007) (2010 – 2015)  
 Associate Investigator, “MYOVISION: A Registry for Patients with Adult or Juvenile Myositis,” Cincinnati Children’s Medical Center (IRB # 2010-1725) (2010 – 2019)  
 Associate Investigator, “Novel Drug Delivery of Sodium Thiosulfate for Calcinosis Associated with Adult and Juvenile Dermatomyositis,” George Washington University (IRB #121131) (2012 – 2016)  
 Associate Investigator, Retrospective Review of Clinicopathologic Findings of Patients with Inflammatory Myositis,” George Washington University (IRB #071419) (2014 – present)  
 Associate Investigator, “Abatacept for the Treatment of Refractory Juvenile Dermatomyositis (JDM) AID (Abatacept in Dermatomyositis) Trial,” George Washington University (IRB #111418) (2015 – 2022)

**FUNDING INFORMATION**

**Current Funding**

**NIH Intramural**

ZIA ES101074	Environmental/Genetic Risk Factors and Pathogenesis of Autoimmune Disease
ZIA ES101081	Assessment, Therapy and Prevention of Autoimmune Disease

**External Funding**

2014 – present	George Washington University Myositis Center- Cure JM Foundation support, Dr. Rodolfo Curiel, Director (\$190,000 per year, average) (10% effort); no funds received by me or NIEHS
2017 – present	Associate Investigator, An Open-label Study of Sodium Thiosulfate for Treatment of Calcinosis Associated with Juvenile and Adult Dermatomyositis (\$1,559,120 CRADA with Hope Pharmaceuticals, EHS-CTCR-1 to NIEHS) (15% effort)
2023 - present	Principal Investigator, Metabolomics and Exposomics in the Plasma of Siblings Discordant for Systemic Autoimmune Diseases, NIH Office of Autoimmune Disease Research, Office of Research in Women’s Health (\$109,056)

**Past External Funding**

2001 – 2002	Co-Investigator, NIAMS R21 grant to Dr. Ann Reed, “Finalization of Outcomes and Design Issues for Myositis Trials” (\$83,000; no funds received by me or NIEHS) (10% effort)
2001, 2002	Co-Principal Investigator, NIH Office of Rare Diseases, NIAMS, and NINDS funding for 2 workshops on Outcome Assessment and Clinical Trial Design in the Idiopathic Inflammatory Myopathies (\$25,000 each year) (10% effort)

2005 – 2009 Co-Principal Investigator, American College of Rheumatology, Development of Outcome Measures for Myositis (\$15,000) (10%)

2006 – 2009 Co-Principal Investigator, Inter-Agency Agreement, NIAMS, Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathies (\$515,586) (10% effort)

2008 – 2014 George Washington University Myositis Center. Cure JM Foundation support of \$100 - \$150,00 per year, no funds received by me or NIEHS (10% effort)

2009 – 2012 “The Myositis Genetics Consortium (MYOGEN)” Cure JM Foundation support of \$75,000/year. This project is identifying new genetic risk and protective factors for myositis via genome-wide association studies. No funds received by me or NIEHS (5% effort)

2011 – 2017 Co-Investigator, “Potential Environmental Triggers of Myositis”, The Myositis Association, from a cooperative agreement with the Department of Defense (W81XWH-11-1-0730) (\$596,575) (5% effort)

2012 – 2015 Co-Principal Investigator, American College of Rheumatology (ACR) - European League Against Rheumatism (EULAR) grant, “Development of Response Criteria for Adult and Juvenile Myositis” (\$130,000) (10% effort)

2013 – 2014 Co-Principal Investigator, Funding for ACR-EULAR Consensus Conference for the Development of Response Criteria for Adult and Juvenile Myositis (\$60,000 from NIH Office of Rare Diseases, NIEHS, NIAMS, Cure JM Foundation, UK Myositis Support Group and The Myositis Association) No funds received by me or NIEHS (10% effort)

2013 – 2019 Cure JM Foundation gift to NIEHS to support studies of juvenile myositis (\$100,000)

2019 – 2020 Associate Investigator, Fatigue in Juvenile Dermatomyositis, PI Josh Woostenhulme and Keith Cole PT, Cure JM Foundation (\$130,000), no funds received by me or NIEHS (5% effort)

2012 – 2021 Associate Investigator, Compassionate Use Treatment Study of Baricitinib for Juvenile Dermatomyositis (drug, pK assay support under CRADA to NIAMS from Lilly)

2015 – 2022 Associate Investigator, George Washington University Myositis Center- Bristol Myers Squibb support for Abatacept trial in juvenile dermatomyositis, Dr. Rodolfo Curiel, Director (\$411,717) (10% effort); no funds received by me or NIEHS

#### **Training Grants and Mentored Trainee Grants**

2002 – 2007 Mentor for Research Fellowship of Dr. Gulnara Mamyrova, The Myositis Association (salary support for 2 years) and Cure JM Foundation (salary support for 3 years); no funds received by me or NIEHS

2015 – 2017 Mentor for Research Fellowship of Dr. Takayuki Kishi, The Myositis Association (\$100,000 salary support and benefits for 2 years) and Cure JM Foundation (\$25,000 salary support); no funds received by me or NIEHS

2015 – 2018	Novel Biomarkers Associated with Disease Activity in JDM, Cure JM Foundation award to NIAMS Schulman Scholar Dr. Hanna Kim (\$125,000 award) (Co-mentor, no funds received by me or NIEHS)
2017 – 2018	Dr. Albert Chow, Pediatric Rheumatology fellow, Seattle Children's/University of Washington, Seattle, WA, NIH T32 fellowship salary support (Co-mentor, no funds received by me or NIEHS)
2018 – 2019	Liubing Li, PhD student, China Scholarship Council Award (Co-mentor, no funds received by me or NIEHS)
2019	Dr. Sara Sabbagh, Clinical research fellowship (\$25,000 training award from Cure JM Foundation); no funds received by me or NIEHS

## **REPORT OF LOCAL TEACHING AND TRAINING**

### **Formal Teaching of Residents, Clinical Fellows, and Research Fellows (post-docs):**

*No presentations below were sponsored by outside entities.*

“Juvenile Myositis”, annual lecture for NIEHS summer students, special volunteers, post-bac IRTAs, post-doctoral fellows (2004 – present)

“Juvenile Myositis”, annual lecture for NIAMS Clinical and Research Fellows, Post-bac IRTA students (2007 – 2016)

“Juvenile Myositis”, annual lecture for George Washington University rheumatology fellows, residents, medical students (2008 – 2016)

“Adult and Juvenile Myositis”, George Washington University Rheumatology lecture series for medical students, July 18, 2008; August 7, 2009

### **Clinical Supervisory and Training Responsibilities:**

#### Walter Reed Army Medical Center Pediatric Rheumatology Clinic (1994 – 2005):

Attending physician and clinical supervisory training of 2 adult rheumatology fellows per year (23 fellows total), as well as internal medicine and pediatrics residents, medical students in clinical care of pediatric rheumatology. Specific trainees not listed.

#### George Washington University Myositis Clinic (2008 – present):

Attending physician and clinical supervisory training of adult and pediatric rheumatology fellows, internal medicine and pediatrics residents, medical students and visiting professors in clinical care of juvenile myositis and related disorders. Clinical research co-mentor for fellows for past 5 years and residents, students on research rotations through the clinic. Listing of major trainees:

Adult Rheumatology fellows: Geeta Nayyar, MD (2008), Olena Guzhva, MD (2008-09), Shiraz Moinuddin, MD (2008-10), Seema Agrawal, MD (2009-11), Anupam Chahal, MD (2010-12), Tina Shah, MD (2011-13), Mahsa Tehrani, MD (2012-13), Heidi Hanna, MD (2013-15), Dareen Almanabri, MD (2014-16); Jonathan Miller, DO (2014-16), Sam Serafi, MD (2015-17) (2016 DC Rheumatism Society Fellows Forum Poster Award Recipient), Marc Phillipotts, MD (2016-18, DC Rheumatism Society Fellows Forum Oral Presentation Award Recipient), Erica McBride, MD (2017-19, 2019 Global Conference on Myositis fellowship travel award, 2019 DC Rheumatism Society Fellows Forum Oral Abstract Award Recipient), Ishita Aggarwal (2018-20), Maha Almackenzie (2019-21), Mamata Chand (2019-21), Sonia Silinsky Krupnikova (2020-22), Mohammed Abdulfatah (2020-22), Kezia Daniel (2021-23), Marta Michalska-Smith (2021-23)

Children's National Medical Center pediatric rheumatology fellows: Ann Marie Szymanski, MD (2015-16), Sara Sabbagh, DO (2016-17, 2019-20), Emily Gotschlich, MD (2017-18), Brian Dizon, MD PhD

(2017-18), Kathleen Vazzana (2018-19), Matthew Sherman (2020-22), Sandra Amara Ogbonnaya-Whittlesey (2021-22)

Visiting faculty: Ignacio Garcia de la Torre MD, Mexico (10/2012), Sabbatical Professor Erkan Demirkaya MD PhD, Turkey (2013-14), Adriana Sallum MD PhD, Brazil (11/2016), Hanna Kim MD, NIAMS (2017-present); Jiram Torres MD, Mexico (2018, 2022), Pallavi Pimpale MD, India (2020-22)

Research trainees: Yaseen Aleatani, MD (2016-17, international fellow), Vladislav Tsaltzkan, MD (2016-17, internal medicine resident), William Nguyen (2021-22, MPH; 2022 DC Rheumatism oral abstract presentation award winner)

NIH Clinical Center:

Clinical supervisory training of NIAMS pediatric rheumatology fellows, adult rheumatology fellows, and NIAMS and NIEHS nurse practitioners and special volunteer physicians in juvenile myositis clinics and NIH Clinical Center consultations (2007– present)

Faculty member, NIAMS-CNMC Pediatric Rheumatology training program (2014 – present)

**Laboratory and Other Research Supervisory and Training Responsibilities:**

Directed research projects and mentored rheumatology fellows, high school and undergraduate summer students, post-bac IRTA students, medical students, PhD, and master's thesis candidates, visiting scientists, at the National Institutes of Health and Food and Drug Administration (1996 – present)

**Formally Mentored Post-Doctoral IRTAs:**

Alexa Boer Kimball M.D., MPH#: NCI Dermatology Fellow (1999 – 2000), Co-mentor with Maria Turner: Project: MRI of Skin and Subcutaneous Tissue in Myositis; currently Professor, Department Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA

Gulnara Mamyrova, MD PhD (2003 – 2008)###: Special Volunteer and recipient of Research Fellowship grant awards from The Myositis Association and Cure JM; recipient DC Rheumatism Society Fellows Research Award (2005 – 2007); Project: Clinical and Autoantibody Phenotypes in Juvenile Myositis and Immunogenetic Risk Factors for Juvenile and Adult Myositis; currently Assistant Research Professor, Division of Rheumatology, George Washington University Department of Medicine

Catherine April Bingham MD (2004 – 2006)#: Special Volunteer, Pediatric Rheumatology Fellow, Columbia University; Project: Lipodystrophy Associated with Juvenile Dermatomyositis; currently Associate Professor, Pediatric Rheumatology, Penn State, Hershey, PA

Kathleen Coyle MD (2007 – 2008)#: NIAMS Rheumatology Fellow; Project: Metabolic Syndrome in Juvenile Myositis; currently, Rheumatologist, Annapolis, MD

Takayuki Kishi MD PhD (6/2015 – 4/2018): Special Volunteer and recipient of Myositis Research Fellowship award from The Myositis Association and Research grant award from Cure JM Foundation; Project: Responses to Treatment in Juvenile Myositis and Associated Phenotypes; Awards: Japan College of Rheumatology 2018 Excellent Abstract Award recipient. Current position: Assistant Professor, Pediatric Rheumatology, Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan

Hanna Kim MD MHS (2015 – 2020)#: NIAMS Schulman Scholar, Co-mentor with Raphaela Goldbach-Mansky: Biomarkers in JDM; Co-mentor with Robert Colbert: Baricitinib Compassionate Use Study for JDM. Recipient of CARRA-Cure JM Foundation grant award, American College of Rheumatology Distinguished Fellow 2015; Global Conference on Myositis Abstract awards 2017; CARRA Early Investigator Award 2022; Current position: Assistant Clinical Investigator, NIAMS, NIH (serve on mentorship committee)

Sara Sabbagh DO (Sept 2017 – March 2020)#: Pediatric Rheumatology Fellow, NIAMS- Children's National Medical Center program, Co-mentor with Andrew Mammen; Projects: Project: Myositis Associated Autoantibodies in Juvenile Myositis; Tofacitinib in JDM; Awards: 2018 Earl J. Brewer

research award winner, ACR annual meeting; Cure JM Foundation grant award; 2019 DC Rheumatism Society Fellows Forum Oral Abstract Award Recipient. Additional clinical and clinical research training under my direction from July 2019 – March 2020. Current position: Assistant Professor, Pediatric Rheumatology, Medical College of Wisconsin

Matthew Sherman MD MHSc (July 2021 – June 2023): Pediatric Rheumatology Fellow, NIAMS-Children's National Medical Center program, Co-mentor with Andrew Mammen; Project: Myositis Associated Autoantibodies in Juvenile Myositis; Earned Master of Health Sciences in Clinical Research degree from NIH-Duke University program; Award: 2022 Rheumatology Research Foundation Pediatric Rheumatology Research Award, ACR Convergence meeting

# - indicates woman, ## - indicates underrepresented minority trainee

### **Other Mentored Trainees and Faculty, Students and Pre-Doc IRTAs**

Ejaz Shamim (1995 – 1996), Special Volunteer, CBER, FDA, recipient American College of Rheumatology Medical Student Research Fellowship Award (1995); MD M.S., Director of Neurology, Kaiser Permanente Mid-Atlantic Permanente Medical Group, Rockville, MD

Elizabeth Zachariah (1995), Undergraduate student University of Maryland at CBER. FDA

Benjamin Laskin (1996), Summer student, CBER, FDA; BA, Duke University, medical student University of Maryland, Baltimore; currently Chief, Division of Nephrology, Children's Hospital of Philadelphia and Associate Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania

Abhijit Pal (1996 – 1997), Student volunteer, International Baccalaureate Program, Richard Montgomery High School; currently Head of Research, Travel Partner Group, Expedia Group

Tina Sanghvi# (2002) NIEHS Summers of Discovery student and 2003 summer student, BA, Duke University; medical student, University of Iowa; currently Adjunct Assistant Professor, Department of Radiology, University of Minnesota

Adam Schiffenbauer (1997 – 1999, 2002): Student volunteer, International Baccalaureate Program, Richard Montgomery High School, NIEHS Summers of Discovery student; currently Staff Clinician, EAG, NIEHS, NIH

Melvina Evereklian# (2003 – 2005) – RN student, Univ Maryland, EAG Special Volunteer. 2005 Beacon Conference award recipient; currently Pediatric Nurse Practitioner, Frederick MD.

Lauren Komarow# (2003): NIEHS Summers of Discovery student, MS in biostatistics, Univ. Michigan; currently Lead Biostatistician, Biostatistics Center, Milken Institute of Public Health, George Washington University, Washington, DC

Leora Vegosen# (2004 – 2005): Master of Environmental Science Student, Johns Hopkins University School of Public Health (mentored portion of thesis work); NIEHS 2004 Summers of Discovery student; Recipient of 2005-06 ACR Research and Education Foundation Medical/Graduate Student Achievement Award. PhD, Epidemiology, Johns Hopkins Bloomberg School of Public Health. Currently Epidemiologist, US Environmental Protection Agency, Cincinnati, OH

Jason Monroe (2005): NIEHS Summers of Discovery student; PhD student in Statistics, UCLA; currently Senior Clinical Information Data Analyst, City of Hope, CA

Michael Harris-Love## PT, MPT, DSc (2005 – 2010): NIEHS Special Volunteer; now Professor and Joanne Posner-Mayer Endowed Chair in Physical Therapy and Associate Dean, Physical Therapy Education, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO

Kim Nguyen# (2008 – 2009): NIEHS Special Volunteer, Montgomery Blair Math Science high school magnet student- senior research project; Undergraduate, University of Maryland College Park; currently Engineer, Research Lab, Laurel MD

Amy Li<sup>#</sup> (2007 – 2008; 2009): NIEHS Special Volunteer, Montgomery Blair Math Science high school magnet student- senior research project and 2009 Summers of Discovery Student; Duke University undergraduate student; Univ Chicago Law school

Jonathan Chipman (2007): NIEHS Summers of Discovery student; Statistics PhD, Vanderbilt University; currently Assistant Professor of Biostatistics, Univ Utah School of Medicine

Lan Wu<sup>#</sup> (2007 – 2012): Part-time NIEHS Special Volunteer, Undergraduate, Johns Hopkins University, Baltimore, MD; subsequently PA student, Pennsylvania State- Hershey Medical Center, Hershey, PA; currently Physician Assistant, Silver Spring, MD

Gulnara Mamyrova<sup>###</sup> MD PhD (2008 – present): Assistant Research Professor, Department of Medicine, George Washington University (research mentor through GWU Myositis Clinic)

Mona Shah<sup>#</sup> (2008 – 2012): NIEHS Special Volunteer, PhD student (mentored PhD dissertation work), George Washington University Department of Epidemiology; currently Program Officer, Robert Wood Johnson Foundation, Princeton, New Jersey

Sepehr Mesdaghinia MD (2010 – 2011): NIEHS Special Volunteer; Rheumatology Fellow, Georgetown University Medical Center, Washington DC; currently Rheumatologist, Leesburg, VA

Anna Patnaik<sup>#</sup> (summer 2011): NIEHS Special Volunteer, Montgomery Blair Math Science high school magnet student- Biostatistics award at Blair magnet student research festival; later BA, University of Maryland, College Park, MD; MD, Univ Maryland; currently Neurology resident, Johns Hopkins University Medical School

Alexis Wilson<sup>#</sup> (summer 2012): NIEHS Summer of Discovery student; Undergraduate, Univ. Florida

Adrienne Yip<sup>#</sup> BA (2010 – 2012): Post-bac IRTA student; Recipient 2011 DC Rheumatism Society Fellows Forum Poster award, 2012 DC Rheumatism Society Fellows Forum award; MD, University of Maryland School of Medicine; currently Emergency Physician, Baltimore, MD

Saad Feroz BA (2012 – 2013): Post-bac IRTA student; MD, Eastern Virginia Medical School, Norfolk, VA; currently Critical Care Fellow, Children's Hospital of Michigan, Detroit MI

Abdullah Faiq MPH (2011 – 2014): NIEHS Special Volunteer and later contractor; MD, Howard University; currently Emergency Medicine physician, Inova Hospital, Fairfax, VA

Esther Habers<sup>#</sup> (2011 – 2016): Mentored portion of PhD thesis in Epidemiology, University of Utrecht, Utrecht, Netherlands: Project: Disease course and predictors of illness course in juvenile myositis; current position, Teacher/Coordinator, Honors College Faculteit der Sociale Wetenschappen, University Leiden, Leiden, The Netherlands

Nastaran Bayat<sup>#</sup> MD (2011 – 2016): NIEHS Special Volunteer; 2016 – present: Protocol Coordinator, Social and Scientific Systems, Inc., Bethesda, MD

Payam Farhadi MD (2011 – 6/2015, 5/2016 – present); NIEHS Special Volunteer and later Kelly's Service contractor, recipient 2015 DC Rheumatism Society Fellows Forum Poster award

Rodolfo Curiel<sup>###</sup> MD PhD (2014 – present): Chief, Division of Rheumatology, Associate Professor, Department of Medicine, George Washington University (Research mentor through GWU Myositis Clinic)

Michal Feldon<sup>#</sup> MD (2015 – 2016): Pediatric rheumatology fellow, Div. Rheumatology, Children's Hospital Medical Center, Dept Pediatrics, Univ. Cincinnati College of Medicine (mentorship committee- projects on quality of life in adult and juvenile myositis using MYOVISION registry); current position: Pediatric rheumatologist, Shamir Medical Center, Sackler School of Medicine, Tel Aviv, Israel

Maya Chudamani<sup>#</sup> (summer 2016): Montgomery Blair Math Science Magnet High School student, senior research project, Silver, Spring, MD (co-mentor with Raphaela Goldbach-Mansky, NIAID); Current position, Software Engineer, Microsoft, Seattle, WA

Albert Chow MD (2017 – 2019): Pediatric Rheumatology fellow, Seattle Children's/University of Washington, Seattle, WA (mentorship committee); Current position: Assistant Professor Pediatric Rheumatology, Loma Linda University



Harini Salgado<sup>#</sup> (summer 2017): NIEHS Summers of Discovery student, college student, Pomona College; Current position: Software Engineer, Amazon, Claremont, CA

Esther Lee<sup>#</sup> (summer 2017 – 2018): Special volunteer, Montgomery Blair Math Science Magnet High School, senior research project (co-mentor with Hanna Kim, NIAMS), Current position: Undergraduate student in Biology, Boston University

Fatima Gunter-Rahman<sup>#</sup> (summer 2018): NIEHS Summers of Discovery student, Massachusetts Institute of Technology college student, Current position: Harvard/MIT PhD student, Health Sciences and Technology Program

Joshua Woostenhulme PT DPT, PhD (2018 – 2019): Assistant Professor, Department of Health, Human Function & Rehabilitation Sciences, The George Washington University School of Medicine & Health Sciences (Research mentor through GWU Myositis Clinic); Current position: Assistant Professor, Idaho State University, Div. Health Sciences, Pocatello, ID

Liubing Li<sup>#</sup> (July 2018 – October 2019): PhD student, Peking Union Medical College, Tsinghua University, China Scholarship Council funding (co-mentor with Fred Miller); Current position: Internal medicine resident and Postdoctoral research fellow, Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

Mythri Ambatipudi<sup>#</sup> (May 2019 – September 2020): NIEHS Summers of Discovery student, EAG Special Volunteer; College student in Biomedical engineering, Harvard University; Current position: Medical student, Harvard Medical School

Jonathan Scalabrini (summer 2021), NIEHS Summers of Discovery student, virtual program, Brown University college student: Current position: Post-bac IRTA, NHLBI, NIH

Maya Goldberg<sup>#</sup> (2021 – 2022, summer 2022; Fall 2022 – present): Special Volunteer, NIEHS Summers of Discovery student, College student, University of Maryland

Iazmin Bauer Ventura<sup>###</sup> MD, MSc (2021 – present): Assistant Professor, Div. Rheumatology, University of Chicago

Didem Saygin, MD<sup>#</sup> (2021 – 2022), Rheumatology Fellow, University of Chicago, IMACS myositis mentor, Current position: Assistant Professor, Division of Rheumatology, University Pittsburgh

Anna Sparling<sup>#</sup> (summer 2023), Duke University undergraduate student (co-mentor with Kakali Sarkar)

# - indicates woman, ### - indicates underrepresented minority trainee

## **REPORT OF REGIONAL, NATIONAL, AND INTERNATIONAL INVITED TEACHING AND PRESENTATIONS**

### **Local Invited Presentations**

*No presentations below were sponsored by outside entities.*

National Institutes of Health Clinical Center Grand Rounds, September 29, 1993; “Juvenile idiopathic inflammatory myopathies” as part of Clinical staff conference “Myositis: Immunologic contributions to understanding causes, therapy”, P.H. Plotz, moderator

National Institutes of Health Clinical Center Grand Rounds, Bethesda, MD, May 27, 1999: “Lipodystrophy in Association with Autoimmune Disease” as part of Clinical Staff Conference; “The importance of Fat: Lipoatrophy, Insulin Resistance and Diabetes”, S. Taylor, moderator

Rheumatology Grand Rounds, George Washington University School of Medicine, Washington DC, March 29, 2007, “Juvenile Myositis”

Dermatology Grand Rounds, NCI, NIH, Bethesda, MD, August 14, 2008, “Adult and Juvenile Myositis” and case discussion, Phenotypes as Clues to Deciphering the Pathogenesis and Treatment of Myositis”, NIH Clinical Center Grand Rounds, Bethesda, MD, February 24, 2010

“Adult and Juvenile Idiopathic Inflammatory Myopathies”, Department of Medicine Grand Rounds, George Washington University, Washington, DC, May 31, 2012

- “Unraveling the Mysteries of Genes and the Environment in Children with Myositis”, NIEHS DIR Council, Bethesda, MD, February 11, 2014
- “Recent Advances in Myositis, Pathogenesis and Treatment: Developments in the Assessment and Treatment of Myositis”, NIH Clinical Center Grand Rounds, Bethesda, MD, June 20, 2018
- “Juvenile Myositis Phenotypes and their Genetic and Environmental Risk Factors”, Clinical Research Branch seminar, Bethesda, MD, October 11, 2018
- NIEHS Summer Intern Program Career Panel, virtual event, July 16, 2021
- “Selected EAG Achievements and Reflections on the 28 Years We Shared”, Terrance P. O’Hanlon PhD Retirement Symposium, virtual event, August 26, 2021
- “COVID-19 and Autoimmune Disease Research”, Office of NIH History and Stetten Museum, National Institutes of Health, Bethesda, MD, November 21, 2022 (Virtual presentation)

### **Regional**

- Those presentations below sponsored by outside entities are so noted and the sponsors are identified.*
- Rheumatology Grand Rounds, Georgetown University School of Medicine, “Juvenile Myositis”, Washington DC, October 25, 2006
- Department of Pediatrics Grand Rounds, Georgetown University School of Medicine, “Juvenile Myositis: A Clinical Update”, Washington DC, May 11, 2007
- Rheumatology Grand Rounds, Georgetown University Medical Center June 16, 2009
- “Juvenile Dermatomyositis: A Research Update”, Pediatric Grand Rounds, Uniformed Services University of the Health Sciences, Bethesda, MD, April 8, 2010
- “The Phenotypes of the Idiopathic Inflammatory Myopathies”, Medicine Grand Rounds, Washington Hospital Center, Washington DC, April 9, 2014

### **National**

- FDA Arthritis Advisory Committee Meeting, February 4-5, 1997: "Juvenile Rheumatoid Arthritis and the Proposed Application of the Pediatric Use Regulation"
- American Academy of Pediatrics, Rheumatology Subsection, November 2, 1997, New Orleans, LA: "The Spectrum of Childhood Inflammatory Myopathies"
- Workshop: Hands on Approach to the Diagnosis and Management of the Child with Rheumatic Disease: Juvenile Dermatomyositis. American Academy of Pediatrics meeting, Washington DC, October 10, 1999
- NIAMS Workshop on Inflammatory Myopathies, April 5-6, 2000, Bethesda, MD: “Juvenile Myositis: Clinical Overview”
- FDA Arthritis Advisory Committee Presentation, Closed Session, Gaithersburg, MD, April 11, 2000.
- American College of Rheumatology Pediatric Subsection Meeting. “Clinical and Serologic Classification of Juvenile Myositis”, October 30, 2000, Philadelphia, PA
- Joseph L Hollander Lectureship, Division of Rheumatology, “Pathogenesis of Dermatomyositis and Polymyositis” and “Myositis-specific and Myositis-associated Autoantibodies in the Juvenile Idiopathic Inflammatory Myopathies”, The Children’s Hospital of Philadelphia and The University of Pennsylvania School of Medicine, January 17, 2001, Philadelphia, PA
- NIAMS Intramural Research Program Workshop on Pediatric Rheumatic Diseases, “Juvenile Dermatomyositis: Future Research Needs”, February 16, 2001, Bethesda, MD
- American College of Rheumatology meeting, November 13, 2001, San Francisco, CA: Presentation of paper, “Lipodystrophy in juvenile dermatomyositis is associated with calcinosis, but not with adipocyte differentiation factor *dIk* levels.”
- “New Developments in the Juvenile Idiopathic Inflammatory Myopathies”, Grand Rounds, Department of Pediatrics, Stanford University, Palo Alto, CA, November 16, 2001

American College of Rheumatology meeting, October 29, 2002, New Orleans, LA: Presentation of 2 papers, "Extra muscular disease activity is frequent in adult and juvenile idiopathic inflammatory myopathies (IIM) and does not correlate with other myositis activity measures" and "Defining clinically relevant change in core set activity measures for adult and juvenile idiopathic inflammatory myopathies."

American College of Rheumatology meeting, Clinical Symposium, "Treatment of Refractory Juvenile Dermatomyositis", October 26, 2002, New Orleans, LA

Rheumatology Grand Rounds, Brigham, and Women's Hospital: Evaluation and Treatment of the Juvenile Idiopathic Inflammatory Myopathies, April 29, 2003, Boston, MA

Schlager Family Visiting Professor Lectureship in Juvenile Dermatomyositis April 30, 2003, Children's Hospital, Boston, MA: "Juvenile Idiopathic Inflammatory Myopathies: Lessons from the Children"

"Meet the Professor: Juvenile Dermatomyositis", American College of Rheumatology meeting, November 12/13, 2001, San Francisco, CA; October 26-27, 2002, New Orleans, LA; October 27-29, 2003; Orlando, FL; October 25/27, 2003, Orlando, FL

Rheumatology Grand Rounds, Hospital for Special Surgery, Cornell Medical College, NY, NY, Feb.11, 2004

Rheumatology Grand Rounds, University of Pittsburgh, Pittsburgh, PA. November 12, 2004

Rituximab in Myositis Investigator's Meeting, "Core Set Measures, including the MMT8, and the Definition of Improvement", and "Rituximab in Myositis Study Protocol" October 29, 2005, and February 6, 2006, Bethesda, MD

American Academy of Pediatrics Workshop, "Juvenile Dermatomyositis Dilemmas: A Case of Flare Following Remission". San Diego, CA, November 15, 2005

Clinical Immunology Society School for Autoimmune Diseases, "Juvenile Myositis". Faculty, Santa Fe, New Mexico, March 15 -18, 2006

Ann Hengel Lecture in Pediatric Rheumatology. "Juvenile Dermatomyositis" Medical College of Wisconsin, Milwaukee, Wisconsin. April 28, 2006

American College of Rheumatology, Pediatric Study Section, "Immunogenetic and Environmental Risk Factors for Juvenile Myositis", Washington DC, November 13, 2006

Faculty member, Clinical Immunology Society School for Autoimmune Diseases, "Immunogenetic and Environmental Risk Factors for Juvenile Myositis". Santa Fe, New Mexico, March 14 -18, 2007

Cure JM Foundation Educational Forum and Panel Discussion, "Juvenile Myositis: Assessing Outcomes and Potential New Therapies", Arlington, VA, October 27, 2007

"Rheumatic Disease Update: Adult and Juvenile Dermatomyositis/Polymyositis", American Rheumatology Health Professionals, Boston, MA, November 10, 2007

Department of Pediatrics Grand Rounds, Children's Memorial Hospital, Northwestern University School of Medicine, "Juvenile Myositis: A Research Perspective", Chicago, IL, November 16, 2007

Invited Participant, CARRA Consensus Conference to Develop Treatment Protocols for Juvenile Dermatomyositis, Toronto, Canada, November 30 - December 2, 2007

"Clinical Databases: Setup and Maintenance for Clinical Data Sharing", NIAMS Conference on SAPHO/Bechet's, Bethesda, MD, September 4, 2008

Invited participant and co-chair, Research opportunities breakout session, Food and Drug Administration Public Workshop on Developing a Consolidated Pediatric Rheumatology Observational Registry, Silver Spring, MD May 12-13, 2009.

Rheumatism Society of Houston, Invited Lecture and Rheumatology Grand Rounds, Texas Medical Center, University of Texas at Houston, "Juvenile Myositis: A Research Update", Houston, TX, August 23, 2009, and Visiting Professorship, Texas Children's Hospital, August 24, 2009

Invited speaker, Educational Forum, "Potential Complications of Juvenile Myositis" and "Research Update from NIH: Genetic and Environmental Factors", Cure JM Foundation. Austin, TX, February 13, 2010

“Practice Potpourri: What should I tell my patient with polymyositis who wants to exercise and lift weights?” American Rheumatology Health Professionals, Atlanta, GA, and “Making the Most of Your Fellowship Training”, American College of Rheumatology Fellows-in-Training mentoring session, Atlanta, GA, November 2010

“Juvenile Myositis: A Clinical and Research Update”, Pediatric Grand Rounds, Hackensack University Medical Center, Hackensack, NJ, May 12, 2011

“Cutaneous Assessment Tools for Dermatomyositis”, “International Myositis Classification Criteria Project”, “NIEHS Twin Sibling Study”, “TMA’s MYOVISION Registry”. CARRA meeting (JDM Working Group), Miami, FL, June 1-2, 2011.

“Juvenile Myositis: From Seattle’s Bedside to Bethesda,” Pediatric Grand Rounds, Children’s Hospital and Medical Center, Seattle, WA. June 23, 2011 (and Expert for Educational Forum on Juvenile Myositis, Cure JM Foundation)

Congressional Briefing, “Environmental Factors in Pediatric Autoimmune Diseases”, as part of Children’s Environmental Health briefing, Capitol Visitor’s Center, Washington DC, October 27, 2011

Congressional Briefing: “Environmental Factors in Autoimmune Disease” as part of “Multi-Generational Impact of Autoimmune Disease: America’s Silent Health Crisis”, Rayburn Building, Washington DC, March 28, 2012

Session Chair, Environmental Issues, “Sex, Gender and Autoimmunity Through the Lifespan”, American Autoimmune Related Diseases Association (AARDA), Chicago, IL, May 17, 2012

“Clinical Presentations and Diagnosis of Juvenile Myositis”, Cure JM Health Professions Meeting, Johns Hopkins University, Baltimore, MD, October 11, 2012 (and Expert for Educational Forum on Juvenile Myositis)

“International Myositis Classification Criteria for Adult and Juvenile Myositis” and “ACR-EULAR Myositis Response Criteria Project”, CARRA meeting, April 21, 2013, Chicago, IL

“Heterogeneity of Juvenile Myositis”, Cure JM Medical Conference, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, July 19, 2013

“International Myositis Classification Criteria for Adult and Juvenile Myositis” and “ACR-EULAR Myositis Response Criteria Project”, CARRA meeting, Orlando, FL, April 2, 2014

“Toward a Better Understanding of Adult and Juvenile Myositis: Phenotype, Phenotype, Phenotype”. Invited keynote speaker, University of Pennsylvania Rheumatology Research Training Day, Philadelphia, PA, June 17, 2014

“Assessment of JDM”, Juvenile Myositis: A 2014 Update on Care and Research: Cure JM Medical Conference, Stanford University, October 3, 2014

“Clinical and Autoantibody Phenotypes of Juvenile Myositis”, American College of Rheumatology meeting, Boston, MA, November 17, 2014

“Polymyositis and Dermatomyositis- Adult and Pediatric”, ARHP Clinical Focus Course- Clinical Advances in Rheumatic Diseases, A Case-Based Approach. American College of Rheumatology meeting, November 7, 2015, San Francisco, CA

“How to Apply the New Response Criteria for Juvenile Dermatomyositis in Clinic and Research”, American College of Rheumatology meeting, San Francisco, CA, November 11, 2015

“The New Classification and Response Criteria for Juvenile Dermatomyositis”, Juvenile Myositis: A 2016 Update on Care and Research, Johns Hopkins All Children’s Hospital, St Petersburg, FL, January 15, 2016

“Myositis Activity Assessment Using IMACS Core Set Measures”, Idera Pharmaceuticals Investigator meeting, January 23, 2016, remotely to Florida.

“Myositis Response Criteria, NIH Studies of Calcinosis and Other Myositis Updates”, CARRA annual meeting, Toronto, Canada, April 16, 2016

“Juvenile Myositis - Tales from the Other Side of JIA”, Dr. Carol Wallace Juvenile Arthritis Research Symposium, Seattle Children’s, May 14, 2016, Seattle WA

“Biologic Therapies for Juvenile Myositis”, Juvenile Myositis: A 2017 Update on Care and Research, Dell Children’s Hospital, February 17, 2017, Austin, TX

“The Many Faces of Juvenile Myositis”, Pediatric Grand Rounds, Suzanne Bowyer Memorial Lectureship, Riley Hospital for Children at Indiana University Health, September 13, 2017

Pediatric Residency Program Poster Tour Guide, American College of Rheumatology annual meeting, San Diego, CA, November 16, 2017

“Updates on Juvenile Myositis: Perspectives of IMACS and NIH”, CARRA Annual Meeting, Denver, CO, April 13, 2018

“Clinical Trials in JDM - Pitfalls and Lessons,” Pediatric Rheumatology Collaborative Study Group Advisory Council Bi-Annual meeting, June 9, 2018, Washington D.C.

“Juvenile Myositis”, Department of Medicine Grand Rounds, George Washington University, Cure JM Medical Conference and Educational Forum, Washington DC, June 29, 2018

Poster Tour Guide, Pediatric Lupus and Juvenile Myositis, and Moderator, Pediatric Rheumatology biomarker abstracts, American College of Rheumatology annual meeting, Chicago IL, October 21 and 24, 2018

“Current Adult and Juvenile Myositis Registries and Repositories”, American College of Rheumatology annual meeting, Chicago, IL, October 23, 2018

Update on juvenile myositis, Childhood Arthritis Rheumatology and Research Alliance annual meeting, Louisville, KY, April 12, 2019

“Juvenile Myositis Phenotypes”, Pediatric Grand Rounds, The Mary Jane Keller Memorial Lecture, Yale University School of Medicine, New Haven, CT, May 22, 2019

“Therapy of JDM: Past, Present and Emerging”, Cure JM Medical Conference Educational Forum, Lurie Children’s Hospital, Chicago, IL, June 21, 2019

“Dermatologic Aspects of Myositis”, Child Health Grand Rounds, University of Missouri, September 26, 2019, Columbia, MO

“Myositis Phenotypes in Adults and Children”, Cassidy Lectureship, 7<sup>th</sup> Annual James and Nancy Cassidy Rheumatology Symposium, Columbia, MO, September 27, 2019

Moderator and invited participant, US FDA Polyarticular Juvenile Idiopathic Arthritis Drug Development Workshop, Silver Spring, MD, October 2, 2019

Invited participant, Food and Drug Administration Listening Session on Inclusion Body Myositis, March 5, 2020, Silver Spring, MD

“Myositis Phenotypes in Adults and Children”, Rheumatology Grand Rounds, Columbia University, NY, NY, March 27, 2020 (conducted virtually by WebEx due to coronavirus pandemic and travel restrictions)

Panelist/discussant, CARRA Kawasaki Disease Workgroup Virtual Meeting, “COVID19-associated DK/Hyperinflammatory Syndromes: An Information Sharing Meeting on Research Initiatives”, June 5, 2020 (virtual meeting)

Panelist, Myositis Mentoring, American College of Rheumatology Convergence Meeting, November 8, 2020 (virtual meeting)

Panelist, Myositis Advisory Board, Myositis Interstitial Lung Disease, Boehringer-Ingelheim, December 8-9, 2020 (virtual meeting)

“NIEHS Intramural Research on Autoimmune Diseases” for National Academy of Sciences, Engineering and Medicine: Committee for the Assessment of NIH Research on Autoimmune Diseases, March 4, 2020 (virtual meeting)

“Juvenile Dermatomyositis”, Invited speaker, FDA Listening Session on Juvenile Dermatomyositis, organized by Cure JM Foundation, March 16, 2021 (virtual meeting)

Pediatric Grand Rounds and Pediatric Rheumatology visiting lectureship, UT Southwestern Medical School, Dallas, Texas, April 7-8, 2021 (virtual meeting)

- “Management of Calcinosis in Juvenile Dermatomyositis,” Lecture and Roundtable Discussion. American College of Rheumatology PRSYM meeting, May 20, 2021 (virtual)
- “Myositis Phenotypes in Adults and Children”, Rheumatology Grand Rounds, Hospital for Special Surgery, Cornell University Medical Center, New York, NY, October 13, 2021 (virtual)
- American College of Rheumatology Annual Meeting: Myositis Poster Tour (taped November 20, 2021), Meet the Experts of Juvenile Myositis (panel discussion, November 6, 2021), How to Get into the Myositis Field (panel discussion, November 7, 2021), virtual meeting.
- “Juvenile Myositis: Phenotypes, Factors and Therapies”, 9<sup>th</sup> Annual Kennedy Lecture, Pediatric Grand Rounds, University of Alabama School of Medicine, Birmingham, AL, November 11, 2021 (virtual)
- “Juvenile Myositis”, Lecture, Cincinnati Children’s Division of Rheumatology, Cincinnati, OH, February 25, 2022 (virtual)
- Rare Disease Day at NIH, Invited Panelist: Session: Our Journey with NIH- How one Rare Disease Organization Forged a Transformational Research Partnership”, February 28, 2022 (virtual), <https://youtu.be/TeYot56Ot1E>
- “Myositis in Adults and Children”, Rheumatology Grand Rounds, Beth Israel Deaconess Medical Center, Boston, MA, May 20, 2022 (virtual)
- “Juvenile Dermatomyositis”, American College of Rheumatology Virtual Rheumatology Practicum-Pediatric, August 2, 2022 (virtual)
- “Meet the Master: Myositis Panel”, Myositis Community Hub, American College of Rheumatology (ACR) Convergence 2022 meeting, Philadelphia, PA, November 14, 2022
- Moderator, “Juvenile Myositis: Beyond Consensus Treatment”, “New Pieces in the Muscle Puzzle: Recent Insights into Myositis”, “Abstract Session: Muscle Biology, Myositis, and Myopathies”, ACR Convergence 2022 meeting, Philadelphia, PA, November 12-14, 2022
- “Myositis Autoantibodies in Juvenile Myositis: What’s New”, ACR PRSYM Meeting, New Orleans, LA, March 30, 2023
- “Abatacept for Juvenile Dermatomyositis and Adult Myositis: A Tale of Two Discordant Trials”, Keynote Speaker, Juvenile Dermatomyositis: Advances in Basic Research, Translational Studies and Clinical Care, Cure JM Foundation and Duke University Symposium, May 13, 2023 (virtual)
- “Meet the Panel: Challenging Cases in Adult and Juvenile Myositis” ACR Convergence, November 12, 2023, San Diego, California (invited)

## **International**

- Park City IV International Pediatric Rheumatology Meeting, Allied Health Professionals section, March 18, 1998, Park City, Utah, “Clinical Evaluation and Management of Childhood Myositis”
- VI Pediatric Rheumatology European Congress/EULAR, Glasgow, Scotland, June 6, 1999: “Classification and epidemiology of the juvenile idiopathic inflammatory myopathies”
- “Acquired Lipodystrophy associated with Autoimmune Diseases”, First International Workshop on Lipotrophic Diabetes and other syndromes of Lipodystrophy, March 23, 2001, Bethesda, MD
- “Assessment of Disease Activity and Damage in Juvenile Dermatomyositis (JDM)”, and Invited Participant, International Consensus Conference to Define Core Sets of Outcome Measures for Juvenile Systemic Lupus Erythematosus and Juvenile Dermatomyositis, March 30 - April 4, 2001, Pavia, Italy
- Meeting Co-organizer, Moderator, and Presentation of several papers on Core Set Outcome Measures in Adult and Juvenile Myositis, for International Workshop on Myositis Outcome Measures and Clinical Trial Design Issues: Defining Improvement in Adult and Juvenile Myositis. November 9-10, 2001, Palace Hotel, San Francisco, CA
- “Scoring of the Cutaneous Manifestations of the MITAX and Myositis Damage Index”; Presentation of Sample Cases of Global Activity and Damage Ratings, and Myositis Workshop Participant in two Myositis Outcome Measure Workshops, London, England (May 2002, March 2001)

Meeting Co-organizer and Presentation of several papers (“Summary of the First Workshop”, “Top Candidate Definitions of Improvement for Adult and Juvenile Myositis”, “Clinical Trial Design Issues”, “Preliminary Study of Disease Damage in Adult and Juvenile Myositis using the Myositis Damage Index”), 2<sup>nd</sup> Workshop, Developing Consensus on Outcomes and Clinical Trial Design Issues in Adult and Juvenile Myositis, October 22 - 23, 2002, New Orleans, LA

American Academy of Pediatrics Pediatric Rheumatology 2003: Park City and Beyond: General Session, “Preliminary Definitions of Improvement for Juvenile and Adult Myositis” (March 26, 2003); Meet the Expert, “Juvenile Dermatomyositis” (March 23, 2003); Concurrent Session, “The Development of Outcome Measures for Juvenile Dermatomyositis” (March 23, 2003), Snowmass, CO

European League Against Rheumatism (EULAR) meeting, “Preliminary Definitions of Improvement for Adult and Juvenile Myositis” and moderated session on Difficult Cases of Myositis/Myopathies, June 20, 2003, Lisbon, Portugal

Invited Participant and Speaker, Pediatric Rheumatology International Trials Organization (PRINTO) International Consensus Conference on Defining Improvement in Juvenile Dermatomyositis. “IMACS Preliminary Definitions of Improvement for Juvenile and Adult Myositis”. September 29 - 30, 2003, Camogli, Italy

Meeting Co-Organizer and Presentation of “Summary of IMACS Definitions of Improvement”, “Future Plans for IMACS”, IMACS Annual Meeting, October 27, 2003, Orlando, FL

“Classification of Juvenile Myositis”, Working Group meeting on the Classification of Idiopathic Inflammatory Myopathies, October 26, 2004, Bethesda, MD

Meeting co-organizer and Moderator, The ACR-EULAR International Myositis Classification Criteria Project Working Group Workshop, Dulles, VA, November 10-11, 2005

Meeting co-organizer and presentation of “IMACS Internet Site” and “IMACS Outcomes Repository”, International Myositis Assessment and Clinical Studies Group (IMACS) Meeting, San Diego, CA, November 13, 2005

Meeting co-organizer and speaker, “IMACS Clinical Data Repository”, International Myositis Assessment and Clinical Studies Group (IMACS) Meeting, Washington, DC, November 14, 2006

Meeting co-organizer and speaker, “IMACS Outcomes Repository”, The International Myositis Assessment and Clinical Studies Group (IMACS) Meeting, Boston, MA, November 10, 2007

“Components and Predictors of Damage in Juvenile Myositis Using the Myositis Damage Index”, American College of Rheumatology Pediatric Rheumatology Meeting, Keystone, CO, March 4, 2008

Meeting co-organizer and co-moderator, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, San Francisco, CA, October 27, 2008

Meeting co-organizer and presentations: IMACS Outcomes Repository and IMACS Collaborations, International Myositis Assessment and Clinical Studies Group (IMACS) Annual Meeting, Philadelphia, PA, October 17, 2009

Meeting co-organizer and presentations: IMACS Outcomes Repository and IMACS Survey Results, International Myositis Assessment and Clinical Studies Group (IMACS) Annual Meeting, Atlanta, GA, November 7, 2010

“Myositis Autoantibody Phenotypes and the Environmental Connection”, Pediatric Rheumatology European Society, Valencia, Spain, September 11, 2011

“How to Assess and Treat Myositis”, Excellence in Rheumatology meeting, Madrid, Spain, January 27, 2012

“Myopathies: from Bedside to Bench”, “Meet the Professor: Treatment of juvenile inflammatory myopathies” and Lecture: “Treatment of Severe Juvenile Dermatomyositis”, XXIX Brazilian Congress of Rheumatology, Vitoria, Brazil, September 20-22, 2012

Co-organizer, International Myositis Classification Criteria Project Meeting, November 9, 2012, Bethesda, MD

Meeting co-organizer and presenter: IMACS Meeting Committee report and GWU Myositis Environmental Flare Study, International Myositis Assessment and Clinical Studies Group (IMACS) Annual Meeting, Washington, DC, November 12, 2012

Meeting co-organizer and presenter: IMACS Meeting Committee report and Myositis Response Criteria study, International Myositis Assessment and Clinical Studies Group (IMACS) Annual Meeting, San Diego, CA, September 12, 2013

“Assessment and Treatment of Juvenile Myositis”, Calgary Children’s Hospital, Alberta, Canada January 31, 2014

“Myositis Phenotypes and the Environmental Connection”, Autoimmune Disease Network Symposium, University of Calgary, Alberta, Canada, January 31, 2014

Meet the Professor Roundtable on Juvenile Dermatomyositis, ACR Pediatric Rheumatology Symposium (PRYSM), Orlando, FL, April 5, 2014

“IMACS Activity and Damage Measures” and “International Myositis Collaboration”, Invited keynote speaker, Canadian Inflammatory Myopathy Consortium meeting, Montreal, Canada, May 16, 2014

Meeting co-organizer, co-lead Pediatric Working Group, and speaker at International Consensus Conference to Develop Improvement Criteria for Juvenile Dermatomyositis and Adult Dermatomyositis and Polymyositis”, Paris France: “Prior Approaches: IMACS Core Set Measures and Preliminary Definitions of Improvement for Adult DM/PM and Juvenile Dermatomyositis”, “Development of New Definitions of Improvement for Myositis: Background on the Current Project”, “Presentation of Top Performing Newly Developed Definitions of Minimal Clinical Improvement and Moderate and Major Clinical Response”, “Combined Group Discussion of Results/Problem Areas from the Workshop, and Future Plans” Paris, France, June 9-10, 2014

Meeting Co-organizer and presenter, Myositis Response Criteria and Meeting and Rehabilitation/Exercise Committee reports, International Myositis Assessment and Clinical Studies Group (IMACS) Annual Meeting, Boston, MA, November 2014

Invited participant, international consensus conference on developing internationally agreed minimal dataset for juvenile dermatomyositis. Liverpool, England, March 22-24, 2015

“Clinical and Autoantibody Phenotypes of Juvenile Myositis and Associated Outcomes”, and “Improvement Criteria for Adult and Juvenile Myositis: Background on Methodology”, and Steering Committee member, First International Conference on Myositis, Stockholm, Sweden, May 8-11, 2015

Meeting co-organizer and presenter: “IMACS System: Past History, Validation and Publications”, “IMACS Core Set Measures for Muscle Weakness and Functional Disability”, and “Myositis Activity Assessment Tool and Myositis Damage Assessment”, 213<sup>th</sup>, ENMC Workshop: Outcome measures and clinical trial readiness in Idiopathic Inflammatory Myopathies (IIM), Heemskerk, The Netherlands, September 18-20, 2015

Meeting co-organizer and presenter, IMACS Meeting Committee report, International Myositis Assessment and Clinical Studies Group (IMACS) Annual Meeting, San Francisco, CA, November 8, 2015

Meeting co-organizer and presentation: Myositis Response Criteria, International Myositis Assessment and Clinical Studies (IMACS) Meeting, Washington DC, November 11, 2016

“Current Adult and Juvenile Myositis Repositories and Registries” and Lead Moderator, Research Directions in Juvenile Myositis”, The Second Global Conference on Myositis, Potomac, MD, May 5-8, 2017

Meet the Professor Roundtable on Juvenile Dermatomyositis, American College of Rheumatology Pediatric Rheumatology Symposium (PRYSM), Houston, TX, May 17-20, 2017



“Similarities and Differences between Juvenile and Adult Myositis”, 9<sup>th</sup> Myositis Workshop 2017, Tokyo, Japan, October 21, 2017

“The New Response Criteria and Approaches to the Treatment of Juvenile Myositis”, Metropolitan Pediatric Rheumatology Conference, Tokyo, Japan, October 23, 2017

Meeting co-organizer and presenter: Overview and Myositis Response Criteria web calculator, International Myositis Assessment and Clinical Studies Group (IMACS) Annual Meeting, San Diego, CA, November 4, 2017

“Update on the classification and treatment of the juvenile idiopathic inflammatory myopathies” 5<sup>th</sup> National Myositis Conference, Beijing, China, April 21, 2018

“Advances in the treatment of the juvenile idiopathic inflammatory myopathies” Department of Rheumatology, Beijing Children’s Hospital, Beijing, China, April 23, 2018

Meeting Co-organizer and presenter, IMACS mentoring program and new Scientific Interest Groups; posters: Microchimerism in juvenile dermatomyositis, MYOVISION: national US patient registry, and IMACS mentoring program, International Myositis Assessment and Clinical Studies Group (IMACS) Annual Meeting, Chicago IL, October 20, 2018

Session moderator, Pediatric Rheumatology - Clinical III: Assessment Tools and Biomarkers, and Poster Tour Leader- Pediatric rheumatology Clinical: Lupus, Sjogren’s Disease, & Myositis; American College of Rheumatology meeting, October 23-24, 2018, Chicago, IL

Co-Chair and Co-Moderator, Team Workshop on Juvenile Dermatomyositis, IMACS update; Workshop for Young Physicians/Researchers, 3<sup>rd</sup> Global conference on Myositis, Berlin, Germany, March 29-30, 2019

Meeting Co-organizer and presenter, IMACS business updates; IMACS mentoring program and new Scientific Interest Groups - oral and poster presentations. International Myositis Assessment and Clinical Studies Group (IMACS) Annual Meeting, Atlanta, GA, November 9, 2019

Session moderator, Pediatric Rheumatology - Clinical II: JIA, and Poster Tour Leader- Pediatric rheumatology- SLE, juvenile dermatomyositis and scleroderma; American College of Rheumatology meeting, November 10, 2019, Atlanta, GA

“Juvenile Dermatomyositis”, PROMISE Exclusive Class for Pediatric Rheumatologists, Webinar with pediatric rheumatologists in India, February 20, 2020

Meeting Co-organizer and presenter, “Overview of IMACS” and “IMACS Scientific Interest Groups”, Welcome to IMACS virtual meeting, September 30, 2020

Keynote speaker, 18th Indian National Pediatric Rheumatology Conference, October 3, 2020, New Delhi, India (virtual meeting), “Assessment of the Patient with Juvenile Myositis”, “Outcomes, Damage and Calcinosis”, discussant of clinical case presentations.

Meeting Co-organizer and presenter, “IMACS Business”, “Use of Telemedicine at the George Washington University Myositis Clinic”, “Tribute to Fred Miller”, IMACS Annual Meeting, November 18, 2020 (virtual meeting)

Invited Panelist, Myositis Mentorship, Myositis Community Hub, American College of Rheumatology meeting, November 7, 2020 (virtual)

Invited Panelist, Advisory Board Meeting, Myositis ILD, Boehringer Ingelheim, December 8-9, 2020 (virtual)

“Pattern Recognition: Juvenile Myositis” and “Correlation between Imaging and Clinical Assessment in Children”, 255th ENMC International Workshop: Muscle Imaging in Idiopathic Inflammatory Myopathies. January 16-22, 2021, Amsterdam, Netherlands (invited participant- virtual meeting)

Invited Mentor, “Disease endotypes - Defining disease endotypes, molecular disease classification”, CARRA Translational Medicine for Juvenile Myositis Working Group, March 4, 2021, Virtual meeting.

“Frederick Miller’s Career Overview and JDM Discoveries”, and Organizer, Frederick Miller Retirement Symposium, March 5, 2021, virtual meeting.

Meeting Co-organizer and presenter, “IMACS Overview and Business”, IMACS Annual Meeting, October 19, 2021 (virtual meeting)

Invited Panelist, Advisory Board Meeting, Juvenile Dermatomyositis, Pfizer, July 30, 2021; March 30, 2022 (virtual)

Invited Speaker and Panelist, “Juvenile Dermatomyositis: What’s New in Calcinosis” and “Management of Difficult Cases”, Virtual Advanced Course on Management of Connective Tissue Diseases, Virtual Winterschool 2022, Lausanne, Switzerland, March 19, 2022, virtual presentation

Invited speaker, “Contrasts in pathomechanisms and treatment targets between adult and paediatric inflammatory myositis”, Session on Inflammatory Myositis – What can we learn from each other? European League Against Rheumatism annual meeting, Copenhagen, Denmark, June 3, 2022, virtual presentation

4<sup>th</sup> Global Conference on Myositis: Moderator, Juvenile Myositis: Juvenile to Adult Transition; Poster Tour Leader; Led session International Myositis Assessment and Clinical Studies Group, June 6-9, 2022, Prague, Czech Republic

Invited Panelist, Advisory Board Meeting, Horizon Therapeutics, June 9, 2022, Prague, Czech Republic

Invited Panelist, Advisory Board Meeting, Dermatomyositis Therapeutic Needs, CSL Behring, June 21, 2022 (virtual)

Invited Participant, 255th ENMC International Workshop: Muscle Imaging in Idiopathic Inflammatory Myopathies. September 10-11, 2022, Amsterdam, Netherlands (hybrid meeting)

Invited Panelist, Advisory Board Meeting, Cabelletta Bio, January 30, 2023 (virtual)

## **REPORT OF CLINICAL ACTIVITIES AND INNOVATIONS**

### **Practice Activities:**

1994 – 2001: NIAMS Special Volunteer. Junior Medical Staff, NIH Clinical Center, Bethesda, MD. Principal investigator, juvenile myositis natural history study protocol in NIAMS- saw all pediatric rheumatology patients in the protocol (primarily with juvenile myositis), consultations in NIH Clinical Center related to juvenile myositis and other pediatric rheumatic diseases.

1994 – 2001: Attending physician, Pediatric rheumatology clinic, Walter Reed Army Medical Center, Washington, D.C.

2001 – present: Senior clinician in Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD. Senior Medical Staff, NIH Clinical Center, Bethesda, MD. Attending physician for all the unit’s pediatric patients, including clinical evaluation, treatment and communications with referring physicians and phone consultation with regional, national and international physicians. Also provide consults to other NIH institutes at the Clinical Center on pediatric rheumatic disease patients, including patients with myositis and related disorders, to NIAID, NHGRI (Undiagnosed Disease Program), NCI, NIAMS, NIDCR.

Sept 2008 – present: Attending physician, Myositis Clinic, Division of Rheumatology, Department of Medicine, George Washington University, Washington, DC. Consultant for regional, nationwide, and worldwide referrals for patients with juvenile myositis and other myopathies.

### **Clinical Innovations:**

Led development of several tools to clinically assess disease activity and damage in juvenile and adult myositis, which are now used nationally and internationally in clinical care and as outcome measures for myositis clinical studies and therapeutic trials. Developed training materials for these tools, which are hosted on the IMACS Group website (<https://www.niehs.nih.gov/research/resources/imacs/>).

Led development of response criteria for myositis. Initial development was of definitions of improvement for adult and juvenile dermatomyositis and polymyositis. Later developed ACR-EULAR myositis response criteria. These are now used internationally as clinical trial endpoints for adult and juvenile

dermatomyositis and polymyositis.

[https://www.niehs.nih.gov/research/resources/imacs/response\\_criteria/index.cfm](https://www.niehs.nih.gov/research/resources/imacs/response_criteria/index.cfm)

Senior author of EULAR-ACR International Myositis Classification Criteria for adult and juvenile dermatomyositis, polymyositis and inclusion body myositis.

<https://www.niehs.nih.gov/research/resources/imacs/classificationcriteria/index.cfm>

“The Myositis Response Criteria Programs” Invention Disclosure filed October 26, 2021 (NIH Reference # E-016-2022).

Co-chair the International Myositis Assessment and Clinical Studies Group (2001 – present), a consortium of more than 600 clinical and research specialists, biopharmaceutical, and patient organization representatives, interested in conducting collaborative clinical research to better the lives of children and adults with myositis to develop better therapies and improve understanding of the causes of these diseases. <https://www.niehs.nih.gov/research/resources/imacs/>

## **REPORT OF EDUCATION OF PATIENTS AND SERVICE TO THE COMMUNITY**

### **National Presentations**

*Those presentations below sponsored by outside entities are so noted and the sponsors are identified.*

Myositis Association of America Annual Conference. Workshop on Juvenile Myositis. October 14, 2000, Fairfax, VA

The Myositis Association Annual Conference. Medical Panel: “Similarities and Differences between Adult and Juvenile Idiopathic Inflammatory Myopathies” and Workshop on “Juvenile Myositis”, September 28, 2002, Atlanta, GA

Invited Alumni Panelist, Duke University Career Week, Durham, NC, January 31, 2004 (sessions on Science and Research, Women and Leadership)

“Juvenile Myositis Handbook”, The Myositis Association, Conference on Juvenile Myositis, May 9, 2004, Bethesda, MD

American Juvenile Arthritis Organization National Conference. “Juvenile Dermatomyositis” Workshop and Roundtable Discussion, Providence, RI, July 29, 2005

The Myositis Association Annual Conference. Medical Panel: “TMA’s Research Program and Funded Research on Juvenile Myositis” and Workshop on “Juvenile Myositis”, October 8, 2005, Cleveland, OH

Invited Alumni Panelist, “Medicine and Research”, Duke University Career Week, Durham, NC, January 28, 2006

“JM News from the NIH: Genetic and Environmental Studies”, Cure JM Annual Family Conference, Seattle, WA June 24, 2011

“The Clinical and Autoantibody Phenotypes of Juvenile Myositis” and “Focus on Disease Diagnostics: Muscle Strength and CMAS Testing”, Cure JM Annual Family Conference, Baltimore, MD, October 12-13, 2012

“Physical Therapy for Juvenile Myositis”, Cure JM Annual Family Conference, Chicago, IL, July 20, 2013

“Research Updates from the NIH and GWU Myositis Center”, Cure JM Annual Family Conference, January 16, 2016, St Petersburg, FL

“Past, Present and Future Therapies for Juvenile Myositis”, and “Clinical Trials for Juvenile Myositis”. Cure JM Annual Family Conference, February 18, 2017, Austin, TX

“New and Emerging Therapies for Juvenile Myositis”, Plenary Session and “Drug Discovery and Emerging Treatments”, Cure JM Family Conference, Alexandria, VA, June 30, 2018

“New and Emerging Treatments for Juvenile Myositis”, Plenary Session; “Understanding Lab Tests and Other Signs of Flare”, “Adding a Cure JM Center of Excellence to Your Care Team: The George Washington University Myositis Center”, Cure JM Family Conference, Oak Brook, IL, June 22, 2019

“COVID-19 Vaccine: What Families Need to Know”, Cure JM Town Hall, virtual, September 9, 2021

“Why Should I Consider Getting a Second Opinion for My JM Child”, Cure JM Town Hall, virtual, September 11, 2022

“Plenary Session: Key Advances in Juvenile Myositis Research Towards New Therapies”, “Genetics, Environmental Triggers and the Disease Process” and “Myositis Autoantibodies”, Cure JM Foundation Family Conference, June 29-July 1, 2023, Gaithersburg, MD

### **Educational Material for Patients and the Lay Community:**

**Rider LG**, Pachman LM, Miller FW and Bollar H, editors. Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers. 2007. The Myositis Association. Washington DC. (note: this book is also used by trainees and now available as an electronic book published by the Cure JM Foundation)

Juvenile Myositis: Information for Newly Diagnosed Families. Cure JM Foundation, 2010. (DVD) [https://www.curejm.org/fsn/video\\_for\\_the\\_newly\\_diagnosed.php](https://www.curejm.org/fsn/video_for_the_newly_diagnosed.php)

Co-author, “What is Juvenile Myositis” educational brochure, Cure JM Foundation, 2012

### **REPORT OF SCHOLARSHIP**

My NCBI Bibliography: <https://www.ncbi.nlm.nih.gov/myncbi/lisa.rider.1/bibliography/public/>

My ORCID: <http://orcid.org/0000-0002-6912-2458> (Scopus Author ID: 7006228500)

Web of Science: <http://www.webofscience.com/wos/author/record/C-7083-2018> (Researcher ID: C-7083-2018)

### **Peer-Reviewed Scholarship in print or other media:**

#### Research Investigations

1. Abramson S, Korchak H, Ludewig R, Edelson H, Haines K, Levin RI, Herman R, **Rider L**, Kimmel S, Weissmann G. Modes of action of aspirin-like drugs. Proc Natl Acad Sci U S A. 1985;82(21):7227-31. Epub 1985/11/01. doi: 10.1073/pnas.82.21.7227. PMID: 2997778; PMCID: PMC390822.
2. **Rider LG**, Niedel JE. Diacylglycerol accumulation and superoxide anion production in stimulated human neutrophils. J Biol Chem. 1987;262(12):5603-8. Epub 1987/04/25. PMID: 3032939.
3. Weissmann G, Korchak H, Ludewig R, Edelson H, Haines K, Levin RI, Herman R, **Rider L**, Kimmel S, Abramson S. Non-steroidal anti-inflammatory drugs: how do they work? Eur J Rheumatol Inflamm. 1987;8(1):6-17. Epub 1987/01/01. PMID: 3040419.
4. **Rider LG**, Dougherty RW, Niedel JE. Phorbol diesters and dioctanoylglycerol stimulate accumulation of both diacylglycerols and alkylacylglycerols in human neutrophils. J Immunol. 1988;140(1):200-7. Epub 1988/01/01. PMID: 2826587.
5. **Rider LG**, Wener MH, French J, Sherry DD, Mendelman PM. Autoantibody production in Kawasaki syndrome. Clin Exp Rheumatol. 1993;11(4):445-9. Epub 1993/07/01. PMID: 8403592.
6. **Rider LG**, Raben N, Miller L, Jelsema C. The cDNAs encoding two forms of the LYN protein tyrosine kinase are expressed in rat mast cells and human myeloid cells. Gene. 1994;138(1-2):219-22. Epub 1994/01/28. doi: 10.1016/0378-1119(94)90811-7. PMID: 8125304.

7. **Rider LG**, Miller FW, Targoff IN, Sherry DD, Samayoa E, Lindahl M, Wener MH, Pachman LM, Plotz PH. A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. *Arthritis Rheum.* 1994;37(10):1534-8. Epub 1994/10/01. doi: 10.1002/art.1780371019. PMID: 7945480.
8. **Rider LG**, Thapa PB, Del Beccaro MA, Gale JL, Foy HM, Farwell JR, Mendelman PM. Cerebrospinal fluid analysis in children with seizures. *Pediatr Emerg Care.* 1995;11(4):226-9. Epub 1995/08/01. doi: 10.1097/00006565-199508000-00009. PMID: 8532568.
9. **Rider LG\***, Hirasawa N\*, Santini F, Beaven MA. Activation of the mitogen-activated protein kinase cascade is suppressed by low concentrations of dexamethasone in mast cells. *J Immunol.* 1996;157(6):2374-80. Epub 1996/09/15. PMID: 8805635. \*These authors contributed equally.
10. **Rider LG**, Feldman BM, Perez MD, Rennebohm RM, Lindsley CB, Zemel LS, Wallace CA, Ballinger SH, Bowyer SL, Reed AM, Passo MH, Katona IM, Miller FW, Lachenbruch PA. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. *Arthritis Rheum.* 1997;40(11):1976-83. Epub 1997/11/19. doi: 10.1002/art.1780401109. PMID: 9365086.
11. **Rider LG**, Gurley RC, Pandey JP, Garcia de la Torre I, Kalovidouris AE, O'Hanlon TP, Love LA, Hennekam RC, Baumbach LL, Neville HE, Garcia CA, Klingman J, Gibbs M, Weisman MH, Targoff IN, Miller FW. Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. *Arthritis Rheum.* 1998;41(4):710-9. Epub 1998/04/29. doi: 10.1002/1529-0131(199804)41:4<710::Aid-art19>3.0.Co;2-k. PMID: 9550481.
12. Buyon JP, Hiebert R, Copel J, Craft J, Friedman D, Katholi M, Lee LA, Provost TT, Reichlin M, **Rider L**, Rupel A, Saleeb S, Weston WL, Skovron ML. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. *J Am Coll Cardiol.* 1998;31(7):1658-66. Epub 1998/06/17. doi: 10.1016/s0735-1097(98)00161-2. PMID: 9626848.
13. Summers RM, Brune AM, Choyke PL, Chow CK, Patronas NJ, Miller FW, White PH, Malley JD, **Rider LG**. Juvenile idiopathic inflammatory myopathy: exercise-induced changes in muscle at short inversion time inversion-recovery MR imaging. *Radiology.* 1998;209(1):191-6. Epub 1998/10/14. doi: 10.1148/radiology.209.1.9769831. PMID: 9769831.
14. **Rider LG**, Shamim E, Okada S, Pandey JP, Targoff IN, O'Hanlon TP, Kim HA, Lim YS, Han H, Song YW, Miller FW. Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: a tale of two loci. *Arthritis Rheum.* 1999;42(6):1285-90. Epub 1999/06/12. doi: 10.1002/1529-0131(199906)42:6<1285::Aid-anr28>3.0.Co;2-1. PMID: 10366124.
15. Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini EH, Hicks JE, Levinson JE, Mier R, Pachman LM, Passo MH, Perez MD, Reed AM, Schikler KN, Smith M, Zemel LS, **Rider LG**. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. *The Juvenile Dermatomyositis*

- Disease Activity Collaborative Study Group. *Arthritis Rheum.* 1999;42(10):2213-9. Epub 1999/10/19. doi: 10.1002/1529-0131(199910)42:10<2213::Aid-anr25>3.0.Co;2-8. PMID: 10524696.
16. **Rider LG\***, Artlett CM\*, Foster CB, Ahmed A, Neeman T, Chanock SJ, Jimenez SA, Miller FW. Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. *Clin Exp Immunol.* 2000;121(1):47-52. Epub 2000/07/11. doi: 10.1046/j.1365-2249.2000.01266.x. PMID: 10886238; PMCID: PMC1905682. \*These authors contributed equally.
  17. Kimball AB, Summers RM, Turner M, Dugan EM, Hicks J, Miller FW, **Rider LG**. Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy. *Arthritis Rheum.* 2000;43(8):1866-73. Epub 2000/08/16. doi: 10.1002/1529-0131(200008)43:8<1866::Aid-anr24>3.0.Co;2-6. PMID: 10943878.
  18. Wise RP, Salive ME, Braun MM, Mootrey GT, Seward JF, **Rider LG**, Krause PR. Postlicensure safety surveillance for varicella vaccine. *JAMA.* 2000;284(10):1271-9. Epub 2000/09/09. doi: 10.1001/jama.284.10.1271. PMID: 10979114.
  19. Artlett CM, Ramos R, Jimenez SA, Patterson K, Miller FW, **Rider LG**. Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Childhood Myositis Heterogeneity Collaborative Group. *Lancet.* 2000;356(9248):2155-6. Epub 2001/02/24. doi: 10.1016/s0140-6736(00)03499-1. PMID: 11191545.  
**Erratum:** Postlicensure safety surveillance for varicella vaccine (Journal of American Medical Association (September 13, 2000) 284 (1271-1279)). *JAMA.* 2000;284(24):3129.
  20. Huber AM, Hicks JE, Lachenbruch PA, Perez MD, Zemel LS, Rennebohm RM, Wallace CA, Lindsley CB, Passo MH, Ballinger SH, Bowyer SL, Reed AM, White PH, Katona IM, Miller FW, **Rider LG\***, Feldman BM\*, Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. *J Rheumatol.* 2001;28(5):1106-11. Epub 2001/05/22. PMID: 11361197. \*These authors contributed equally.
  21. Miller FW\*, **Rider LG\***, Chung YL, Cooper R, Danko K, Farewell V, Lundberg I, Morrison C, Oakley L, Oakley I, Pilkington C, Vencovsky J, Vincent K, Scott DL, Isenberg DA, International Myositis Outcome Assessment Collaborative Study Group. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. *Rheumatology (Oxford).* 2001;40(11):1262-73. doi: 10.1093/rheumatology/40.11.1262 . PMID: 11709610. \*These authors contributed equally.
  22. Artlett CM, Miller FW, **Rider LG**. Persistent maternally derived peripheral microchimerism is associated with the juvenile idiopathic inflammatory myopathies. *Rheumatology (Oxford).* 2001;40(11):1279-84. Epub 2001/11/16. doi: 10.1093/rheumatology/40.11.1279. PMID: 11709612.

23. Hicks JE, Drinkard B, Summers RM, **Rider LG**. Decreased aerobic capacity in children with juvenile dermatomyositis. *Arthritis Rheum.* 2002;47(2):118-23. Epub 2002/04/16. doi: 10.1002/art.10237. PMID: 11954004.
24. Shamim EA, **Rider LG**, Pandey JP, O'Hanlon TP, Jara LJ, Samayoa EA, Burgos-Vargas R, Vazquez-Mellado J, Alcocer-Varela J, Salazar-Paramo M, Kutzbach AG, Malley JD, Targoff IN, Garcia-De la Torre I, Miller FW. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. *Arthritis Rheum.* 2002;46(7):1885-93. Epub 2002/07/19. doi: 10.1002/art.10358. PMID: 12124873.
25. **Rider LG\***, Schiffenbauer AS\*, Zito M, Lim KL, Ahmed A, Zemel LS, Rennebohm RM, Passo MH, Summers RM, Hicks JE, Lachenbruch PA, Heyes MP, Miller FW, Juvenile Dermatomyositis Disease Activity Collaboration Study Group. Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. *Clin Chem.* 2002;48(10):1681-8. Epub 2002/09/27. PMID: 12324484. \*These authors contributed equally.
26. **Rider LG**, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, Lachenbruch PA, Miller FW, International Myositis Assessment Clinical Studies Group. Defining Clinical Improvement in Adult and Juvenile Myositis. *J Rheumatol.* 2003;30(3):603-17. Epub 2003/03/01. PMID: 12610824.
27. Artlett CM, O'Hanlon TP, Lopez AM, Song YW, Miller FW, **Rider LG**. HLA-DQA1 is not an apparent risk factor for microchimerism in patients with various autoimmune diseases and in healthy individuals. *Arthritis Rheum.* 2003;48(9):2567-72. Epub 2003/09/18. doi: 10.1002/art.11235. PMID: 13130476.
28. Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM, Garay S, Kuis W, Machado C, Pachman L, Prieur AM, **Rider LG**, Silverman E, Tsitsami E, Woo P, Giannini EH, Martini A. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. *Rheumatology (Oxford).* 2003;42(12):1452-9. Epub 2003/07/02. doi: 10.1093/rheumatology/keg403. PMID: 12832713.
29. Drinkard BE, Hicks J, Danoff J, **Rider LG**. Fitness as a determinant of the oxygen uptake/work rate slope in healthy children and children with inflammatory myopathy. *Can J Appl Physiol.* 2003;28(6):888-97. Epub 2004/03/03. doi: 10.1139/h03-063. PMID: 14992126.
30. Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, Oddis C, Pilkington C, Plotz P, Scott D, Vencovsky J, Cooper R, **Rider L**, Miller F. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. *Rheumatology (Oxford).* 2004;43(1):49-54. Epub 2003/07/18. doi: 10.1093/rheumatology/keg427. PMID: 12867580.
31. Lohmann Siegel K, Hicks JE, Koziol DE, Gerber LH, **Rider LG**. Walking ability and its relationship to lower-extremity muscle strength in children with idiopathic inflammatory myopathies. *Arch Phys Med Rehabil.* 2004;85(5):767-71. Epub 2004/05/07. doi: 10.1016/j.apmr.2003.07.005. PMID: 15129401.

32. Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, Zemel LS, Wallace CA, Ballinger SH, Passo MH, Reed AM, Summers RM, White PH, Katona IM, Miller FW, Lachenbruch PA, **Rider LG**. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. *Arthritis Rheum.* 2004;50(5):1595-603. Epub 2004/05/18. doi: 10.1002/art.20179. PMID: 15146430.
33. Rennebohm RM, Jones K, Huber AM, Ballinger SH, Bowyer SL, Feldman BM, Hicks J, Katona IM, Lindsley CB, Miller FW, Passo MH, Perez MD, Reed AM, Wallace CA, White PH, Zemel LS, Lachenbruch PA, Hayes JR, **Rider LG**, International Myositis A, Clinical Studies G. Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. *Arthritis Rheum.* 2004;51(3):365-70. Epub 2004/06/10. doi: 10.1002/art.20397. PMID: 15188320.
34. **Rider LG**, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, Lachenbruch PA, Miller FW. International consensus on preliminary definitions of improvement in adult and juvenile myositis. *Arthritis Rheum.* 2004;50(7):2281-90. Epub 2004/07/13. doi: 10.1002/art.20349. PMID: 15248228.
35. Chung YL, **Rider LG**, Bell JD, Summers RM, Zemel LS, Rennebohm RM, Passo MH, Hicks J, Miller FW, Scott DL. Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies. *Arthritis Rheum.* 2005;53(4):565-70. Epub 2005/08/06. doi: 10.1002/art.21331. PMID: 16082628.
36. Oddis CV\*, **Rider LG\***, Reed AM, Ruperto N, Brunner HI, Koneru B, Feldman BM, Giannini EH, Miller FW. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. *Arthritis Rheum.* 2005;52(9):2607-15. Epub 2005/09/06. doi: 10.1002/art.21291. PMID: 16142757. \*These authors contributed equally.
37. Mamyrova G, **Rider LG**, Haagenson L, Wong S, Brown KE. Parvovirus B19 and onset of juvenile dermatomyositis. *JAMA.* 2005;294(17):2170-1. Epub 2005/11/03. doi: 10.1001/jama.294.17.2170. PMID: 16264157.
38. O'Hanlon TP, Carrick DM, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel PA, Malley JD, Malley K, Dreyfuss J, Shamim EA, **Rider LG**, Chanock SJ, Foster CB, Bunch T, Plotz PH, Love LA, Miller FW. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in Caucasians. *Medicine (Baltimore).* 2005;84(6):338-49. Epub 2005/11/04. doi: 10.1097/01.md.0000189818.63141.8c. PMID: 16267409.
39. Nagaraju K, **Rider LG**, Fan C, Chen YW, Mitsak M, Rawat R, Patterson K, Grundtman C, Miller FW, Plotz PH, Hoffman E, Lundberg IE. Endothelial cell activation and neovascularization are prominent in dermatomyositis. *J Autoimmune Dis.* 2006;3:2. Epub 2006/03/01. doi: 10.1186/1740-2557-3-2. PMID: 16504012; PMCID: PMC1397829.
40. Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, Turner ML, Akpek G, Gilman A, McDonald G, Schubert M, Berger A, Bross P, Chien JW, Couriel D, Dunn JP, Fall-Dickson J, Farrell A, Flowers ME, Greinix H, Hirschfeld S, Gerber L, Kim S, Knobler R, Lachenbruch PA, Miller FW, Mittleman B, Papadopoulos E, Parsons SK, Przepiorka D, Robinson M, Ward M, Reeve B, **Rider LG**, Shulman H, Schultz KR, Weisdorf D, Vogelsang GB.



Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. *Biol Blood Marrow Transplant*. 2006;12(3):252-66. Epub 2006/03/01. doi: 10.1016/j.bbmt.2006.01.008. PMID: 16503494.

41. O'Hanlon TP, Carrick DM, Targoff IN, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel PA, Malley JD, Malley K, Shamim EA, **Rider LG**, Chanock SJ, Foster CB, Bunch T, Blackshear PJ, Plotz PH, Love LA, Miller FW. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. *Medicine (Baltimore)*. 2006;85(2):111-27. Epub 2006/04/13. doi: 10.1097/01.md.0000217525.82287.eb. PMID: 16609350.
42. O'Hanlon TP, **Rider LG**, Mamyrova G, Targoff IN, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel PA, Malley JD, Malley K, Shamim EA, Chanock SJ, Foster CB, Bunch T, Reed AM, Love LA, Miller FW. HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. *Arthritis Rheum*. 2006;54(11):3670-81. Epub 2006/11/01. doi: 10.1002/art.22205. PMID: 17075818.
43. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, Miller FW\*, **Rider LG\***. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. *Arthritis Rheum*. 2006;54(11):3682-9. Epub 2006/11/01. doi: 10.1002/art.22164. PMID: 17075819. \*These authors contributed equally.
44. Mamyrova G, O'Hanlon TP, Monroe JB, Carrick DM, Malley JD, Adams S, Reed AM, Shamim EA, James-Newton L, Miller FW, **Rider LG**. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. *Arthritis Rheum*. 2006;54(12):3979-87. Epub 2006/11/30. doi: 10.1002/art.22216. PMID: 17133612; PMCID: PMC2063456.
45. Jain M, Smith M, Cintas H, Koziol D, Wesley R, Harris-Love M, Lovell D, **Rider LG**, Hicks J. Intra-rater and inter-rater reliability of the 10-point Manual Muscle Test (MMT) of strength in children with juvenile idiopathic inflammatory myopathies (JIIM). *Phys Occup Ther Pediatr*. 2006;26(3):5-17. Epub 2006/09/13. doi: 10.1300/J006v26n03\_02. PMID: 16966313.
46. Vegosen LJ, Weinberg CR, O'Hanlon TP, Targoff IN, Miller FW, **Rider LG**. Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures. *Arthritis Rheum*. 2007;56(8):2719-28. Epub 2007/08/01. doi: 10.1002/art.22751. PMID: 17665425; PMCID: PMC2151046.
47. Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, Lindsley CB, Rennebohm RM, Wallace CA, Passo MH, Reed AM, Bowyer SL, Ballinger SH, Miller FW, **Rider LG**. The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy. *Rheumatology (Oxford)*. 2007;46(10):1606-11. Epub 2007/09/25. doi: 10.1093/rheumatology/kem179. PMID: 17890275; PMCID: PMC2598780.
48. Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, Lindsley CB, Rennebohm RM, Wallace CA, Passo MH, Reed AM, Bowyer SL, Ballinger SH, Miller FW, **Rider LG**, Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Preliminary

validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. *Arthritis Rheum.* 2008;59(2):214-21. Epub 2008/02/02. doi: 10.1002/art.23340. PMID: 18240194.

49. Huber AM, Lachenbruch PA, Dugan EM, Miller FW, **Rider LG**, Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Alternative scoring of the cutaneous assessment tool in juvenile dermatomyositis: Results using abbreviated formats. *Arthritis Rheum-Arthritis Care Res.* 2008;59(3):352-6. Epub 2008/03/04. doi: 10.1002/art.23313. PMID: 18311761; PMCID: PMC2598766.
50. Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, Kleiner D, James-Newton L, Targoff IN, Pandey JP, Carrick DM, Sebring N, O'Hanlon TP, Ruiz-Hidalgo M, Turner M, Gordon LB, Laborda J, Bauer SR, Blackshear PJ, Imundo L, Miller FW, **Rider LG**. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. *Medicine (Baltimore).* 2008;87(2):70-86. Epub 2008/03/18. doi: 10.1097/MD.0b013e31816bc604. PMID: 18344805; PMCID: PMC2674585.
51. O'Hanlon TP, **Rider LG**, Schiffenbauer A, Targoff IN, Malley K, Pandey JP, Miller FW. Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. *Arthritis Rheum.* 2008;58(10):3239-46. Epub 2008/09/30. doi: 10.1002/art.23899. PMID: 18821675; PMCID: PMC2682358.
52. Mamyrova G, O'Hanlon TP, Sillers L, Malley K, James-Newton L, Parks CG, Cooper GS, Pandey JP, Miller FW, **Rider LG**. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. *Arthritis Rheum.* 2008;58(12):3941-50. Epub 2008/11/28. doi: 10.1002/art.24039. PMID: 19035492; PMCID: PMC2674642.
53. Lachenbruch PA, Miller FW, **Rider LG**. On Determining the Effects of Therapy on Disease Damage in Non- randomized Studies with Multiple Treatments: A study of Juvenile Myositis. *Commun Stat Theory Methods.* 2009;38(18):3268-81. Epub 2009/01/01. doi: 10.1080/03610920802468681. PMID: 20209035; PMCID: PMC2832328.
54. Harris-Love MO, Shrader JA, Koziol D, Pahlajani N, Jain M, Smith M, Cintas HL, McGarvey CL, James-Newton L, Pokrovnichka A, Moini B, Cabalar I, Lovell DJ, Wesley R, Plotz PH, Miller FW, Hicks JE, **Rider LG**. Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. *Rheumatology (Oxford).* 2009;48(2):134-9. Epub 2008/12/17. doi: 10.1093/rheumatology/ken441. PMID: 19074186; PMCID: PMC2634286.
55. Eidelman N, Boyde A, Bushby AJ, Howell PG, Sun J, Newbury DE, Miller FW, Robey PG, **Rider LG**. Microstructure and mineral composition of dystrophic calcification associated with the idiopathic inflammatory myopathies. *Arthritis Res Ther.* 2009;11(5):R159. Epub 2009/10/28. doi: 10.1186/ar2841. PMID: 19857267; PMCID: PMC2787294.
56. **Rider LG**, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldman BM, Villalba ML, Myones BL, Pachman LM, Rennebohm RM, Reed AM, Miller FW. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. *Arthritis Rheum.* 2009;60(11):3425-35. Epub 2009/10/31. doi: 10.1002/art.24904. PMID: 19877055; PMCID: PMC2793533.

57. Coyle K, Rother KI, Weise M, Ahmed A, Miller FW, **Rider LG**. Metabolic abnormalities and cardiovascular risk factors in children with myositis. *J Pediatr*. 2009;155(6):882-7. Epub 2009/08/01. doi: 10.1016/j.jpeds.2009.06.009. PMID: 19643439; PMCID: PMC2809424.
58. Javierre BM, Fernandez AF, Richter J, Al-Shahrour F, Martin-Subero JI, Rodriguez-Ubrega J, Berdasco M, Fraga MF, O'Hanlon TP, **Rider LG**, Jacinto FV, Lopez-Longo FJ, Dopazo J, Forn M, Peinado MA, Carreño L, Sawalha AH, Harley JB, Siebert R, Esteller M, Miller FW, Ballestar E. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. *Genome Res*. 2010;20(2):170-9. Epub 2009/12/24. doi: 10.1101/gr.100289.109. PMID: 20028698; PMCID: PMC2813473.
59. Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, Pachman LM, Pilkington C, Reed AM, Rennebohm RM, **Rider LG**, Wallace CA, Feldman BM. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. *Arthritis Care Res (Hoboken)*. 2010;62(2):219-25. doi: 10.1002/acr.20071. PMID: 20191521; PMCID: PMC2909837.
60. **Rider LG**, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, Feldman BM, Wright SJ, Lindsley CB, Pachman LM, Villalba ML, Lovell DJ, Bowyer SL, Plotz PH, Miller FW, Hicks JE. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. *Arthritis Care Res (Hoboken)*. 2010;62(4):465-72. Epub 2010/04/15. doi: 10.1002/acr.20035. PMID: 20391500; PMCID: PMC2924143.
61. Ruperto N, Pistorio A, Ravelli A, **Rider LG**, Pilkington C, Oliveira S, Wulffraat N, Espada G, Garay S, Cuttica R, Hofer M, Quartier P, Melo-Gomes J, Reed AM, Wierzbowska M, Feldman BM, Harjacek M, Huppertz HI, Nielsen S, Flato B, Lahdenne P, Michels H, Murray KJ, Punaro L, Rennebohm R, Russo R, Balogh Z, Rooney M, Pachman LM, Wallace C, Hashkes P, Lovell DJ, Giannini EH, Gare BA, Martini A. The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. *Arthritis Care Res (Hoboken)*. 2010;62(11):1533-41. Epub 2010/06/29. doi: 10.1002/acr.20280. PMID: 20583105; PMCID: PMC2964396.
62. **Rider LG**, Wu L, Mamyrova G, Targoff IN, Miller FW. Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies. *Rheumatology (Oxford)*. 2010;49(12):2381-90. Epub 2010/08/31. doi: 10.1093/rheumatology/keq277. PMID: 20802007; PMCID: PMC2981509.
63. O'Hanlon TP, **Rider LG**, Gan L, Fannin R, Paules RS, Umbach DM, Weinberg CR, Shah RR, Mav D, Gourley MF, Miller FW. Gene expression profiles from discordant monozygotic twins suggest that molecular pathways are shared among multiple systemic autoimmune diseases. *Arthritis Res Ther*. 2011;13(2):R69. Epub 2011/04/28. doi: 10.1186/ar3330. PMID: 21521520; PMCID: PMC3132064.
64. Katz JD, Mamyrova G, Agarwal S, Jones OY, Bollar H, Huber AM, **Rider LG**, White PH. Parents' perception of self-advocacy of children with myositis: an anonymous online survey. *Pediatr Rheumatol Online J*. 2011;9(1):10. Epub 2011/06/09. doi: 10.1186/1546-0096-9-10. PMID: 21649897; PMCID: PMC3118375.

65. O'Hanlon TP, Li Z, Gan L, Gourley MF, **Rider LG**, Miller FW. Plasma proteomic profiles from disease-discordant monozygotic twins suggest that molecular pathways are shared in multiple systemic autoimmune diseases. *Arthritis Res Ther.* 2011;13(6):R181. Epub 2011/11/03. doi: 10.1186/ar3506. PMID: 22044644; PMCID: PMC3315681.
66. Forsberg LA, Rasi C, Razzaghian HR, Pakalapati G, Waite L, Thilbeault KS, Ronowicz A, Wineinger NE, Tiwari HK, Boomsma D, Westerman MP, Harris JR, Lyle R, Essand M, Eriksson F, Assimes TL, Iribarren C, Strachan E, O'Hanlon TP, **Rider LG**, Miller FW, Giedraitis V, Lannfelt L, Ingelsson M, Piotrowski A, Pedersen NL, Absher D, Dumanski JP. Age-related somatic structural changes in the nuclear genome of human blood cells. *Am J Hum Genet.* 2012;90(2):217-28. Epub 2012/02/07. doi: 10.1016/j.ajhg.2011.12.009. PMID: 22305530; PMCID: PMC3276669.
67. Volochayev R, Csako G, Wesley R, **Rider LG**, Miller FW. Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ Among Clinical and Demographic Groups. *Open Rheumatol J.* 2012;6:54-63. Epub 2012/06/23. doi: 10.2174/1874312901206010054. PMID: 22723809; PMCID: PMC3377888.
68. Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, Miller FW, **Rider LG**. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. *Medicine (Baltimore).* 2013;92(1):25-41. Epub 2012/12/25. doi: 10.1097/MD.0b013e31827f264d. PMID: 23263716; PMCID: PMC4580479.
69. Oddis CV, Reed AM, Aggarwal R, **Rider LG**, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. *Arthritis Rheum.* 2013;65(2):314-24. Epub 2012/11/06. doi: 10.1002/art.37754. PMID: 23124935; PMCID: PMC3558563.
70. Parks CG, D'Aloisio AA, DeRoo LA, Huiber K, **Rider LG**, Miller FW, Sandler DP. Childhood socioeconomic factors and perinatal characteristics influence development of rheumatoid arthritis in adulthood. *Ann Rheum Dis.* 2013;72(3):350-6. Epub 2012/05/16. doi: 10.1136/annrheumdis-2011-201083. PMID: 22586176; PMCID: PMC5029277.
71. Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C, Wulffraat NM, Malattia C, Garay SM, Hofer M, Quartier P, Dolezalova P, Penades IC, Ferriani VP, Ganser G, Kasapcopur O, Melo-Gomes JA, Reed AM, Wierzbowska M, **Rider LG**, Martini A, Ruperto N. The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. *Ann Rheum Dis.* 2013;72(5):686-93. Epub 2012/06/28. doi: 10.1136/annrheumdis-2012-201483. PMID: 22736096; PMCID: PMC5040631.
72. Shah M, Targoff IN, Rice MM, Miller FW, **Rider LG**. Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. *Arthritis Rheum.* 2013;65(7):1934-41. Epub 2013/05/10. doi: 10.1002/art.37985. PMID: 23658122; PMCID: PMC3727975. (**NIEHS Environmental Factor August 2013 Intramural Paper of the Month**)
73. **Rider LG**, Shah M\*, Mamyrova G\*, Huber AM, Rice MM, Targoff IN, Miller FW. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. *Medicine*

(Baltimore). 2013;92(4):223-43. Epub 2013/07/24. doi: 10.1097/MD.0b013e31829d08f9. PMID: 23877355; PMCID: PMC3721421. \*These authors contributed equally.

74. Razzaghian HR, Forsberg LA, Prakash KR, Przerada S, Paprocka H, Zywicka A, Westerman MP, Pedersen NL, O'Hanlon TP, **Rider LG**, Miller FW, Srutek E, Jankowski M, Zegarski W, Piotrowski A, Absher D, Dumanski JP. Post-zygotic and inter-individual structural genetic variation in a presumptive enhancer element of the locus between the IL10R $\beta$  and IFNAR1 genes. PLoS One. 2013;8(9):e67752. Epub 2013/09/12. doi: 10.1371/journal.pone.0067752. PMID: 24023707; PMCID: PMC3762855.
75. Mamyrova G, Katz JD, Jones RV, Targoff IN, Lachenbruch PA, Jones OY, Miller FW, **Rider LG**. Clinical and laboratory features distinguishing juvenile polymyositis and muscular dystrophy. Arthritis Care Res (Hoboken). 2013;65(12):1969-75. Epub 2013/08/09. doi: 10.1002/acr.22088. PMID: 23925923; PMCID: PMC5083635.
76. Miller FW\*, Cooper RG\*, Vencovský J, **Rider LG**, Danko K, Wedderburn LR, Lundberg IE, Pachman LM, Reed AM, Ytterberg SR, Padyukov L, Selva-O'Callaghan A, Radstake TR, Isenberg DA, Chinoy H, Ollier WE, O'Hanlon TP, Peng B, Lee A, Lamb JA, Chen W, Amos CI\*\*, Gregersen PK\*\*. Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum. 2013;65(12):3239-47. Epub 2013/08/29. doi: 10.1002/art.38137. PMID: 23983088; PMCID: PMC3934004.  
\*,\*\*These authors contributed equally to this work.  
**(NIEHS Environmental Factor November 2013 Intramural Paper of the Month)**
77. Gan L, O'Hanlon TP, Gordon AS, **Rider LG**, Miller FW, Burbelo PD. Twins discordant for myositis and systemic lupus erythematosus show markedly enriched autoantibodies in the affected twin supporting environmental influences in pathogenesis. BMC Musculoskelet Disord. 2014;15:67. Epub 2014/03/08. doi: 10.1186/1471-2474-15-67. PMID: 24602337; PMCID: PMC3973849.
78. Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, **Rider LG**, Harris-Love MO, Levesque MC, Oddis CV. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol. 2014;66(3):740-9. Epub 2014/02/28. doi: 10.1002/art.38270. PMID: 24574235; PMCID: PMC3987896.
79. Huber AM, Mamyrova G, Lachenbruch PA, Lee JA, Katz JD, Targoff IN, Miller FW, **Rider LG**. Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken). 2014;66(5):732-40. Epub 2013/10/24. doi: 10.1002/acr.22212. PMID: 24151254; PMCID: PMC4646219.
80. **Rider LG**, Yip AL, Horkayne-Szakaly I, Volochayev R, Shrader JA, Turner ML, Kong HH, Jain MS, Jansen AV, Oddis CV, Fleisher TA, Miller FW. Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial. Clin Exp Rheumatol. 2014;32(5):689-96. Epub 2014/07/30. PMID: 25068290; PMCID: PMC4644185.
81. Wing S, **Rider LG**, Johnson JR, Miller FW, Matteson EL, Crowson CS, Gabriel SE. Do solar cycles influence giant cell arteritis and rheumatoid arthritis incidence? BMJ Open.

2015;5(5):e006636. Epub 2015/05/17. doi: 10.1136/bmjopen-2014-006636. PMID: 25979866; PMCID: PMC4442155.

82. Artlett CM, Sassi-Gaha S, Ramos RC, Miller FW, **Rider LG**. Chimeric cells of maternal origin do not appear to be pathogenic in the juvenile idiopathic inflammatory myopathies or muscular dystrophy. *Arthritis Res Ther*. 2015;17(1):238. Epub 2015/09/05. doi: 10.1186/s13075-015-0732-0. PMID: 26338728; PMCID: PMC4558637.
83. Miller FW, Chen W, O'Hanlon TP, Cooper RG, Vencovsky J, **Rider LG**, Danko K, Wedderburn LR, Lundberg IE, Pachman LM, Reed AM, Ytterberg SR, Padyukov L, Selva-O'Callaghan A, Radstake TR, Isenberg DA, Chinoy H, Ollier WE, Scheet P, Peng B, Lee A, Byun J, Lamb JA, Gregersen PK, Amos CI. Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. *Genes Immun*. 2015;16(7):470-80. Epub 2015/08/21. doi: 10.1038/gene.2015.28. PMID: 26291516; PMCID: PMC4840953.
84. Gan L, O'Hanlon TP, Lai Z, Fannin R, Weller ML, **Rider LG**, Chiorini JA, Miller FW. Gene Expression Profiles from Disease Discordant Twins Suggest Shared Antiviral Pathways and Viral Exposures among Multiple Systemic Autoimmune Diseases. *PLoS One*. 2015;10(11):e0142486. Epub 2015/11/12. doi: 10.1371/journal.pone.0142486. PMID: 26556803; PMCID: PMC4640563.
85. Van der Stap DK, **Rider LG**, Alexanderson H, Huber AM, Gualano B, Gordon P, van der Net J, Mathiesen P, Johnson LG, Ernste FC, Feldman BM, Houghton KM, Singh-Grewal D, Kutzbach AG, Alemo Munters L, Takken T. Proposal for a Candidate Core Set of Fitness and Strength Tests for Patients with Childhood or Adult Idiopathic Inflammatory Myopathies. *J Rheumatol*. 2016;43(1):169-76. Epub 2015/11/15. doi: 10.3899/jrheum.150270. PMID: 26568594; PMCID: PMC4698199.
86. Yao L, Yip AL, Shrader JA, Mesdaghinia S, Volochayev R, Jansen AV, Miller FW, **Rider LG**. Magnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies. *Rheumatology (Oxford)*. 2016;55(3):441-9. Epub 2015/09/29. doi: 10.1093/rheumatology/kev344. PMID: 26412808; PMCID: PMC4757924.
87. Habers GE, Huber AM, Mamyrova G, Targoff IN, O'Hanlon TP, Adams S, Pandey JP, Boonacker C, van Brussel M, Miller FW, van Royen-Kerkhof A, **Rider LG**. Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset with Disease Course in Juvenile Myositis. *Arthritis Rheumatol*. 2016;68(3):761-8. Epub 2015/10/17. doi: 10.1002/art.39466. PMID: 26474155; PMCID: PMC4767657.
88. Rothwell S, Cooper RG, Lundberg IE, Miller FW, Gregersen PK, Bowes J, Vencovsky J, Danko K, Limaye V, Selva-O'Callaghan A, Hanna MG, Machado PM, Pachman LM, Reed AM, **Rider LG**, Cobb J, Platt H, Molberg Ø, Benveniste O, Mathiesen P, Radstake T, Doria A, De Bleecker J, De Paepe B, Maurer B, Ollier WE, Padyukov L, O'Hanlon TP, Lee A, Amos CI, Gieger C, Meitinger T, Winkelmann J, Wedderburn LR, Chinoy H, Lamb JA. Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. *Ann Rheum Dis*. 2016;75(8):1558-66. Epub 2015/09/13. doi: 10.1136/annrheumdis-2015-208119. PMID: 26362759; PMCID: PMC5300750.

89. Lintner KE, Patwardhan A\*, **Rider LG\***, Abdul-Aziz R, Wu YL, Lundström E, Padyukov L, Zhou B, Alhomosh A, Newsom D, White P, Jones KB, O'Hanlon TP, Miller FW, Spencer CH, Yu CY. Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis. *Ann Rheum Dis*. 2016;75(9):1599-606. Epub 2015/10/24. doi: 10.1136/annrheumdis-2015-207762. PMID: 26493816; PMCID: PMC5321713. \*These authors contributed equally.
90. Nagaraju K, Ghimbovschi S, Rayavarapu S, Phadke A, **Rider LG**, Hoffman EP, Miller FW. Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients. *Rheumatology (Oxford)*. 2016;55(9):1673-80. Epub 2016/05/25. doi: 10.1093/rheumatology/kew213. PMID: 27215813; PMCID: PMC5854096.
91. Kim S, Kahn P, Robinson AB, Lang B, Shulman A, Oberle EJ, Schikler K, Curran ML, Barillas-Arias L, Spencer CH, **Rider LG**, Huber AM. Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. *Pediatr Rheumatol Online J*. 2017;15(1):1. Epub 2017/01/13. doi: 10.1186/s12969-016-0134-0. PMID: 28077146; PMCID: PMC5225591.
92. Hong KM, Kim HK, Park SY, Poojan S, Kim MK, Sung J, Tsao BP, Grossman JM, Rullo OJ, Woo JM, McCurdy DK, **Rider LG**, Miller FW, Song YW. CD3Z hypermethylation is associated with severe clinical manifestations in systemic lupus erythematosus and reduces CD3ζ-chain expression in T cells. *Rheumatology (Oxford)*. 2017;56(3):467-76. Epub 2016/12/13. doi: 10.1093/rheumatology/kew405. PMID: 27940592; PMCID: PMC5850282.
93. **Rider LG\***, Aggarwal R\*\*, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SK, Lindsley CB, Pilkington CA, Punaro M, Ravelli A, Reed AM, Rouster-Stevens K, van Royen-Kerkhof A, Dressler F, Magalhaes CS, Constantin T, Davidson JE, Magnusson B, Russo R, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J\*\*, Ruperto N\*\*. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. *Arthritis Rheumatol*. 2017;69(5):911-23. Epub 2017/04/07. doi: 10.1002/art.40060. PMID: 28382778; PMCID: PMC5577002. \*,\*\*These authors contributed equally to this work.
94. Aggarwal R\*, **Rider LG\***, Ruperto N, Bayat N, Erman B, Feldman BM, Oddis CV, Amato AA, Chinoy H, Cooper RG, Dastmalchi M, Fiorentino D, Isenberg D, Katz JD, Mammen A, de Visser M, Ytterberg SR, Lundberg IE, Chung L, Danko K, García-De la Torre I, Song YW, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW\*\*, Vencovsky J\*\*. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. *Arthritis Rheumatol*. 2017;69(5):898-910. Epub 2017/04/07. doi: 10.1002/art.40064. PMID: 28382787; PMCID: PMC5407906. \*,\*\*These authors contributed equally to this work.
95. **Rider LG\***, Aggarwal R\*, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SK, Lindsley CB, Pilkington CA, Punaro M, Ravelli A, Reed AM, Rouster-Stevens K, van Royen-Kerkhof A, Dressler F, Saad Magalhaes C, Constantin T, Davidson JE,

- Magnusson B, Russo R, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J\*\*, Ruperto N\*\*. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. *Ann Rheum Dis*. 2017;76(5):782-91. Epub 2017/04/08. doi: 10.1136/annrheumdis-2017-211401. PMID: 28385804; PMCID: PMC5517365. \*,\*\*These authors contributed equally to this work.
96. Aggarwal R\*, **Rider LG\***, Ruperto N, Bayat N, Erman B, Feldman BM, Oddis CV, Amato AA, Chinoy H, Cooper RG, Dastmalchi M, Fiorentino D, Isenberg D, Katz JD, Mammen A, de Visser M, Ytterberg SR, Lundberg IE, Chung L, Danko K, García-De la Torre I, Song YW, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW\*\*, Vencovsky J\*\*. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. *Ann Rheum Dis*. 2017;76(5):792-801. Epub 2017/04/08. doi: 10.1136/annrheumdis-2017-211400. PMID: 28385805; PMCID: PMC5496443. \*,\*\*These authors contributed equally to this work.
97. Kishi T\*, **Rider LG\***, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, Shaham B, Weiss PF, Horkayne-Szakaly I, Targoff IN, Miller FW, Mammen AL. Association of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies with DRB1\*07:01 and Severe Myositis in Juvenile Myositis Patients. *Arthritis Care Res (Hoboken)*. 2017;69(7):1088-94. Epub 2017/01/28. doi: 10.1002/acr.23113. PMID: 28129483; PMCID: PMC5487292. \*These authors contributed equally.
98. Mamyrova G, **Rider LG**, Ehrlich A, Jones O, Pachman LM, Nickeson R, Criscone-Schreiber LG, Jung LK, Miller FW, Katz JD. Environmental factors associated with disease flare in juvenile and adult dermatomyositis. *Rheumatology (Oxford)*. 2017;56(8):1342-7. Epub 2017/04/27. doi: 10.1093/rheumatology/kex162. PMID: 28444299; PMCID: PMC5850835.
99. Tiao J, Feng R, Berger EM, Brandsema JF, Coughlin CC, Khan N, Kichula EA, Lerman MA, Lvovich S, McMahon PJ, **Rider LG**, Rubin AI, Scalzi LV, Smith DM, Taxter AJ, Treat JR, Williams RP, Yum SW, Okawa J, Werth VP. Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists. *Br J Dermatol*. 2017;177(4):1086-92. Epub 2017/04/20. doi: 10.1111/bjd.15596. PMID: 28421601; PMCID: PMC5648622.
100. **Rider LG\***, Ruperto N\*, Pistorio A, Erman B, Bayat N, Lachenbruch PA, Rockette H, Feldman BM, Huber AM, Hansen P, Oddis CV, Lundberg IE, Amato AA, Chinoy H, Cooper RG, Chung L, Danko K, Fiorentino D, García-De la Torre I, Reed AM, Wook Song Y, Cimaz R, Cuttica RJ, Pilkington CA, Martini A, van der Net J, Maillard S, Miller FW, Vencovsky J\*\*, Aggarwal R\*\*. 2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects. *Rheumatology (Oxford)*. 2017;56(11):1884-93. Epub 2017/10/05. doi: 10.1093/rheumatology/kex226. PMID: 28977549; PMCID: PMC5850656. \*,\*\*These authors contributed equally to this work.



101. Bottai M, Tjärnlund A, Santoni G, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, García-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinka M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Wook Song Y, Vencovsky J, Ytterberg SR, Miller FW, **Rider LG**, Lundberg IE. EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. *RMD Open*. 2017;3(2):e000507. Epub 2017/11/28. doi: 10.1136/rmdopen-2017-000507. PMID: 29177080; PMCID: PMC5687535.
102. Feldon M, Farhadi PN, Brunner HI, Itert L, Goldberg B, Faiq A, Wilkerson J, Rose KM, **Rider LG**, Miller FW\*, Giannini EH\*. Predictors of Reduced Health-Related Quality of Life in Adult Patients with Idiopathic Inflammatory Myopathies. *Arthritis Care Res (Hoboken)*. 2017;69(11):1743-50. Epub 2017/01/25. doi: 10.1002/acr.23198. PMID: 28118525; PMCID: PMC5524619. \*These authors contributed equally.
103. Lundberg IE, Tjärnlund A\*, Bottai M\*, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dankó K, Dimachkie MM, Feldman BM, Torre IG, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW\*\*, **Rider LG\*\***. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. *Ann Rheum Dis*. 2017;76(12):1955-64. Epub 2017/10/29. doi: 10.1136/annrheumdis-2017-211468. PMID: 29079590; PMCID: PMC5736307. \*,\*\*These authors contributed equally to this work.
104. Lundberg IE, Tjärnlund A\*, Bottai M\*, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dankó K, Dimachkie MM, Feldman BM, Garcia-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW\*\*, **Rider LG\*\***. 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. *Arthritis Rheumatol*. 2017;69(12):2271-82. Epub 2017/11/07. doi: 10.1002/art.40320. PMID: 29106061; PMCID: PMC5846474. \*,\*\*These authors contributed equally to this work.
105. McCann LJ, Pilkington CA, Huber AM, Ravelli A, Appelbe D, Kirkham JJ, Williamson PR, Aggarwal A, Christopher-Stine L, Constantin T, Feldman BM, Lundberg I, Maillard S, Mathiesen P, Murphy R, Pachman LM, Reed AM, **Rider LG**, van Royen-Kerkof A, Russo R, Spinty S, Wedderburn LR, Beresford MW. Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. *Ann Rheum Dis*. 2018;77(2):241-50. Epub 2017/11/01. doi: 10.1136/annrheumdis-2017-212141. PMID: 29084729; PMCID: PMC5816738.
106. Yeker RM\*, Pinal-Fernandez I\*, Kishi T, Pak K, Targoff IN, Miller FW, **Rider LG\*\***, Mammen AL\*\*; Childhood Myositis Heterogeneity Collaborative Study Group. Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis. *Ann Rheum Dis*. 2018;77(5):714-9. Epub 2018/01/25. doi: 10.1136/annrheumdis-2017-212436. PMID: 29363513; PMCID: PMC5898976. \*,\*\*These authors contributed equally to this work.

107. Mamyrova G, Kishi T, Targoff IN, Ehrlich A, Curiel RV, **Rider LG**. Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis; Childhood Myositis Heterogeneity Collaborative Study Group. *Rheumatology (Oxford)*. 2018;57(11):1956-63. Epub 2018/07/18. doi: 10.1093/ rheumatology/key190. PMID: 30016492; PMCID: PMC6199536.
108. Kishi T, Bayat N, Ward MM, Huber AM, Wu L, Mamyrova G, Targoff IN, Warren-Hicks WJ, Miller FW, **Rider LG**; Childhood Myositis Heterogeneity Study Group. Medications received by patients with juvenile dermatomyositis. *Semin Arthritis Rheum*. 2018;48(3):513-22. Epub 2018/05/19. doi: 10.1016/ j.semarthrit.2018.03.016. PMID: 29773230; PMCID: PMC6162169.
109. Sabbagh S\*, Pinal-Fernandez I\*, Kishi T, Targoff IN, Miller FW, **Rider LG\*\***, Mammen AL\*\*; Childhood Myositis Heterogeneity Collaborative Study Group. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. *Ann Rheum Dis*. 2019;78(7):988-95. Epub 2019/04/26. doi: 10.1136/annrheumdis-2018-215004. PMID: 31018961; PMCID: PMC7570952. \*,\*\*These authors contributed equally to this work.
110. Rothwell S, Chinoy H, Lamb JA, Miller FW, **Rider LG**, Wedderburn LR, McHugh NJ, Mammen AL, Betteridge ZE, Tansley SL, Bowes J, Vencovský J, Deakin CT, Dankó K, Vidya L, Selva-O'Callaghan A, Pachman LM, Reed AM, Molberg Ø, Benveniste O, Mathiesen PR, Radstake T, Doria A, de Bleecker J, Lee AT, Hanna MG, Machado PM, Ollier WE, Gregersen PK, Padyukov L, O'Hanlon TP, Cooper RG, Lundberg IE. Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. *Ann Rheum Dis*. 2019;78(7):996-1002. Epub 2019/05/30. doi: 10.1136/annrheumdis-2019-215046. PMID: 31138531; PMCID: PMC6585280.
111. Seto N, Torres-Ruiz JJ, Carmona-Rivera C, Pinal-Fernandez I, Pak K, Purmalek MM, Hosono Y, Fernandes-Cerqueira C, Gowda P, Arnett N, Gorbach A, Benveniste O, Gómez-Martín D, Selva-O'Callaghan A, Milisenda JC, Grau-Junyent JM, Christopher-Stine L, Miller FW, Lundberg IE, Kahlenberg JM, Schiffenbauer AI, Mammen A, **Rider LG**, Kaplan MJ. Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. *JCI Insight*. 2020;5(3). Epub 2020/01/17. doi: 10.1172/jci.insight.134189. PMID: 31945019; PMCID: PMC7098779.
112. Tsaltskan V, Aldous A, Serafi S, Yakovleva A, Sami H, Mamyrova G, Targoff IN, Schiffenbauer A, Miller FW, Simmens SJ, Curiel R, Jones OY, **Rider LG**. Long-term outcomes in Juvenile Myositis patients. *Semin Arthritis Rheum*. 2020;50(1):149-55. Epub 2019/07/16. doi: 10.1016/j.semarthrit.2019.06.014. PMID: 31303436; PMCID: PMC6934928.
113. Smith MA, Chiang CC, Zerrouki K, Rahman S, White WI, Streicher K, Rees WA, Schiffenbauer A, **Rider LG**, Miller FW, Manna Z, Hasni S, Kaplan MJ, Siegel R, Sinibaldi D, Sanjuan MA, Casey KA. Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus. *Sci Rep*. 2020;10(1):4462. Epub 2020/03/12. doi: 10.1038/s41598-020-60563-9. PMID: 32157125; PMCID: PMC7064569.
114. de Jesus AA, Hou Y, Brooks S, Malle L, Biancotto A, Huang Y, Calvo KR, Marrero B, Moir S, Oler AJ, Deng Z, Montealegre Sanchez GA, Ahmed A, Allenspach E, Arabshahi B, Behrens E, Benseler S, Bezrodnik L, Bout-Tabaku S, Brescia AC, Brown D, Burnham JM, Caldirola MS, Carrasco R, Chan AY, Cimaz R, Dancey P, Dare J, DeGuzman M, Dimitriades V, Ferguson I,

Ferguson P, Finn L, Gattorno M, Grom AA, Hanson EP, Hashkes PJ, Hedrich CM, Herzog R, Horneff G, Jerath R, Kessler E, Kim H, Kingsbury DJ, Laxer RM, Lee PY, Lee-Kirsch MA, Lewandowski L, Li S, Lilleby V, Mammadova V, Moorthy LN, Nasrullayeva G, O'Neil KM, Onel K, Ozen S, Pan N, Pillet P, Piotto DG, Punaro MG, Reiff A, Reinhardt A, **Rider LG**, Rivas-Chacon R, Ronis T, Rösen-Wolff A, Roth J, Ruth NM, Rygg M, Schmeling H, Schulert G, Scott C, Seminario G, Shulman A, Sivaraman V, Son MB, Stepanovskiy Y, Stringer E, Taber S, Terreri MT, Tiffit C, Torgerson T, Tosi L, Van Royen-Kerkhof A, Wampler Muskardin T, Canna SW, Goldbach-Mansky R. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. *J Clin Invest.* 2020;130(4):1669-82. Epub 2019/12/25. doi: 10.1172/jci129301. PMID: 31874111; PMCID: PMC7108905.

115. Kim H, Gunter-Rahman F, McGrath JA, Lee E, de Jesus AA, Targoff IN, Huang Y, O'Hanlon TP, Tsai WL, Gadina M, Miller FW, Goldbach-Mansky R\*, **Rider LG\***. Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. *Arthritis Res Ther.* 2020;22(1):69. Epub 2020/04/08. doi: 10.1186/s13075-020-02160-9. PMID: 32252809; PMCID: PMC7137415. \*These authors contributed equally.
116. Kishi T, Chipman J, Evereklian M, Nghiem K, Stetler-Stevenson M, Rick ME, Centola M, Miller FW, **Rider LG**. Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis. *J Rheumatol.* 2020;47(7):1011-8. Epub 2019/08/03. doi: 10.3899/jrheum.181275. PMID: 31371656; PMCID: PMC6994352.
117. Parks CG, Wilkerson J, Rose KM, Faiq A, Noroozi Farhadi P, Long CS, Bayat N, Brunner HI, Goldberg B, McGrath JA, Miller FW, **Rider LG**. Association of Ultraviolet Radiation Exposure with Dermatomyositis in a National Myositis Patient Registry. *Arthritis Care Res (Hoboken).* 2020;72(11):1636-44. Epub 2019/09/04. doi: 10.1002/acr.24059. PMID: 31478597; PMCID: PMC7051886.
118. Brunner HI, Schanberg LE, Kimura Y, Dennon A, Co DO, Colbert RA, Fuhlbrigge RC, Goldmuntz E, Kingsbury DJ, Patty-Resk C, Mintz S, Onel K, **Rider LG**, Schneider R, Watts A, von Scheven E, Lovell DJ, Beukelman T. New Medications Are Needed for Children with Juvenile Idiopathic Arthritis. *Arthritis Rheumatol.* 2020;72(11):1945-51. Epub 2020/06/12. doi: 10.1002/art.41390. PMID: 32524767; PMCID: PMC7722045.
119. Sabbagh SE, Neely J, Chow A, DeGuzman M, Lai J, Lvovich S, McGrath T, Pereira M, Pinal-Fernandez I, Roberts J, Rouster-Stevens K, Schmeling H, Sura A, Tarshish G, Tucker L, **Rider LG**, Kim S; CARRA JDM Workgroup and the Childhood Myositis Heterogeneity Study Group. Risk factors associated with *Pneumocystis jirovecii* pneumonia in juvenile myositis in North America. *Rheumatology (Oxford).* 2021;60(2):829-36. Epub 2020/09/06. doi: 10.1093/rheumatology/keaa436. PMID: 32889531; PMCID: PMC7850515.
120. Mamyrova G, Kishi T, Shi M, Targoff IN, Huber AM, Curiel RV, Miller FW, **Rider LG**; Childhood Myositis Heterogeneity Collaborative Study Group. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America. *Rheumatology (Oxford).* 2021;60(4):1839-49. Epub 2020/11/04. doi: 10.1093/rheumatology/keaa429. PMID: 33140079; PMCID: PMC8023991.
121. Kishi T, Warren-Hicks W, Bayat N, Targoff IN, Huber AM, Ward MM, **Rider LG**; with the Childhood Myositis Heterogeneity Study Group. Corticosteroid discontinuation, complete clinical

response and remission in juvenile dermatomyositis. *Rheumatology (Oxford)*. 2021;60(5):2134-45. Epub 2020/10/18. doi: 10.1093/ rheumatology/keaa371. PMID: 33067611; PMCID: PMC8121446.

122. Sattui SE, Liew JW, Kennedy K, Sirotich E, Putman M, Moni TT, Akpabio A, Alpízar-Rodríguez D, Berenbaum F, Bulina I, Conway R, Singh AD, Duff E, Durrant KL, Gheita TA, Hill CL, Howard RA, Hoyer BF, Hsieh E, El Kibbi L, Kilian A, Kim AH, Liew DFL, Lo C, Miller B, Mingolla S, Nudel M, Palmerlee CA, Singh JA, Singh N, Ugarte-Gil MF, Wallace J, Young KJ, Bhana S, Costello W, Grainger R, Machado PM, Robinson PC, Sufka P, Wallace ZS, Yazdany J, Harrison C, Larché M, Levine M, Foster G, Thabane L, **Rider LG**, Hausmann JS, Simard JF, Sparks JA. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. *RMD Open*. 2021;7(3). Epub 2021/09/09. doi: 10.1136/rmdopen-2021-001814. PMID: 34493645; PMCID: PMC8424419.
123. Sabbagh SE, Pinal-Fernandez I, Casal-Dominguez M, Albayda J, Paik JJ, Miller FW, **Rider LG**, Mammen AL, Christopher-Stine L; Johns Hopkins Myositis Center Group. Anti-mitochondrial autoantibodies are associated with cardiomyopathy, dysphagia, and features of more severe disease in adult-onset myositis. *Clin Rheumatol*. 2021;40(10):4095-100. Epub 2021/04/15. doi: 10.1007/s10067-021-05730-7. PMID: 33851273; PMCID: PMC8463345.
124. Pinal-Fernandez I, Pak K, Gil-Vila A, Baucells A, Plotz B, Casal-Dominguez M, Derfoul A, Martinez-Carretero MA, Selva-O'Callaghan A, Sabbagh S, Casciola-Rosen L, Albayda J, Paik J, Tiniakou E, Danoff SK, Lloyd TE, Miller FW, **Rider LG**, Christopher-Stine L, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group. Anti-Cortactin Autoantibodies Are Associated with Key Clinical Features in Adult Myositis but Are Rarely Present in Juvenile Myositis. *Arthritis Rheumatol*. 2022;74(2):358-64. Epub 2021/07/28. doi: 10.1002/art.41931. PMID: 34313394; PMCID: PMC8792092.
125. Scalabrini JC, Schiffenbauer AI, Farhadi PN, Volochayev R, Bayat N, Jansen A, Targoff IN, Miller FW, **Rider LG**. Environmental factors associated with juvenile idiopathic inflammatory myopathy clinical and serologic phenotypes. *Pediatr Rheumatol*. 2022;20(1):10. Epub 2022/04/14. doi: 10.1186/s12969-022-00684-9. PMID: 35414090; PMCID: PMC9004071.
126. Mamyrova G, McBride E, Yao L, Shrader JA, Jain M, Yao J, Curiel RV, Miller FW, Harris-Love MO, **Rider LG**. Preliminary validation of muscle ultrasound in juvenile dermatomyositis (JDM). *Rheumatology (Oxford)*. 2022;61(Si):Si48-si55. Epub 2021/11/19. doi: 10.1093/rheumatology/keab833. PMID: 34791066; PMCID: PMC9015026.
127. Angkeow JW, Monaco DR, Chen A, Venkataraman T, Jayaraman S, Valencia C, Sie BM, Liechti T, Farhadi PN, Funez-dePagnier G, Sherman-Baust CA, Wong MQ, Ruczinski I, Caturegli P, Sears CL, Simner PJ, Round JL, Duggal P, Laserson U, Steiner TS, Sen R, Lloyd TE, Roederer M, Mammen AL, Longman RS, **Rider LG**, Larman HB. Phage display of environmental protein toxins and virulence factors reveals the prevalence, persistence, and genetics of antibody responses. *Immunity*. 2022;55(6):1051-66.e4. Epub 2022/06/02. doi: 10.1016/j.immuni.2022.05.002. PMID: 35649416; PMCID: PMC9203978.
128. **Rider LG**, Parks CG, Wilkerson J, Schiffenbauer AI, Kwok RK, Noroozi Farhadi P, Nazir S, Ritter R, Sirotich E, Kennedy K, Larche MJ, Levine M, Sattui SE, Liew JW, Harrison CO, Moni

- TT, Miller AK, Putman M, Hausmann J, Simard JF, Sparks JA, Miller FW. Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. *Rheumatology (Oxford)*. 2022;61(Si2):Si143-si50. Epub 2022/04/24. doi: 10.1093/rheumatology/keac249. PMID: 35460240; PMCID: PMC9248066. **(NIEHS Environmental Factor June 2022 Intramural Paper of the Month)**
129. Scofield RH, Lewis VM, Cavitt J, Kurien BT, Assassi S, Martin J, Gorlova O, Gregersen P, Lee A, **Rider LG**, O'Hanlon T, Rothwell S, Lilleker J, Kochi Y, Terao C, Igoe A, Stevens W, Sahhar J, Roddy J, Rischmueller M, Lester S, Proudman S, Chen S, Brown MA, Mayes MD, Lamb JA, Miller FW. 47XXY and 47XXX in Scleroderma and Myositis. *ACR Open Rheumatol*. 2022;4(6):528-33. Epub 2022/03/31. doi: 10.1002/acr2.11413. PMID: 35352506; PMCID: PMC9190224.
  130. Karasawa R, Yudoh K, Sato T, Tanaka M, Tamaki M, Sabbagh SE, O'Hanlon TP, Noroozi-Farhadi P, Targoff IN, Flegel WA, Mammen AL, Miller FW, Hicar MD, **Rider LG**, Jarvis JN. Association of anti-HSC70 autoantibodies with cutaneous ulceration and severe disease in juvenile dermatomyositis. *Rheumatology (Oxford)*. 2022;61(7):2969-77. Epub 2021/11/19. doi: 10.1093/rheumatology/keab846. PMID: 34791087; PMCID: PMC9258543.
  131. Deakin CT, Bowes J, **Rider LG**, Miller FW, Pachman LM, Sanner H, Rouster-Stevens K, Mamyrova G, Curiel R, Feldman BM, Huber AM, Reed AM, Schmeling H, Cook CG, Marshall LR, Li Wilkinson MG, Eyre S, Raychaudhuri S\*, Wedderburn LR\*. Association with HLA-DR $\beta$ 1 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis. *Hum Mol Genet*. 2022;31(14):2471-81. Epub 2022/01/31. doi: 10.1093/hmg/ddac019. PMID: 35094092; PMCID: PMC9307311. \*These authors contributed equally.
  132. Parkes JE, Boehler JF, Li N, Kendra RM, O'Hanlon TP, Hoffman EP, Peterson JM, Miller FW, **Rider LG**, Nagaraju K. A novel estrogen receptor 1-sphingomyelin phosphodiesterase acid like 3B pathway mediates rituximab response in myositis patients. *Rheumatology (Oxford)*. 2022. Epub 2022/12/09. doi: 10.1093/rheumatology/keac687. PMID: 36478205; PMCID: PMC Journal – In Process.
  133. Rothwell S, Amos CI, Miller FW, **Rider LG**, Lundberg IE, Gregersen PK, Vencovsky J, McHugh N, Limaye V, Selva-O'Callaghan A, Hanna MG, Machado PM, Pachman LM, Reed AM, Molberg Ø, Benveniste O, Mathiesen P, Radstake T, Doria A, De Bleecker JL, De Paepe B, Maurer B, Ollier WE, Padyukov L, O'Hanlon TP, Lee A, Wedderburn LR, Chinoy H, Lamb JA, Myositis Genetics Consortium. Identification of Novel Associations and Localization of Signals in Idiopathic Inflammatory Myopathies Using Genome-Wide Imputation. *Arthritis Rheumatol*. 2022. Epub 2022/12/30. doi: 10.1002/art.42434. PMID: 36580032; PMCID: PMC Journal – In Process.
  134. Curiel RV, Nguyen W, Mamyrova G, Jones D, Ehrlich A, Brindle KA, Haji-Momenian S, Sheets R, Kim H, Jones OY, **Rider LG**, Abatacept in Dermatomyositis Trial Investigators. Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy. *Arthritis Rheumatol*. 2023. Epub 2023/01/20. doi: 10.1002/art.42450. PMID: 36657109; PMCID: PMC Journal – In Process.
  135. Morales M, Alayi TD, Tawalbeh SM, Sydenstricker AV, Spathis R, Kim H, Nagaraju K, Hathout Y, **Rider LG**. Urine proteomics by mass spectrometry identifies proteins involved in key

pathogenic pathways in patients with juvenile dermatomyositis. *Rheumatology (Oxford)*. 2023. Epub 2023/01/21. doi: 10.1093/rheumatology/kead033. PMID: 36661295; PMCID: PMC Journal – In Process. (**NIEHS Environmental Factor March 2023 Intramural Paper of the Month**)

136. Sherman MA, Graf R, Sabbagh SE, Galindo-Feria AS, Pinal-Fernandez I, Pak K, Kishi T, Flegel WA, Targoff IN, Miller FW, Lundberg IE, **Rider LG\***, Mammen AL\*; Childhood Myositis Heterogeneity Collaborative Study Group. Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features. *Rheumatology (Oxford)*. 2023;62(Si2):Si226-si34. Epub 2022/08/13. doi: 10.1093/rheumatology/keac428. PMID: 35961028; PMCID: PMC9949705. \*These authors contributed equally.
137. Zhou D, King EH, Rothwell S, Krystufkova O, Notarnicola A, Coss S, Abdul-Aziz R, Miller KE, Dang A, Yu GR, Drew J, Lundström E, Pachman LM, Mamyrova G, Curiel RV, De Paepe B, De Bleecker JL, Payton A, Ollier W, O'Hanlon TP, Targoff IN, Flegel WA, Sivaraman V, Oberle E, Akoghlianian S, Driest K, Spencer CH, Wu YL, Nagaraja HN, Ardoin SP, Chinoy H, **Rider LG**, Miller FW, Lundberg IE, Padyukov L, Vencovský J, Lamb JA, Yu CY. Low copy numbers of complement C4 and C4A deficiency are risk factors for myositis, its subgroups, and autoantibodies. *Ann Rheum Dis*. 2023;82(2):235-45. Epub 2022/09/29. doi: 10.1136/ard-2022-222935. PMID: 36171069; PMCID: PMC9887400.
138. Hossain MM, Wilkerson J, McGrath JA, Farhadi PN, Brokamp C, Khan MTF, Goldberg B, Brunner HI, Macaluso M, Miller FW, **Rider LG**. The Geospatial Distribution of Myositis and Its Phenotypes in the United States and Associations with Roadways: Findings from a National Myositis Patient Registry. *Front Med (Lausanne)*. 2022;9:842586. Epub 2022/04/05. doi: 10.3389/fmed.2022.842586. PMID: 35372396; PMCID: PMC8966380.
139. Kim H\*, Saygin D\*, Douglas C, Wilkerson J, Erman B, Pistorio A, McGrath JA, Reed AM, Oddis CV, Bracaglia C, van Royen-Kerkhof A, Bica B, Dolezalova P, Ferriani VPL, Flato B, Bernard-Medina AG, Herlin T, Miller FW, Vencovsky J, Ruperto N, Aggarwal R, **Rider LG**, International Myositis Assessment and Clinical Studies Group (IMACS), Paediatric Rheumatology International Trials Organization (PRINTO). Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles. *Rheumatology (Oxford)*. 2023. Epub 2023/03/18. doi: 10.1093/rheumatology/kead111. PMID: 36929918; PMCID: PMC Journal – In Process. \*These authors contributed equally.
140. Saygin D\*, Kim H\*, Douglas C, Erman B, Wilkerson J, McGrath JA, Oddis CV, Lundberg IE, Amato AA, García-De La Torre I, Chinoy H, Fiorentino D, Chung L, Song YW, Miller FW, Ruperto N, Vencovsky J, Aggarwal R, **Rider LG**, International Myositis Assessment and Clinical Studies Group. Performance of the 2016 ACR-EULAR myositis response criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles. *Rheumatology (Oxford)*. 2023. Epub 2023/03/18. doi: 10.1093/rheumatology/kead110. PMID: 36929923; PMCID: PMC Journal – In Process. \*These authors contributed equally.
141. Sherman MA, Pak K, Pinal-Fernandez I, Flegel WA, Targoff IN, Miller FW, **Rider LG\***, Mammen AL\*, Childhood Myositis Heterogeneity Collaborative Study Group. Anti-Sp4 autoantibodies co-occur with anti-TIF1 and are associated with distinct clinical features and immunogenetic risk factors in juvenile myositis. *Arthritis Rheumatol*. 2023. Epub 2023/03/31. doi: 10.1002/art.42512. PMID: 36996276; PMCID: PMC Journal – In Process. \*These authors contributed equally.

142. Karasawa R, Yudoh K, Sato T, Tanaka M, Sabbagh SE, Flegel WA, Mammen AL, Jarvis JN\*, Rider LG\*; Childhood Myositis Heterogeneity Study Group. Association of Anti-TPM4 autoantibodies with vasculopathic cutaneous manifestations in juvenile dermatomyositis. *Rheumatology (Oxford)*. 2023 May 5:kead203. doi: 10.1093/rheumatology/kead203. Online ahead of print. PMID: 37144941; PMCID: PMC Journal – In Process. \*These authors contributed equally.
143. Ward J, Ambatipudi M, O'Hanlon TP, Smith MA, de Los Reyes M, Schiffenbauer A, Rahman S, Zerrouki K, Miller FW, Sanjuan MA, Li JL, Casey KA, **Rider LG**. Shared and Distinctive Transcriptomic and Proteomic Pathways in Adult and Juvenile Dermatomyositis. *Arthritis Rheumatol.*, 2023 May 25. doi: 10.1002/art.42615. Online ahead of print. PMID: 37229703; PMCID: PMC Journal – In Process. (***NIEHS Environmental Factor July 2023 Intramural Paper of the Month***)
144. Cervantes BA, Gowda P, **Rider LG**, Miller FW, Chen MY, Schiffenbauer A. Development of a computed tomography calcium scoring technique for assessing calcinosis distribution, pattern and burden in dermatomyositis. *Rheumatology (Oxford)*. 2023 Jun 7:kead256. doi: 10.1093/rheumatology/kead256. Online ahead of print. PMID: 37286372; PMCID: PMC Journal – In Process.
145. Koester S\*, Chow A\*\*, Pepper-Tunick E, Lee P, Eckert M, Brenchley L, Gardner P, Li N, Schiffenbauer A, Volochayev R, Bayat N, McLean J, **Rider L\*\***, Sheno S\*\*, Stevens A\*\*, Dey N\*\*. Familial clustering of dysbiotic oral and fecal microbiomes in juvenile dermatomyositis. 1 August 2022. doi: 10.21203/rs.3.rs-1620914/v1. 2022, Preprint server: <https://www.researchsquare.com/article/rs-1620914/v>. \*\*These authors contributed equally.

#### Other peer-reviewed scholarship

1. **Rider LG**, Miller FW. Laboratory evaluation of the inflammatory myopathies. *ClinDiagnLab Immunol*. 1995;2(1):1-9. doi: 10.1128/cdli.2.1.1-9.1995. PMID: 7719899; PMCID: PMC170091.
2. Plotz PH, **Rider LG**, Targoff IN, Raben N, O'Hanlon TP, Miller FW. Myositis: Immunologic contributions to understanding cause, pathogenesis, and therapy. *Annals Internal Medicine*. 1995;122(9):715-24. doi: 10.7326/0003-4819-122-9-199505010-00010. PMID: 7702234.
3. **Rider LG**. Calcinosis in Juvenile Dermatomyositis: Pathogenesis and Current Therapies. *Pediatric Rheumatology Online Journal*. 2003;1:2
4. Lachenbruch PA, Miller FW, **Rider LG**. Developing international consensus on measures of improvement for patients with myositis. *Stat Methods Med Res*. 2007;16(1):51-64. doi: 10.1177/0962280206070652. PMID: 17338294.
5. Feldman BM, **Rider LG**, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. *Lancet*. 2008;371(9631):2201-12. doi: 10.1016/s0140-6736(08)60955-1. PMID: 18586175.
6. Dugan EM, Huber AM, Miller FW, **Rider LG**, International Myositis A, Clinical Studies G. Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies. *Dermatol Online J*. 2009;15(2):2. Epub 20090215. PMID: 19336019.

7. **Rider LG**, Miller FW. Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. *JAMA*. 2011;305(2):183-90. doi: 10.1001/jama.2010.1977. PMID: 21224460; PMCID: PMC4047218.
8. **Rider LG**, Aggarwal R, Machado PM, Hogrel JY, Reed AM, Christopher-Stine L, Ruperto N. Update on outcome assessment in myositis. *Nat Rev Rheumatol*. 2018;14(5):303-18. Epub 20180412. doi: 10.1038/nrrheum.2018.33. PMID: 29651119; PMCID: PMC6702032.
9. Brunner HI, **Rider LG**, Kingsbury DJ, Co D, Schneider R, Goldmuntz E, Onel KB, Giannini EH, Lovell DJ. Pediatric Rheumatology Collaborative Study Group - over four decades of pivotal clinical drug research in pediatric rheumatology. *Pediatr Rheumatol Online J*. 2018;16(1):45. Epub 20180711. doi: 10.1186/s12969-018-0261-x. PMID: 29996857; PMCID: PMC6042275.

#### **Scholarship without named authorship.**

1. Okada S, Weatherhead E, Targoff IN, Wesley R, Miller FW; **International Myositis Collaborative Study Group**. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. *Arthritis Rheum*. 2003;48(8):2285-93. doi: 10.1002/art.11090. PMID: 12905483.
2. Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N; **Childhood Arthritis Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group**, Paediatric Rheumatology International Trials Organization. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. *Arthritis Care Res (Hoboken)*. 2011;63(7):929-36. Epub 2011/07/01. doi: 10.1002/acr.20497. PMID: 21717596.
3. Reed AM, Crowson CS, Hein M, de Padilla CL, Olazagasti JM, Aggarwal R, Ascherman DP, Levesque MC, Oddis CV; **RIM Study Group**. Biologic predictors of clinical improvement in rituximab-treated refractory myositis. *BMC Musculoskelet Disord*. 2015;16:257. Epub 2015/09/19. doi: 10.1186/s12891-015-0710-3. PMID: 26382217; PMCID: PMC4574570.
4. Parkes JE, Rothwell S, Day PJ, McHugh NJ, Betteridge ZE, Cooper RG, Ollier WE, Chinoy H, Lamb JA; **Myositis Genetics Consortium (MYOGEN)**. Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies. *Arthritis Res Ther*. 2016;18(1):156. Epub 2016/07/09. doi: 10.1186/s13075-016-1061-7. PMID: 27388770; PMCID: PMC4936183.
5. Acosta-Herrera M, Kerick M, González-Serna D, Wijmenga C, Franke A, Gregersen PK, Padyukov L, Worthington J, Vyse TJ, Alarcón-Riquelme ME, Mayes MD, Martin J; **Myositis Genetics Consortium**. Genome-wide meta-analysis reveals shared new loci in systemic seropositive rheumatic diseases. *Ann Rheum Dis*. 2019;78(3):311-9. Epub 20181220. doi: 10.1136/annrheumdis-2018-214127. PMID: 30573655; PMCID: PMC6800208.
6. Concha JSS, Pena S, Gaffney RG, Patel B, Tarazi M, Kushner CJ, Merola JF, Fiorentino D, Dutz JP, Goodfield M, Nyberg F, Volc-Platzer B, Fujimoto M, Ang CC, Werth VP; **Skin Myositis Delphi Group**. Developing classification criteria for skin-predominant dermatomyositis: the Delphi process. *The British Journal of Dermatology*. 2020;182(2):410-7. Epub 20190929. doi: 10.1111/bjd.18096. PMID: 31049930.



7. Weiss PF, Fuhlbrigge RC, von Scheven E, Lovell DJ, Colbert RA, Brunner HI; **PRCSG Advisory Council** and the CARRA Executive Committee. Children With Enthesitis-Related Arthritis and Possible Benefits From Treatments for Adults With Spondyloarthritis. *Arthritis Care Res (Hoboken)*. 2022;74(7):1058-64. Epub 20220415. doi: 10.1002/acr.24529. PMID: 33278336; PMCID: PMC8178413.
8. Johnson C, Schiffenbauer AI, Miller FW, Perin J, Danoff SK, Diwadkar AR, Joo J, Himes BE, Meyer NJ; **Myositis-ILD Study Group**. Human Leukocyte Antigen Alleles Associated with Interstitial Lung Disease in North Americans with Idiopathic Inflammatory Myopathy. *Am J Respir Crit Care Med*. 2023;207(5):619-22. doi: 10.1164/rccm.202206-1116le. PMID: 36269757. *PMC Journal – In Process*

### Non-peer reviewed scientific/medical publications

1. **Rider LG**, Miller GW. Environmental Risk Factors in Pediatric Systemic Autoimmune Diseases: There's still much to learn. *The Rheumatologist*, Vol 11 - No 3 - March 2017, pages 49-53.

### Proceedings of meetings

1. Barron KS, Wallace C, Woolfrey CEA, Laxer RM, Hirsch R, Horwitz M, Siegel J, Filipovich L, Wulffraat N, Passo M, **Rider LG**. Autologous stem cell transplantation for pediatric rheumatic diseases. *J Rheumatol*. 2001;28(10):2337-58. PMID: 11669179.
2. Benveniste O, **Rider LG**. 213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015. *Neuromuscul Disord*. 2016;26(8):523-34. Epub 2016/06/18. doi: 10.1016/j.nmd.2016.05.014. PMID: 27312023; PMCID: PMC5118225.
3. Schanberg LE, Mulugeta LY, Akinlade B, Brunner HI, Chen J, Colbert RA, Delgaizo V, Gastonguay MR, Glaser R, Imundo L, Lovell DJ, Leu JH, Mostafa NM, Nelson RM, Nigrovic PA, Nikolov NP, **Rider LG**, Rothwell R, Sahajwalla C, Singh R, Sinha V, Yancey CL, Yao L. Therapeutics Development in Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA): Extrapolation, Dose Selection and Clinical Trial Design; Workshop Proceedings and Recent Updates. *Arthritis Rheumatol*. 2023 Apr 17. doi: 10.1002/art.42534. Epub ahead of print. PMID: 37067688, *PMC Journal – In Process*

### Reviews, Chapter, Monographs and Editorials

1. Abramson, S., H. Korchak, R. Ludewig, H. Edelson, K. Haines, R.I. Levin, **L. Rider**, and G. Weissmann. Modes of action of aspirin-like drugs. *Advances in Inflammation Research*. 1985; 10: 31-35.
2. **Rider LG**, Miller FW. New perspectives on the idiopathic inflammatory myopathies of childhood. *Curr Opin Rheumatol*. 1994;6(6):575-82. doi: 10.1097/00002281-199411000-00005. PMID: 7865376.
3. **Rider LG**. Assessment of disease activity and its sequelae in children and adults with myositis. *Curr Opin Rheumatol*. 1996;8(6):495-506. doi: 10.1097/00002281-199611000-00002. PMID: 9018452.

4. **Rider LG**, Miller FW. Classification and treatment of the juvenile idiopathic inflammatory myopathies. *Rheum Dis Clin North Am.* 1997 Aug;23(3):619-55. doi: 10.1016/s0889-857x(05)70350-1. PMID: 9287380.
5. **Rider LG** and Targoff IN. Single organ systems and autoimmunity: Muscle Diseases. *Textbook of Autoimmune Diseases*, ed. R.G. Lahita, N. Chiorazzi, W.H. Reeves. Lipincott- Raven, Philadelphia, PA. 2000; pg 429-474.
6. **Rider LG**, Miller FW. Idiopathic inflammatory muscle disease: clinical aspects. *Baillieres Best Pract Res Clin Rheumatol.* 2000;14(1):37-54. doi: 10.1053/berh.1999.0076. PMID: 10882213.
7. Shamim EA, **Rider LG**, Miller FW. Update on the genetics of the idiopathic inflammatory myopathies. *Curr Opin Rheumatol.* 2000;12(6):482-91. doi: 10.1097/00002281-200011000-00002. PMID: 11092196.
8. **Rider LG**. Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies. *Rheum Dis Clin North Am.* 2002;28(4):935-77. doi: 10.1016/s0889-857x(02)00027-3. PMID: 12506779.
9. **Rider LG**. Juvenile dermatomyositis (chapter 12.10). *Rudolph's Pediatrics*, 21st edition. CD Rudolph, AM Rudolph, eds. McGraw-Hill, NY. 2003; 853-856.
10. **Rider LG**, Pachman LM, Miller FW, Bollar H. Introduction. *Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers.* 2007. The Myositis Association, Washington DC. Page 1-8.
11. **Rider LG** and Miller FW. What is Juvenile Myositis? *Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers.* 2007. The Myositis Association, Washington DC. Pages 9-22.
12. **Rider LG**, Pilkington C, Malleson P. Possible Medicines During the Course. *Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers.* 2007, The Myositis Association, Washington DC. Pages 153-172.
13. **Rider LG**, Pilkington C, Ruperto N, Isenberg, D. Charting Your Child's Progress. *Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers.* 2007, The Myositis Association, Washington DC. Pages 127-138.
14. **Rider LG** and Pachman LM. Calcinosis. *Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers.* 2007, The Myositis Association, Washington DC. Pages 231-240.
15. Rennebohm R, Feldman B, Huber A, Spencer C, Sundel R, and **Rider LG**. The clinical course and outcome of juvenile myositis. *Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers.* 2007, The Myositis Association, Washington DC. pages 341-350.
16. **Rider LG**. The heterogeneity of juvenile myositis. *Autoimmun Rev.* 2007;6(4):241-7. Epub 20060905. doi: 10.1016/j.autrev.2006.08.009. PMID: 17317616; PMCID: PMC1850932.

17. Mellins ED, **Rider LG**. Clinical research networks: a step towards evidence-based practice in pediatric rheumatology. *Nat Clin Pract Rheumatol*. 2007;3(2):59. doi: 10.1038/ncprheum0405. PMID: 17299440.
18. **Rider LG** and Miller FW. Pathology and pathogenesis of idiopathic inflammatory myopathies. *Primer on Rheumatic Diseases*. Ed Klippel JH, Stone JH, Crofford LJ, White PH. Springer. 2007. Pg 368-374.
19. **Rider LG**, Leschek EW. Does early growth hormone therapy prevent glucocorticoid-associated growth retardation in children with JIA? *Nat Clin Pract Rheumatol*. 2008;4(8):394-5.
20. Yao L and **Rider LG**. Chapter 54: Idiopathic inflammatory myopathy. *Imaging of the Musculoskeletal System*, 1st Edition. TL Pope, HL Bloem, J Beltran, WB Morrison, DJ Wilson, editors. Elsevier. Philadelphia, PA. 2008. Pages 1171-1179.
21. Dugan EM, Huber AM, Miller FW, **Rider LG**; International Myositis Assessment and Clinical Studies Group. Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. *Dermatol Online J*. 2009 Feb 15;15(2):1. PMID: 19336018.
22. **Rider LG**. Outcomes and Assessment for Inflammatory Muscle Disease. Ed. Lawrence Kagen. *The Inflammatory Myopathies*. Humana Press, Springer, Dordrecht. 2009. Pages 253-276.
23. Reed AM, Pilkington CA, Feldman BM, Pachman LM, **Rider LG**. Juvenile Dermatomyositis. In: *A Clinician's Pearls & Myths in Rheumatology*. Ed. Stone JH. First edition. Springer (Dordrecht, Heidelberg, London, New York). 2009. Pages 201-210.
24. Wedderburn LR, **Rider LG**. Juvenile dermatomyositis: new developments in pathogenesis, assessment, and treatment. *Best Pract Res Clin Rheumatol*. 2009;23(5):665-78. doi: 10.1016/j.berh.2009.07.007. PMID: 19853831; PMCID: PMC2774891.
25. **Rider LG**. Juvenile dermatomyositis. Section 15, Chapter 205. *Rudolph's Pediatrics*. 22nd edition. AM Rudolph, C Rudolph, L First, G Lister, AA Gershon, eds. McGraw-Hill, NY. 2010. Pages 15-27 to 15-31.
26. **Rider LG**, Lindsley C, Cassidy J. Chapter 24: Juvenile dermatomyositis. In *Textbook of Pediatric Rheumatology*, 6th edition, Ed Cassidy J, Petty R, Laxer R. Lindsley C. Saunders Elsevier. 2011. Pages 375-413.
27. **Rider LG** and Miller FW. Editorial: Mast cells and type I interferon responses in the skin of patients with juvenile dermatomyositis: are current therapies just scratching the surface? *Arthritis Rheum*. 2010; 62(9): 2619-2622. doi: 10.1002/art.27525. PMID: 20506242. PMCID: PMC2946445.
28. **Rider LG**, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, Herbelin L, Barohn R, Isenberg D, Miller FW. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative

- Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). *Arthritis Care Res(Hoboken)*. 2011;63 Suppl 11(0 11):S118-S57. doi: 10.1002/acr.20532. PMID: 22588740; PMCID: PMC3748930.
29. Yao L and **Rider LG**. Chapter 55: Idiopathic inflammatory myopathy. *Imaging of the Musculoskeletal System*, 2nd Edition. TL Pope, HL Bloem, J Beltran, WB Morrison, DJ Wilson, editors. Elsevier. Philadelphia, PA. 2012, Pages 1171-1179.
  30. **Rider LG**, Katz JD, Jones OY. Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies. *Rheum Dis Clin North Am*. 2013;39(4):877-904. Epub 20130919. doi: 10.1016/j.rdc.2013.06.001. PMID: 24182859; PMCID: PMC3817412.
  31. **Rider LG**, Danko K, Miller FW. Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research. *Curr Opin Rheumatol*. 2014;26(6):724-41. doi: 10.1097/bor.000000000000119. PMID: 25225838; PMCID: PMC5081267.
  32. Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, **Rider LG**. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. *Curr Rheumatol Rep*. 2014;16(12):467. doi: 10.1007/s11926-014-0467-y. PMID: 25366934; PMCID: PMC5118224.
  33. **Rider LG**, Lindsley C, Miller FW. Chapter 26: Juvenile dermatomyositis. In *Textbook of Pediatric Rheumatology*, 7th edition, Ed Petty R, Laxer R. Lindsley C, Wedderburn L. Saunders Elsevier. 2015. pages 351-384.
  34. **Rider LG**, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. *J Intern Med*. 2016;280(1):24-38. Epub 2016/03/31. doi: 10.1111/joim.12444. PMID: 27028907; PMCID: PMC4914449.
  35. **Rider LG** and Miller FW. Chapter 16. Outcome Assessment in the Idiopathic Inflammatory Myopathies. In *Myositis (Oxford Rheumatology Library)*, edited by Hector Chinoy and Robert Cooper. Oxford University Press, 2018, pages 161-170.
  36. **Rider LG**. Chapter 202: Juvenile Dermatomyositis. *Rudolph's Pediatrics*. Edited by MW Kline, S Blaney, AP Giardino, JS Orange, DJ Penny, GE Schutze, LS Shekerdemian, McGraw-Hill, NY. 2018, pages 951-958.
  37. Curiel R and **Rider LG**. Distinguishing Disease Activity and Damage in Myositis. In *Managing Myositis: A Practical Guide*, Editors R Aggarwal and CV Oddis, Springer International, 2020, Chapter 35: pgs 345-354.
  38. Chung MP, Richardson C, Kirakossian D, Orandi AB, Saketkoo LA, **Rider LG**, Schiffenbauer A, von Mühlen CA, Chung L. Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis. *Autoimmun Rev*. 2020;19(6):102533. Epub 20200328. doi: 10.1016/j.autrev.2020.102533. PMID: 32234404; PMCID: PMC7225028.
  39. Tansley SL, Snowball J, Pauling JD, Lissina A, Kuwana M, **Rider LG**, Rönnelid J, McHugh NJ. The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis.

Arthritis Res Ther. 2020;22(1):117. Epub 20200515. doi: 10.1186/s13075-020-02210-2. PMID: 32414409; PMCID: PMC7227250.

40. Isenberg DA, Chinoy H, Dimachkie MM, Miller FW, **Rider LG**. The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS). *Clin Exp Rheumatol*. 2022;40(2):214-8. Epub 20220120. doi: 10.55563/clinexprheumatol/yg743i. PMID: 35225220.; PMC Journal – In Process
41. Pachman LM, Tansley S, Reed AM, Pilkington CM, Feldman BM, **Rider LG**. Chapter 17, Juvenile Dermatomyositis. In: *A Clinicians Myths & Pearls in Rheumatology*, Second edition, Editor Stone JH, Springer Nature Switzerland AG, Cham Switzerland, 2023, pgs 275-286.
42. Sanner H and **Rider LG**. Long-term Outcomes in Juvenile Idiopathic Inflammatory Myopathies. CHAPTER 48, *The Myositis Handbook: An Inclusive Guide to the Inflammatory Myopathies*. Edited by Christopher-Stine L and Lundberg IE. Jaypee Brothers Medical Publishers, New Delhi, India, 2023. In press.
43. Yao L, Schiffenbauer A, **Rider LG**. Idiopathic Inflammatory Myopathies. In "Musculoskeletal Imaging" Editors: Thomas Pope, JL Bloem, WB Morrison, DJ Wilson, LM White. Springer Nature, Switzerland Cham, Switzerland. 2023. In press.
44. Kim, H and **Rider LG**. Juvenile Myositis. Section 15, Chapter 202. *Rudolph's Pediatrics*. 24th edition. Kline MW, Orange J, Giardino A, Harris ZL, Rathore M and Cabrera A, eds. McGraw-Hill, NY. 2023. In press.
45. McCann LJ, Mammen AL, **Rider LG**. Chapter 171, Inflammatory Myopathies. Ashwal S, et al., eds: *Swaimans Pediatric Neurology*, 7th ed. Philadelphia: Elsevier, 2024. In press.

### Case reports

1. **Rider LG**, Sherry DD, Glass ST. Neonatal lupus erythematosus simulating transient myasthenia gravis at presentation. *J Pediatr*. 1991;118(3):417-9. doi: 10.1016/s0022-3476(05)82160-2. PMID: 1999784.
2. **Rider LG**, Clarke WR, Rutledge J. Pulmonary hypertension in a seventeen-year-old boy. *J Pediatr*. 1992;120(1):149-59. doi: 10.1016/s0022-3476(05)80622-5. PMID: 1731014.
3. **Rider LG**, Buyon JP, Rutledge J, Sherry DD. Treatment of neonatal lupus: case report and review of the literature. *J Rheumatol*. 1993;20(7):1208-11. PMID: 8371220.
4. Laskin BL, Choyke P, Keenan GF, Miller FW, **Rider LG**. Novel gastrointestinal tract manifestations in juvenile dermatomyositis. *J Pediatr*. 1999;135(3):371-4. doi: 10.1016/s0022-3476(99)70137-x. PMID: 10484806.
5. Mitchell JP, Dennis GJ, **Rider LG**. Juvenile dermatomyositis presenting with anasarca: A possible indicator of severe disease activity. *J Pediatr*. 2001;138(6):942-5. doi: 10.1067/mpd.2001.113363. PMID: 11391348.
6. Mamyrova G, Kleiner DE, James-Newton L, Shaham B, Miller FW, **Rider LG**. Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from

chronic endarteropathy. *Arthritis Rheum.* 2007;57(5):881-4. doi: 10.1002/art.22782. PMID: 17530691; PMCID: PMC2099313.

7. **Rider LG**, Atkinson JC. Images in clinical medicine. Gingival and periungual vasculopathy of juvenile dermatomyositis. *N Engl J Med.* 2009;360(15):e21. doi: 10.1056/nejmicm062850. PMID: 19357401; PMCID: PMC2802054.
8. Arabshahi B, Silverman RA, Jones OY, **Rider LG**. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. *J Pediatr.* 2012;160(3):520-2. Epub 20120113. doi: 10.1016/j.jpeds.2011.11.057. PMID: 22244459; PMCID: PMC3306811.
9. Lanis A\*, Volochayev R\*, Kleiner DE, Vittal A, Heller T, **Rider LG\*\***, Shenoi S\*\*. Nodular Regenerative Hyperplasia of the liver in Juvenile Dermatomyositis. *Pediatr Rheumatol Online J.* 2022;20(1):30. Epub 20220420. doi: 10.1186/s12969-022-00690-x. PMID: 35443665; PMCID: PMC9022230. \*,\*\* These authors contributed equally.

#### Research Letters (peer reviewed)

1. **Rider LG**, Mendelman PM, French J, Sherry DD. Group A streptococcal infection and Kawasaki syndrome. *Lancet.* 1991;337(8749):1100-1. doi: 10.1016/0140-6736(91)91751-f. PMID: 1673524.
2. Sabbagh S\*, Almeida de Jesus A\*, Hwang S, Kuehn HS, Kim H, Jung L, Carrasco R, Rosenzweig S, Goldbach-Mansky R\*\*, **Rider LG\*\***. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. *Brain.* 2019;142(11):e59. doi: 10.1093/brain/awz293. PMID: 31603187; PMCID: PMC6821280. \*,\*\*These authors contributed equally to this work.
3. Eleryan MG, Awosika O, Akhiyat S, Qureshi A, Rengifo-Pardo M, Curiel R, **Rider LG**, Ehrlich A. Treatment of calcinosis with adult and juvenile dermatomyositis using topical sodium thiosulfate via fractionated CO2 laser treatment. *Clin Exp Rheumatol* 2019 Nov-Dec;37(6):1092-1093. Epub 2019 Nov 18. PMID: 31796160; PMCID: PMC7108296.  
**Erratum corrigé:** M.G. Eleryan et al. Treatment of calcinosis with adult and juvenile dermatomyositis using topical sodium thiosulfate via fractionated CO2 laser treatment. *Clin Exp Rheumatol.* 2020 Jan-Feb;38(1):174. Epub 2020 Feb 6. Erratum for: *Clin Exp Rheumatol.* 2019 Nov-Dec;37(6):1092-1093. PMID: 32041681.
4. Kim H, Dill S, O'Brien M, Vian L, Li X, Manukyan M, Jain M, Adejojo LW, George J, Perez M, Grom AA, Sutter M, Feldman BM, Yao L, Millwood M, Brundidge A, Pichard DC, Cowen EW, Shi Y, Lu S, Tsai WL, Gadina M, **Rider LG**, Colbert RA. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. *Ann Rheum Dis.* 2021;80(3):406-8. Epub 20200825. doi: 10.1136/annrheumdis-2020-218690. PMID: 32843325; PMCID: PMC7904969.

#### Letters to the Editor

1. Miller FW, **Rider LG**, Plotz PH, Isenberg DA, Oddis CV. Diagnostic criteria for polymyositis and dermatomyositis. *Lancet.* 2003;362(9397):1762-3. doi: 10.1016/s0140-6736(03)14862-3. PMID: 14643132.

2. Miller FW, **Rider LG**, Plotz PH, Rutkove SB, Pestronk A, Wortmann RL, Lundberg IE, Argov Z, Isenberg DA, Lacomis D, Oddis CV. Polymyositis: an overdiagnosed entity. *Neurology*. 2004;63(2):402. PMID: 15277657.
3. Takken T, van der Net J, Helders PJ. Childhood myositis assessment scale and muscle strength testing in patients with juvenile dermatomyositis: comment on the article by Huber **et al**. *Arthritis Rheum*. 2005;52(1):368; author reply -9. doi: 10.1002/art.20757. PMID: 15641070.
4. **Rider LG**, Lachenbruch P, Isenberg DA, Miller FW. Applicability of the paediatric rheumatology international trials organisation disease activity core set for juvenile dermatomyositis: comment on the article by Ruperto **et al**. *Arthritis Rheum*. 2008;59(8):1197-8. doi: 10.1002/art.23919. PMID: 18668578.
5. Huber AM, Lovell DJ, Pilkington CA, Rennebohm RM, **Rider LG**. Confusion concerning multiple versions of the childhood myositis assessment scale. *Arthritis Care Res (Hoboken)*. 2014;66(4):648. doi: 10.1002/acr.22239. PMID: 24285368.
6. Sabbagh S, Pinal Fernandez I, Miller FW, **Rider LG**, Mammen AL. Response to: 'Comment on: 'Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis' by Sabbagh S **et al**' by Yang **et al**. *Ann Rheum Dis*. 2020;79(8):e97. Epub 20190617. doi: 10.1136/annrheumdis-2019-215693. PMID: 31208959; PMCID: PMC8466717.
7. Lundberg IE, Miller FW, **Rider LG**, Werth VP, Tjärnlund A, Bottai M. Response to: 'Correspondence on 'EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups" by Irfan **et al**. *Ann Rheum Dis*. 2023;82(2):e41. Epub 20210113. doi: 10.1136/annrheumdis-2020-219436. PMID: 33441297.
8. Mammen AL, Pinal-Fernandez I, **Rider LG**. Conflicting reports of anti-cytosolic 5'-nucleotidase 1A autoantibodies in juvenile dermatomyositis: comment on the article by Rietveld **et al**. *Arthritis Rheumatol*. 2022;74(5):911-2. Epub 20220328. doi: 10.1002/art.42059. PMID: 34962359; PMCID: PMC9050856.

#### **Professional educational materials or reports in print or other media.**

IMACS Group Website: <http://www.niehs.nih.gov/research/resources/collab/imacs/main.cfm>

#### **Clinical Guidelines and Reports**

Guidance for Industry: Clinical Development Programs of Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis. Food and Drug Administration, February 1999. <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071579.pdf>.

#### **Multimedia**

Brief career biography video- released to Lab TV and NIH You Tube, National Institutes of Health, 2015 <http://www.nih.gov/health-information/nih-clinical-research-trials-you/researcher-stories-why-we-became-scientists> at [www.LabTV.com](http://www.LabTV.com).

Award video for 2016 PhRMA Research and Hope Awards. [https://youtu.be/IlhTARJkh\\_I](https://youtu.be/IlhTARJkh_I)

## Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings

(146 published):

1. **Rider LG**, CA Wallace, DD Sherry, and FW Miller. Autoimmune diseases in family members of children with idiopathic inflammatory myopathies. *Arthritis Rheumatism*. 1994; 37(suppl): S403.
2. **Rider LG**, IN Targoff, RL Leff, KJ Bloch, BL Gruber, CV Oddis, DD Sherry, and FW Miller. Association of autoantibodies to the U5-ribonucleoprotein (U5-RNP) with idiopathic inflammatory myopathy. *Arthritis Rheumatism*. 1994; 37(suppl): S242.
3. **Rider LG**, IN Targoff, ES Taylor-Albert, LI Ray, R Pappu, JC Jacobs, LM Pachman, FW Miller. Anti-Jo1 autoantibodies define a clinically homogenous subset of childhood idiopathic inflammatory myopathy. *Arthritis Rheum*. 1995; 38 (suppl): S362.
4. **Rider LG**, S Okada, DD Sherry, CA Wallace, LS Zemel, CB Lindsley, RM Rennebohm, RS Rivas-Chacon, S Sheehy, SA Vogelgesang, DA Person, JC Olson, JJ Miller, S Stein-Yandashevskaya, KL Madson, IM Katona, BH Athreya, PH White, JC Jacobs, FW Miller, for the Childhood Myositis Heterogeneity Study Group. Presentations and disease courses of juvenile idiopathic inflammatory myopathy. *Arthritis Rheum*. 1995; 38 (suppl): S362.
5. **Rider L**, K Prasad, B Feldman, M Perez, C Lindsley, L Zemel, R Rennebohm, S Ballinger, S Bowyer, S Okada, J Miller, A Rosenberg, A Reed, C Wallace, R Sundel, M Passo, I Katona, P White, L Pachman, P Lachenbruch, and F Miller, for the JDM Disease Activity Collaborative Study Group. Relationships among laboratory tests and global disease activity assessments in juvenile dermatomyositis. *Arthritis Rheum*. 1996; 39 (suppl): S191.
6. **Rider L**, B Sonies, D Sapper, B Solomon, I Katona, S George, C Lindsley, P White, and F Miller. Swallowing and oral motor abnormalities are frequent in juvenile idiopathic inflammatory myopathy. *Arthritis Rheum*. 1996; 39 (suppl): S191.
7. Shamim E, **L Rider**, M Perez, G Cawkwell, R Wise and F Miller. Demographic and clinical features of patients who develop myositis following immunization. *Arthritis Rheum*. 1998; 41 (suppl.): S204.
8. Feldman BM, **LG Rider**, L Dugan, FW Miller, and R Schneider, for the Juvenile Myositis Collaborative Study Group. Nailfold capillaries as indicators of disease activity in juvenile idiopathic inflammatory myopathies. *Arthritis Rheum*. 1999; 42 (suppl.): S664.
9. Jain M, M Smith, J Danoff, **L Rider**, J Hicks. Comparison of the Pediatric Evaluation Disability Inventory (PEDI) and the Childhood Health Assessment Questionnaire (CHAQ) in children with juvenile dermatomyositis. *Arthritis Rheum*. 2000; 43 (suppl.): S180.
10. Hicks J, R Wesley, D Koziol, B Feldman, K Whitney, E Adams, M Villalba, M Jain, C Lindsley, S Wright, L Pachman, P Plotz, E Giannini, F Miller, **L Rider**. Consensus and economic advantages in use of abbreviated manual muscle testing in the assessment of idiopathic inflammatory myopathies. *Arthritis Rheum*. 2001; 44 (suppl.): S352.
11. **L Rider**, B Sonies, B Solomon, B Feldman, M Perez, L Zemel, R Rennebohm, C Wallace, C Lindsley, S Bowyer, S Ballinger, A Reed, P White, I Katona, J Hicks, P Lachenbruch, F Miller, for the JDM Disease Activity Collaborative Study Group. Voice abnormalities are frequent in juvenile



idiopathic inflammatory myopathies and correlate with muscle strength and function. *Arthritis Rheum.* 2001; 44 (suppl.): S293.

12. Pilkington C, K Murray, D Isenberg, V Farewell, J Davidson, B Feldman, A Ravelli, R Rennebohm, C Ryder, E Allen, F Miller, **L Rider**. Development of disease activity and damage indices for myositis: Initial testing of four tools in juvenile dermatomyositis. *Arthritis Rheum.* 2001; 44 (suppl.): S294.
13. **Rider L**, A Schiffenbauer, M Villalba, E Adams, G Joe, M Harris-Love, L James-Newton, J Hicks, C Pilkington, D Isenberg, P Lachenbruch, F Miller, and the JDM Disease Activity Collaborative Study Group. Extra muscular disease activity is frequent in adult and juvenile idiopathic inflammatory myopathies (IIM) and does not correlate with other myositis activity measures. *Arthritis Rheum.* 2002; 46 (suppl.): S612 - 613.
14. C Pilkington, D Isenberg, V Farewell, J Davidson, B Feldman, A Ravelli, R Rennebohm, C Ryder, E Allen, F Miller, and **L Rider**. Development of disease damage indices for juvenile myositis: Preliminary reliability and content validity. *Arthritis Rheum.* 2002; 46 (suppl.): S308.
15. **L Rider**, M Villalba, E Adams, G Joe, M Harris-Love, S Hill, L James-Newton, J Hicks, P Plotz, P Lachenbruch, F Miller, and the JDM Disease Activity Collaborative Study Group. Validity of the Myositis Disease Activity Assessment Tool (MDAAT) for Assessing Extra-muscular Disease Activity in Adult and Juvenile Idiopathic Inflammatory Myopathies (IIM). *Arthritis Rheum.* 2005; 52 (suppl): S315.
16. **L Rider**, P Lachenbruch, L James-Newton, I Cabalar, B Feldman, A Ravelli, B Myones, R Rennebohm, L Pachman, M Villalba, E Adams, C Lindsley, C Wallace, L Zemel, A Reed, F Miller, for the IMACS Group Predictors of Calcinosis in Juvenile and Adult Myositis. *Arthritis Rheum.* 2008; 58 (suppl): S230.
17. **L. Rider**, P. Lachenbruch, L. James-Newton, I. Cabalar, B.M. Feldman, A. Ravelli, B. Myones, R. Rennebohm, L. Pachman, M. Villalba, E. Adams, C. Lindsley, C. Wallace, S. Ballinger, L. Zemel, A. Reed, F. Miller, IMACS Group Effects of Treatment on Disease Damage in Juvenile and Adult Myositis. *Arthritis Rheum*, 2008; 58S, S229.
18. **L. Rider**, L. Li, J. Chipman, R. Costello, T. O'Hanlon, T. Fleisher, G. Csako and F. Miller. Biomarkers of Juvenile Dermatomyositis (JDM) Aid in Assessing Disease Activity Over Enzymes Alone. *Arthritis Rheum*, 2009. 60S: S565. (Blue Ribbon Award - top 15%)
19. A Tjärnlund, **LG Rider**, FW Miller, VP Werth, CA Pilkington, M de Visser, E Forslund, AA Amato, RJ Barohn, M Bottai, R Finkel, HE Paulus, GJD Hengstman, M Liang, JA Singh, IE Lundberg, With the International Myositis Classification Criteria Project (IMCCP) consortium. Ethnic but not Gender Differences in Disease Manifestations in Dermatomyositis Patients. *Arthritis Rheum*, 2011, 63: S87.
20. A Schiffenbauer, E Turkbey, S Hill, I Whitt, F Miller, **L Rider**, D Bluemke. Comparison of Whole Body Versus Targeted Magnetic Resonance Imaging for Assessing Disease Activity and Damage in Idiopathic Inflammatory Myopathies. *Arthritis Rheum*, 2013. 65 (suppl). S90-91.
21. **Rider LG**, Faiq A, Farhadi PN, Bayat N, Itert L, Chase M, Ulrey R, Malley K, Wilkerson J, Johnson A, Rose K, Morris R, Parks C, Giannini EH, Brunner H, Goldberg B, Miller FW. A58:

demographics, clinical features and therapies of patients with juvenile dermatomyositis participating in a national myositis patient registry. *Arthritis Rheumatol.* 2014 Mar;66 Suppl 11: S86-7.

22. Faiq A, Noroozi Farhadi P, Bayat N, Chase M, Jansen A, Malley K, Wilkerson J, Rose K, Co K, Itret L, Johnson A, Morris R, Parks C, Gianni E, Brunner H, Miller F, Goldberg B, **Rider L**. Epidemiologic and Clinical Features of Patients with Adult and Juvenile Dermatomyositis, Polymyositis and Inclusion Body Myositis from Myovision, a National Myositis Patient Registry. *Arthritis Rheumatol.* 2014; 66 (S11): S963.
23. Faiq A, Noroozi Farhadi P, Wilkerson J, Bayat N, Jansen A, Rose K, Iterlt L, Johnson A, Parks C, Giannini E, Brunner H, Goldberg B, Morris R, Miller F, **Rider L**. Predictors of Myositis Treatments Received and Associated Treatment Responses in Myovision, a National Myositis Patient Registry. *Arthritis Rheumatol.* 2014; 66 (S11): S967-968.
24. Mamyrova G, Wu L, Huber A, Targoff IN, Miller FW, **Rider LG**. Illness Onset Features and Misdiagnosis in Juvenile Idiopathic Inflammatory Myopathies (JIIM) Differ Among Clinical and Autoantibody (Ab) Subgroups. *Arthritis Rheumatol.* 2014; 66 (S11): S579.
25. Hanaoka BY, Nagareddy PR, Campbell M, Crofford LJ, **Rider LG**, Miller FW, and Peterson CA. Impaired satellite cell activation and myofiber transition during skeletal muscle regeneration in patients with polymyositis and dermatomyositis. *Arthritis Rheumatol.*, 2016; 68 (suppl 10). <http://acrabstracts.org/abstract/impaired-satellite-cell-activation-and-myofiber-transition-during-skeletal-muscle-regeneration-in-patients-with-polymyositis-and-dermatomyositis/>.
26. Giancane G, Lavarello C, Pistorio A, **Rider LG**, Aggarwal R, Oliveira SK, Cuttica R, Fischbach M, Sterba G, Brochard K, Dressler F, Barone P, Burgos-Vargas R, Chalom EC, Desjonqueres M, Espada G, Fasth A, Gary SM, Herbigneaux RM, Hoyoux C, Deslandre CJ, Miller FW, Vencovsky J, Ravelli A, Martini A, and Ruperto N. Comparison of the PRINTO 2010 and PRINTO/IMACS Improvement Criteria in the PRINTO Trial in New Onset Juvenile Dermatomyositis. *Arthritis Rheumatol*, 2016; 68 (suppl 10). <http://acrabstracts.org/abstract/comparison-of-the-printo-2010-and-printointernational-myositis-and-clinical-studies-group-imacs-2016-improvement-criteria-in-the-printo-trial-in-new-onset-juvenile-dermatomyositis/>.
27. Schiffenbauer A, **Rider LG**, Faghihi-Kashani S, Patel K, and Miller FW. The Effectiveness of social media in Recruiting for Rare Rheumatic Diseases. *Arthritis Rheumatol*, 2016; 68 (suppl 10). <http://acrabstracts.org/abstract/the-effectiveness-of-social-media-in-recruiting-for-rare-rheumatic-diseases/>.
28. Kim H, Biancotto A, Cheung F, O'Hanlon TP, Targoff IN, Huang Y, Miller FW, Goldbach-Mansky R, **Rider LG**. Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) and Myositis Autoantibody Groups. *Arthritis Rheumatol.* 2017; 69 (suppl 10). Accessed November 13, 2017. <http://acrabstracts.org/abstract/novel-serum-broad-based-proteomic-discovery-analysis-identifies-proteins-and-pathways-dysregulated-in-juvenile-dermatomyositis-jdm-and-myositis-autoantibody-groups/>.

29. Kim H, Biancotto A, Cheung F, O'Hanlon T, Targoff I, Huang Y, Miller FW, Goldbach-Mansky R, **Rider L**. Novel serum broad-based proteomic discovery analysis identifies proteins and pathways dysregulated in juvenile dermatomyositis (JDM). *Pediatric Rheumatology*. 2017; 15(Suppl 2): O8.
30. Prakash H, Song D, Lichy D, Rao P, Jain M, Shrader J, Miller FW, Schiffenbauer A, Gorbach A, **Rider LG**. Quantitative Nailfold Video Capillaroscopy Parameters Correlate with Dermatomyositis Activity and Damage. *Arthritis Rheumatol*. 2017; 69 (suppl 10). <http://acrabstracts.org/abstract/quantitative-nailfold-video-capillaroscopy-parameters-correlate-with-dermatomyositis-activity-and-damage/>.
31. **Rider LG**, Noroozi Farhadi P, Bayat N, Wilkerson J, Faiq A, McGrath J, Brunner HI, Goldberg B, Miller FW. Infections and Medications Associated with Onset of Myositis in Myovision, a National Myositis Patient Registry. *Arthritis Rheumatol*. 2017; 69 (suppl 10). <http://acrabstracts.org/abstract/infections-and-medications-associated-with-onset-of-myositis-in-myovision-a-national-myositis-patient-registry/>.
32. Phillipotts M, Mamyrova G, Jones O, **Rider L**, Curiel R. Intravenous Immunoglobulin in Combination with Intravenous Methylprednisolone in the Treatment of Calcinosis Associated with Juvenile Dermatomyositis (JDM). DC Rheumatism Society Fellows Forum, May 19, 2018, Washington DC. Oral abstract award.
33. Kishi T, Wilkerson J, Smith M, Bayat N, Henrickson M, Lang B, Passo M, Miller FW, Ward M, **Rider LG**. Early Treatment with Intravenous Pulse Methylprednisolone or Methotrexate Is Associated with Decreased Medication Requirements at 12 and 24 Months in Patients with Juvenile Dermatomyositis: A Propensity Score Analysis. *Arthritis Rheumatol*. 2018; 70 (suppl 9). <https://acrabstracts.org/abstract/early-treatment-with-intravenous-pulse-methylprednisolone-or-methotrexate-is-associated-with-decreased-medication-requirements-at-12-and-24-months-in-patients-with-juvenile-dermatomyositis-a-propensi/>.
34. Phillipotts M, Alshaikh E, Aleatany Y, Jones OY, Mamyrova G, **Rider LG**, Curiel R. Intravenous Immunoglobulin in Combination with Intravenous Methylprednisolone in the Treatment of Calcinosis Associated with Juvenile Dermatomyositis (JDM). *Arthritis Rheumatol*. 2018; 70 (suppl 9). <https://acrabstracts.org/abstract/intravenous-immunoglobulin-in-combination-with-intravenous-methylprednisolone-in-the-treatment-of-calcinosis-associated-with-juvenile-dermatomyositis-jdm/>.
35. Kim H, Biancotto A, Cheung F, O'Hanlon TP, Huang Y, Miller FW, Goldbach-Mansky R, **Rider LG**. Proteomic Discovery Analysis Identifies Unique Proteins and Pathways Correlating with Different Clinical Activity and Damage Measures in Juvenile Dermatomyositis (JDM). *Arthritis Rheumatol*. 2018; 70 (suppl 9). <https://acrabstracts.org/abstract/proteomic-discovery-analysis-identifies-unique-proteins-and-pathways-correlating-with-different-clinical-activity-and-damage-measures-in-juvenile-dermatomyositis-jdm/>.
36. Faghihi-Kashani S, **Rider LG**, Bluemke D, Malayeri A, Turkbey E, Shrader J, McGrath J, Jones E, Marco J, Miller FW, Schiffenbauer A. A Semi-Quantitative Whole Body Magnetic Resonance Imaging Assessment Tool to Define Musculoskeletal Abnormalities in Patients with Idiopathic Inflammatory Myopathies. *Arthritis Rheumatol*. 2018; 70 (suppl 9). <https://acrabstracts.org/abstract/a-semi-quantitative-whole-body-magnetic-resonance-imaging->

[assessment-tool-to-define-musculoskeletal-abnormalities-in-patients-with-idiopathic-inflammatory-myopathies/](#).

37. N Arnett, H Prakash, AI Gorbach, F Miller, **L Rider**, A Schiffenbauer. Novel Nailfold Video Capillaroscopy Parameters for Monitoring Juvenile and Adult Dermatomyositis. BMC Rheumatology. 2019, 3(Suppl 1): 31, 9.
38. S Nazir, L Rider, I Targoff, S Naides, A Mammen, S Greenberg, A Schiffenbauer. Performance of Commercial Autoantibody Testing in Comparison to Recognized Gold Standards in Myositis Autoantibody Testing. Arthritis Rheumatol. 2021; 73 (suppl 9). <https://acrabstracts.org/abstract/performance-of-commercial-autoantibody-testing-in-comparison-to-recognized-gold-standards-in-myositis-autoantibody-testing/>. Accessed February 24, 2023.
39. S Coss, R Abdul Aziz, D Zhou, B Zhou, KE Miller, YL Wu, SP Ardoin, E Oberle, K Driest, OA Ahmed, A Patwardhan, S Akoghlanian, V Sivaraman, F Barber-Smilely, J Drew, C Spencer, L Pachman, GA Morgan, G Mamyrova, R Curiel, T O'Hanlon, LG Rider, FW Miller, L Padyukov, I Lundberg, A Notarnicola, J Vencovský, B Stibůrková, O Kryštůfková, and CY Yu. Complement C4 gene copy number variations and polymorphisms, autoantibodies, and clinical manifestations of juvenile dermatomyositis– a multi-center study. CARRA annual meeting, 2022.
40. Almackenzie M, Rider LG, Curiel R. Anti-HMGCR Autoantibodies in Juvenile Idiopathic Inflammatory Myopathies: A Case Series. Clin Exp Rheumatol, 2023; 41 (2):480; 4th Global Conference on Myositis, June 6-9, 2022, Prague, Czech Republic.
41. Jia S, Williams CB, Miller FW, Rider LG, Hessner MJ, Sabbagh SE. A plasma-induced transcriptome signature in treatment-resistant juvenile and adult myositis patients is associated with activated IFN, IL-6 and inhibited IL-15 signaling pathways, as well as regulators of NK and CD4 T cell differentiation. Clin Exp Rheumatol, 2023; 41 (2): 481-482; 4th Global Conference on Myositis, June 6-9, 2022, Prague. (Oral presentation)
42. Karasawa R, Yudoh K, Sato T, Tanaka M, O'Hanlon TP, Noroozi-Farhadi P, Flegel WA, Jarvis JN, Rider LG. Anti-Peroxiredoxin 6 and Anti- Myosin Light Polypeptide 6 Autoantibodies with Interstitial Lung Disease and Severe Disease in Juvenile Dermatomyositis. Arthritis Rheumatol. 2022; 74 (suppl 9). <https://acrabstracts.org/abstract/anti-peroxiredoxin-6-and-anti-myosin-light-polypeptide-6-autoantibodies-with-interstitial-lung-disease-and-severe-disease-in-juvenile-dermatomyositis/>. Accessed February 24, 2023.
43. Nazir S, Rouster-Stevens K, Fuller J, Kim H, Do V, Volochayev R, Jansen A, Bayat N, Rider L, Schiffenbauer A. Validity of the Mawdsley Calcinosis Questionnaire in Adult and Juvenile Dermatomyositis (DM, JDM) Patients with Calcinosis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). <https://acrabstracts.org/abstract/validity-of-the-mawdsley-calcinosis-questionnaire-in-adult-and-juvenile-dermatomyositis-dm-jdm-patients-with-calcinosis/>. Accessed November 7, 2022.
44. Nelson M, Schiffenbauer A, Kim H, Gillespie S, Do V, Fuller J, Rider L, Rouster-Stevens K. Intrarater Validation of Calcinosis Durometer Measurements in Juvenile and Adult Dermatomyositis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). <https://acrabstracts.org/abstract/intra-rater->

[validation-of-calcinosis-durometer-measurements-in-juvenile-and-adult-dermatomyositis/](#).  
Accessed November 7, 2022.

## **PRESS AND MEDIA REPORTS DURING THE REVIEW PERIOD (2017 – PRESENT)**

- 1- Kathy Holliman, ACR/EULAR Response Criteria Approved for Adult, Juvenile Myositis, Rheumatologist; Apr 2017. <https://www.the-rheumatologist.org/article/acreular-response-criteria-approved-adult-juvenile-myositis/>
- 2- Joanna Collison, Adult and paediatric experts unite for new response criteria, Nature Review Rheumatology; May 2017. <https://www.nature.com/articles/nrrheum.2017.61>
- 3- Kelly Lenox, Lisa Rider receives lifetime achievement award from Cure JM, Environmental Factor; May 2017. [Lisa Rider receives lifetime achievement award from Cure JM](#)
- 4- John Yewell, Myositis Conference Joins Researchers, Patients, NIH RECORD; June 2017. <https://nihrecord.nih.gov/2017/06/30/myositis-conference-joins-researchers-patients>
- 5- Kelly Lenox, The Myositis Association honors Rider's research, Environmental Factor; Oct 2018. <https://factor.niehs.nih.gov/2018/10/awards-recognition/myositis>
- 6- Marla Broadfoot, Rare disease group earns praise for international collaboration, Environmental Factor; Oct 2019. <https://factor.niehs.nih.gov/2019/10/awards-recognition/rare-disease>
- 7- Mitchel Zoler, Rare rheumatologic disease registries expand and produce results, Rare Rheumatologic Diseases; Oct 2019. [https://cdn.mdedge.com/files/s3fs-public/rare\\_rheum\\_2019\\_final.pdf](https://cdn.mdedge.com/files/s3fs-public/rare_rheum_2019_final.pdf)
- 8- Nancy Walsh, Dermatomyositis: A Link With Sunburn?, MEDPAGETODAY; Sep 2019. <https://www.medpagetoday.com/dermatology/generaldermatology/82148>
- 9- Emily Pond, Endothelial Biomarker Levels Elevated and Linked to Extramuscular Activity in Juvenile Dermatomyositis, Rheumatology Advisor; Feb 2020. <https://www.rheumatologyadvisor.com/home/topics/pediatric-rheumatology/endothelial-biomarker-levels-elevated-in-juvenile-dermatomyositis-and-linked-to-extramuscular-activity/>
- 10- Janelle Weaver, Lisa Rider earns a top award in pediatric rheumatology, Environmental Factor; Dec 2020. <https://factor.niehs.nih.gov/2020/12/awards-recognition/lisa-rider>
- 11- Researchers Identify Distinct Phenotype of Juvenile Dermatomyositis in North America, GW School of Medicine & Health Sciences; Aug 2021. <https://smhs.gwu.edu/news/researchers-identify-distinct-phenotype-juvenile-dermatomyositis-north-america>
- 12- Florencia Pascual, Scientific Journeys: From basic researcher to leader in autoimmunity, Environmental Factor; July 2021. <https://factor.niehs.nih.gov/2021/7/science-highlights/lisa-rider>

- 13- Lisa Rider receives lifetime achievement award from Cure JM, Inergency; July 2022. <https://inergency.com/lisa-rider-receives-lifetime-achievement-award-from-cure-jm-environmental-factor-may-2017/>
- 14- Robert Burleson, I felt like someone was looking out for me, Clinical Center News; Summer 2022. <https://clinicalcenter.nih.gov/about/news/newsletter/2022/summer/story-03.html>
- 15- Susan Cosier, Lisa Rider recognized for excellence in mentoring, Environmental Factor; Dec 2022. <https://factor.niehs.nih.gov/2022/12/feature/2-feature-lisa-rider>
- 16- Erich Martin, Disease flares requiring therapy change 'relatively uncommon' after COVID-19 vaccination, Healio Rheumatology; June 2022. <https://www.healio.com/news/rheumatology/20220628/disease-flares-requiring-therapy-change-relatively-uncommon-after-covid19-vaccination>
- 17- Janelle Weaver & Meklit Daniel, Papers of the Month: Urine biomarkers may hold promise for patients with muscle diseases, Environmental Factor; Mar 2023. <https://factor.niehs.nih.gov/2023/3/papers/dir>
- 18- Janelle Weaver & Meklit Daniel, Intramural Papers of the Month: Assessing gene and protein regulation in children and adults with autoimmune disease, Environmental Factor; July 2023. <https://factor.niehs.nih.gov/2023/7/papers/dir#a3>